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6Abstract 
In 2015, the European Commission Initiative on Breast Cancer (ECIBC) started the development 
of the European guidelines for breast cancer screening and diagnosis (henceforth the European 
Breast Guidelines) under the auspices of the Directorate-General for Health and Food Safety (DG 
SANTE) and the technical and scientific coordination of the Directorate-General Joint Research 
Centre (JRC). To support the JRC in this task, a Guidelines Development Group (GDG), consisting 
of independent experts and individuals, was established. 
The European Breast Guidelines’ scope (The Scope) represented the first output of the development 
process of the European Breast Guidelines. Via a public call for feedback, stakeholders and 
individual citizens were invited to provide their feedback on The Scope. 
The call for feedback was open from 18 December 2015 to 17 January 2016 and an online 
questionnaire was made available on the ECIBC web hub via the EU Survey platform. The JRC 
received a total of 82 valid responses, from 40 individuals from 18 different countries and from 
42 organisations from 20 different countries.
During a meeting held in Varese (Italy) in March 2016, the GDG discussed the new version 
of The Scope which was prepared taking into account the results of the call for feedback. The 
Scope was finalised and approved by the GDG after some minor editing on 6 September 2016 
and was later made publicly available together with this report.
71. Introduction
In December 2012, the Directorate-General for Health and Consumers (now the Directorate-
General for Health and Food Safety – DG SANTE) assigned the task of coordinating the European 
Commission Initiative on Breast Cancer (ECIBC) to the Joint Research Centre (JRC). 
The ECIBC’s main tasks, as defined in the DG SANTE published document, are: 
• To develop the European guidelines for breast cancer screening and diagnosis (European
Breast Guidelines) based on updated evidence.
• To develop a voluntary European Quality Assurance scheme for Breast Cancer Services
(European QA scheme) covering all care processes and based on the EU legislative
framework on accreditation and underpinned by the evidence provided by the guidelines.
For recommendations on care processes other than screening and diagnosis (treatment, rehabilitation, 
follow-up and survivorship care, palliative care, and all relevant horizontal aspects), it is envisaged that 
an ECIBC platform for breast cancer guidelines (the Guidelines Platform) will host existing evidence-
based, high-quality guidelines. In addition, Reference documents will be collected to support the 
implementation of evidence-based recommendations included in the existing guidelines for those 
aspects, e.g. related to diagnosis, where best practice guidance would be useful.
The ECIBC project also includes the definition of a concept for training professionals in breast 
cancer screening and the development of a dedicated web hub. It is foreseen that the ECIBC web 
hub will host all the tools developed (including the guidelines) and to make them available to and 
usable by all interested parties.
All these tasks are coordinated at the JRC level by a dedicated team, the ECIBC coordination team. 
The European Breast Guidelines are being developed in a web-based format and structured along 
PICO1 questions/recommendations adopting GRADE2 methodology for evaluating the available 
evidence and using it to support recommendations (1). To support the EC in the development 
of the European Breast Guidelines, a Guidelines Development Group (GDG) was established in 
2015 following a Call for Expression of Interest3 organised by DG SANTE and works under the 
JRC’s technical and scientific coordination.
The European Breast Guidelines´scope (The Scope) represents the GDG’s first output and 
defines the topics, considered important to the target audience, that the guidelines will cover 
within the ECIBC mandate limits and alongside what was agreed with the GDG regarding the 
purpose of the European Breast Guidelines, target population, healthcare setting, types of 
interventions, and key stakeholders and users. 
To ensure that from this early stage of development the scope proposed for the European Breast 
Guidelines would be inclusive and feasible for different health systems, countries and contexts, 
stakeholders and individual citizens were invited via a call for feedback to provide their 
opinion on The Scope. This report is about the results of this exercise.
1  PICO stands for: Population under study (for example, women of a certain age); Intervention (for 
example, a medical examination); Comparator (other main options such as an alternative medical 
examination); and Outcomes (results).
2  GRADE (Grading of Recommendations Assessment, Development and Evaluation) – provides a sys-
tem for rating quality of evidence and strength of recommendations that is structured and explicit. 
3 http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/call_ecibc_en.htm
82. Methodology of the call for feedback
2.1 The questionnaire
The ECIBC coordination team drafted The Scope and submitted it to the GDG for approval in 
December 2015. The version approved by the GDG was submitted to the call for feedback, 
and participants in the call were also asked to propose questions relevant for inclusion in the 
European Breast Guidelines.
The public call for feedback took place from 18 December 2015 to 17 January 2016 (four 
weeks) in the form of an online questionnaire, using the EU Survey tool, published on the 
ECIBC web hub. This online consultation was open to all interested parties. To ensure that 
all relevant stakeholders were informed, several information channels were used, including 
the ECIBC web hub, DG SANTE’s newsletter and the European Public Health Association’s 
(EUPHA) newsletter. In addition, all the entities (including those reported in past ECIBC 
publications (2-4)) and individuals (including also the officially nominated ECIBC National 
Contacts) identified as ECIBC stakeholders received a targeted communication before and just 
after the publication of the public call for feedback. 
To maximise the response rate, a reminder was sent on 11 January 2016 and, finally, an e-mail 
was sent to thank all participants following the closure of the survey.
The online questionnaire comprised four main sections: 
The first section concerned general information about the respondents. They had to identify 
themselves and indicate whether they were replying as an ‘individual’ or ‘on behalf of 
an organisation’. The responses from the ECIBC National Contacts were considered as ‘on 
behalf of an organisation’ because it was implied that they had responded on behalf of the 
corresponding country. Respondents could indicate how their contribution would appear: 
under the name supplied (and consent to publication of all the information contributed), 
anonymously (and consent to publication of all the information contributed excluding the 
name of the respondent and/or organisation), or ask that the contribution be treated 
confidentially, allowing for internal use within the European Commission only.
The second section included questions on the different parts of The Scope:
• Purpose of the guidelines;
• Target population;
• Healthcare settings;
• Types of interventions;
• Key stakeholders and users;
• Existing documents.
9The third section gave the respondents an opportunity to provide general comments regarding 
The Scope. 
In the fourth section, the respondents were asked to suggest questions that should be addressed 
by the European Breast Guidelines for each of the agreed chapters:
• Screening
• Diagnosis
• Communication
• Training
• Interventions to reduce inequalities
• Monitoring and evaluation of screening and diagnosis.
The full questionnaire is available as Annex I to this report.
A functional mailbox (JRC-ECIBC@ec.europa.eu), managed by the ECIBC coordination team 
based at the JRC’s Ispra site (Italy), was available for requests for technical support. 
2.2 Data collection and processing
Responses were collected and processed by the ECIBC coordination team. In particular, all 
personal data were treated pursuant to Regulation 45/2001/EC on the protection of individuals 
with regards to the processing of personal data by the Community institutions and bodies and 
on the free movement of such data.
Only comments submitted before the deadline and relating to the content of the documents were 
considered. Comments were excluded if they included complaints against institutions, personal 
accusations, irrelevant or offensive statements or material, or content not related to policy 
aspects relevant for the ECIBC or outside the scope of ECIBC’s activity. 
A draft feedback report, including descriptive statistics about the distribution of responses and 
the list of comments, was shared with the GDG along with their input as to how each 
section of The Scope could be modified according to the comments received. GDG replies to 
respondents' inputs were integrated accordingly to produce the final version of The Scope.
In this report, aggregated data are displayed for all the responses received. Comments from 
individuals and entities requiring anonymity are reported without the contributor’s name, whilst 
comments from individuals and entities asking for confidential treatment of the contribution are 
not reported at all. The full database of responses received, with the exception of confidential 
ones, is available upon request. 
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3. Results
3.1. Information about respondents
The JRC received a total of 82 valid responses, from 40 individuals (49 % of total) and 42 organisations 
(51 %). Please note that affiliation is based on self-identification by respondents and has not been 
validated.
Figure 1: Distribution of survey responses to the public call for feedback (n=82)
Individuals
The vast majority of individuals, 37 out of 40 (92 %), identified themselves as professionals 
working in an area related to breast cancer. Five percent identified him/herself as a patient/
consumer and another 3 % as ‘other’. Three of the respondents asked for their comments to be 
treated confidentially. The participation of patients/consumers as individuals was relatively small, 
although they also contributed on behalf of patient advocacy organisations (see table 1 below). 
Figure 2: Survey responses from individuals, according to their background (n=40)
Individuals' responses came from 18 different countries, with the largest number of 
respondents (ten) from Italy. All but three of the responses (one from Israel and two from 
Norway) came from EU individuals, representing 16 (57 %) of the 28 Member States. 
51 %49 %
As an individual
On behalf of an organisation
3 % 5 %
92 %
Consumer
Professional
Other
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Figure 3: Geographical distribution of survey responses from individuals (n=40)
Organisations
Forty-two contributions were received from organisations, corresponding to seven different main 
types of entities. The majority of responses (29 %) were from professional societies or 
organisations, including guidelines development organisations. Another substantial contribution 
(21 %) came from healthcare organisations. The proportion of responses from the rest of the 
main entities varied from 5 % for the patient advocacy organisation to 14 % for the ECIBC 
National Contacts. In addition, there was a group of seven (17 %) respondents who identified 
themselves as other types of entity. One contributor responding on behalf of an organisation 
asked for confidential treatment of his/her comments. 
Figure 4: Survey responses from organisations, according to the type of entity (n=42)
Responses came from organisations from 20 countries. Sixteen of the 28 EU Member States 
participated, as well as three European countries outside the EU (Serbia, Switzerland and 
Turkey) and one non-European country (Canada). The highest number of contributors came 
from Italy (seven), Belgium (four) and Netherlands (four). 
21%
5%
29%14%
7%
7%
17%
Patient advocacy  organisation
Healthcare organisation
Professional society or organisation, including 
guideline development organisations
ECIBC National contact
Academic / Research organisation
Industry
Other
21 %
5 %
29 %14 %
7 %
7 %
17 %
Patient advocacy  organisation
Healthcare organisation
Professional society or organisation, including 
guideline development orga isations
ECIBC National contact
Academic / Research organisation
Industry
Other
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Figure 5: Geographical distribution of survey responses from organisations (n=42)
Table 1: List of organisations contributing to the call for feedback and not asking 
for anonymity or confidentiality, arranged by type of organisation
NAME* TYPE COUNTRY
Europa Donna - The European 
Breast Cancer Coalition Patient advocacy organisation Italy
Borstkanker Actie Patient advocacy organisation Netherlands
Turkish Cancer Control 
Department of MoH Healthcare organisation Turkey
Croatian Institute of Public Health Healthcare organisation Croatia
Ministry of Health Healthcare organisation Republic of Cyprus
Ministry of Health Healthcare organisation Italy
Department of Health, Ireland Healthcare organisation Ireland
Kooperationsgemeinschaft 
Mammographie (mammography 
cooperative), Berlin
Healthcare organisation Germany
CPO-Piemonte, AOU Città della 
salute e della scienza, Torino Healthcare organisation Italy
Istituto per lo studio e la prevenzione 
oncologica, Regione Toscana Healthcare organisation Italy
Danish Health Authority Healthcare organisation Denmark
Hellenic Society  
of Breast Surgeons
Professional society or organisation, 
including guidelines development 
organisations
Greece
European Reference Organisation 
for Quality Assured Breast 
Screening and Diagnostic
Professional society or organisation, 
including guidelines development 
organisations
Netherlands
BCCERT
Professional society or organisation, 
including guidelines development 
organisations
Italy
National Institute for Public Health and 
the Environment/ Centre  
for Population Screening
Professional society or organisation, 
including guidelines development 
organisations
Netherlands
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NAME TYPE COUNTRY
Europa Donna -The European 
Breast Cancer Coalition Patient advocacy organisation Italy
Borstkanker Actie Patient advocacy organisation Netherlands
Turkish Cancer Control 
Department of MoH Healthcare organisation Turkey
Croatian Institute of Public Health Healthcare organisation Croatia
Ministry of Health Healthcare organisation Republic of Cyprus
Ministry of Health Healthcare organisation Italy
Department of Health, Ireland Healthcare organisation Ireland
Kooperationsgemeinschaft 
Mammographie (mammography 
cooperative), Berlin
Healthcare organisation Germany
CPO-Piemonte, AOU Città della 
salute e della scienza, Torino Healthcare organisation Italy
Istituto per lo studio e la prevenzione
oncologica, Regione Toscana Healthcare organisation Italy
Danish Health Authority Healthcare organisation Denmark
Hellenic Society 
of Breast Surgeons
Professional society or organisation, 
including guidelines development 
organisations
Greece
EUREF
Professional society or organisation, 
including guidelines development 
organisations
Netherlands
BCCERT
Professional society or organisation, 
including guidelines development 
organisations
Italy
National Institute for Public Health and 
the Environment/ Centre 
for Population Screening
Professional society or organisation, 
including guidelines development 
organisations
Netherlands
NAME* TYPE COUNTRY
ESTRO, European Society  
for Radiotherapy & Oncology
Professional society or organisation, 
including guidelines development 
organisations
Belgium
EUSOMA
Professional society or organisation, 
including guidelines development 
organisations
Italy
Austrian Federal Ministry 
of Health
Professional society or organisation, 
including guidelines development 
organisations
Austria
Bundesverband Deutscher Pathologen 
e.V.
Professional society or organisation, 
including guidelines development 
organisations
Germany
Europrev
Professional society or organisation, 
including guidelines development 
organisations
Belgium
Centre Communautaire de Référence 
pour le dépistage  
des cancers (CCR asbl)
Professional society or organisation, 
including guidelines development 
organisations
Belgium
EFOMP
Professional society or organisation, 
including guidelines development 
organisations
United Kingdom
EUSOBI
Professional society or organisation, 
including guidelines development 
organisations
Netherlands
The Breast Clinical Reference 
Group, NHS England ECIBC national contact United Kingdom
Ministry of Health ECIBC national contact Slovakia
Accreditation Body of Serbia ECIBC national contact Serbia
Institute of Public Health 
of Republic of Serbia ECIBC national contact Serbia
Swiss Federal Office of Public Health 
FOPH, Health and Accident Insurance 
Directorate
ECIBC national contact Switzerland
SENATURK Academic/Research institution Turkey
EORTC Academic/Research institution Portugal
Österreichische Röntgengesellschaft 
ÖRG, Chair of Breast Imaging  
Work Group
Academic/Research institution Austria
GE Healthcare  Industry France
Roche  Industry Switzerland 
COCIR  Industry Belgium
United Kingdom Accreditation Service  Other United Kingdom
Czech Accreditation 
Institute Other Czech Republic
Hamburg Cancer Registry Other Germany
ITALCERT Srl Other Italy
Badai Other Austria
Cancer Screening Programmes. Catalan 
Cancer Plan Other Spain
Canadian Breast Cancer 
Screening Network Other Canada
In total, 29 countries participated in the survey, including six non-EU countries. Twenty-
three (82 %) out of 28 EU Member states sent responses – only as an individual (six 
countries), only on behalf of an organisation (seven countries) or both (ten countries).
14
Figure 6: Number of responses from individuals and organisations from all 
countries which participated in the survey (*non-EU countries)
3.2. Results concerning the different parts of The Scope
In the following paragraphs, the results of the call for feedback will be reported question by 
question. Thereby, the relevant section from the survey will be presented first, followed by a 
figure, showing the distribution of responses, a summary of the comments and the final text in 
The Scope with the parts which were modified according to the comments highlighted in 
yellow. Annex II contains the comments received from the respondents, and the reasoning 
provided by GDG/JRC for each comment, for modification of The Scope. 
3.2.1 Purpose of the guidelines
Clarity of objectives in the European Breast Guidelines
The first question related to the clarity of the Objectives section in The Scope:
The primary objectives of the European Breast Guidelines are: (1) to provide users of breast 
cancer screening and diagnosis services (citizens and patients) and healthcare providers 
with clear, objective and independent guidance on breast cancer screening and diagnosis 
in order to promote informed decisions; and (2) to guide healthcare managers and policy-
makers when planning, commissioning and organising services for breast cancer screening 
and diagnosis. This includes the development of evidence-based recommendations 
supporting quality assurance of breast cancer screening and diagnosis. According to these 
objectives, it can be anticipated that some questions of the European Breast Guidelines 
will take more than one perspective, e.g. an individual and a population perspective (see 
section ‘3b. Perspective of the European Breast Guidelines’).
The majority of the respondents (89 %) said that the objectives are clear. 
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Figure 7: Clarity of European Breast Guidelines objectives (n=82)
In addition to YES/NO responses, nine comments were received:  two from individuals and 
seven on behalf of an organisation, which are presented in Annex II, table 1. 
As regards the first objective, it was suggested it should be rephrased to make it clearer that 
both healthcare users and healthcare providers will be provided with guidance to enable them 
to take informed decisions regarding breast cancer screening and diagnosis. One of the comments 
was related to the guidance for healthcare professionals and managers on how to ensure the 
participation of women in the screening: this will be considered in the communications section 
in the European Breast Guidelines and no further change was made in The Scope.
One comment, linked to the second objective, suggested an emphasis on quality of processes, 
as well as on improvement of outcomes. Another comment, relating to the use of ‘common 
practice’ for diagnostic procedures where no evidence-based recommendations are available, 
was not implemented in the objectives section of The Scope, although it will be considered 
in general within the ECIBC project, via Reference Documents. These documents are 
meant to support the implementation of evidence-based recommendations included in the 
existing guidelines for those aspects, e.g. related to diagnosis, where best practice guidance 
would be useful.
The explanation that ‘some recommendations of the European Breast Guidelines include more than 
one perspective, e.g. an individual and a population perspective’ was already in the Objectives 
section of The Scope, so no further modifications were made following this comment by an 
individual.
No
Yes
11 %
89 %
No
Yes
11%
89%
16
The modified text according to the comments is: 
The primary objectives of the European Breast Guidelines are:
1. to provide both healthcare users and healthcare providers with clear, objective and
independent guidance on breast cancer screening and diagnostic services to enable them 
to take informed decisions; and
2. to guide healthcare providers and policymakers when planning, (de)commissioning and
organising services for breast cancer screening and diagnosis. This is done by developing 
evidence-based recommendations to support the quality assurance of breast cancer 
screening and diagnosis, with an emphasis on improvement of outcomes and quality 
of the processes. 
In accordance with these objectives, it is anticipated that some recommendations of the 
European Breast Guidelines include more than one perspective, e.g., an individual and 
a population perspective (see section ‘3.2 Perspective of the European Breast Guidelines’).
Expected outcomes
This question investigated whether the proposed expected outcomes were considered relevant. 
Respondents were asked to reply if they agreed or had concerns and to provide comments 
regarding the following paragraph in The Scope:
Expected outcomes influenced by the guidelines
An ‘outcome’ is the impact that a test, treatment, policy, program or other intervention 
has on a person, group or population. The importance of outcomes is likely to vary within 
and across cultures or when considered from the perspectives of the citizens, patients, 
clinicians or policy-makers. Cultural diversity will often influence the relative importance 
of outcomes, particularly when developing recommendations for an international audience.
It is anticipated that the European Breast Guidelines will impact on outcomes important for 
the citizens and the health systems, such as:
• Mortality due to breast cancer
• Quality of life
• Patient safety
• Equity in healthcare
• Unnecessary variability in clinical practice
17
Eighty percent of the respondents replied that they agreed with the proposed expected outcomes 
and did not have comments, 15 % agreed in general but also provided comments, and 5 % had 
concerns for which they provided comments. 
Figure 8: Relevance of proposed expected outcomes influenced by the European 
Breast Guidelines (n=82)
Twelve comments (five from individuals and seven on behalf of an organisation) were 
received from the respondents who replied with ‘generally, I agree’ – Annex II, table 2. 
The comments suggested addressing additional outcomes such as: 
• over-diagnosis and over-treatment;
• inequalities because of insufficient resources, healthcare organisation
or cultural background;
• survivorship;
• patient satisfaction;
• cost effectiveness.
A modification of The Scope was not considered because these and other relevant outcomes will 
be taken into account when selecting outcomes for the specific PICO (Population, Intervention, 
Comparator, Outcomes) questions. 
Comments related to unnecessary variability in clinical practice, target groups that have different 
needs, different cultural backgrounds and health systems, issues concerning communication and 
quality of services were not considered for modification of The Scope. However, some of them 
will be addressed in PICOs or by the European QA scheme, while others are considered in view 
of implementation aspects for each recommendation that will be issued. 
There were four comments on behalf of an organisation from those who replied ‘I have concerns’ 
– Annex II, table 3. They mainly suggested additional outcomes, which will be considered in the
definition of the relevant and specific PICOs, so no changes were made in The Scope. One comment 
related to the inclusion of ‘treatment and organisation of breast care’, but no modification was 
made to this section of The Scope because a footnote was added to the target population section, 
explaining that the ‘Guidelines Platform, a collection of existing evidence-based guidelines, can 
include recommendations on treatment for all breast cancer patients’. 
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I have concerns; 
see comments below
5 %
15 %
80 %
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I have concerns; 
see co ents below
5%
15%
80%
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No changes were implemented to The Scope regarding the expected outcomes. However, 
the suggested additional outcomes will be considered in the definition of the relevant and 
specific PICOs. 
3.2.2 Target population
This question investigated whether the proposed population groups, which will be addressed 
by the European Breast Guidelines, are adequate. Respondents were asked to reply if they 
agreed or had concerns and to provide comments regarding the relevant paragraphs in The 
Scope about: 1) groups that will be covered, and 2) groups that will not be covered.
Groups that will be covered
Women eligible for breast cancer screening.
Women attending breast diagnostic services because of symptoms or because of a recall 
on the basis of their screening examination.
Seventy-seven percent of the respondents replied that they agreed with the proposed groups 
and did not have comments, 19 % agreed in general but also provided comments, and 4 % had 
concerns for which they provided comments.
Figure 9: Adequacy of proposed population groups which will be covered by the 
European Breast Guidelines (n=82)
There were 15 comments received by respondents who replied with ‘generally, I agree’ – ten 
from individuals and five on behalf of an organisation – Annex II, table 4. 
Five of the comments concerned the screening age groups. These comments will be considered 
in the definition of the relevant PICOs, so no modifications were made in The Scope.
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
4 %
19 %
77 %
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Several comments related to addressing women at high risk (BRCA1/2, positive family history 
and other). No change was made in The Scope, but some PICO questions may relate to varying 
the screening regimen depending on certain risk factors. 
Two of the comments related to opportunistic screening and target population. These will be taken 
into account when formulating the relevant specific PICOs, so no modifications were made in The 
Scope.
Three comments suggested clarification about groups covered and not covered – namely about 
women with symptoms or a previous diagnosis of breast cancer, and men. Modifications of The 
Scope were made to clarify that diagnostic procedures in breast cancer patients with suspected 
recurrences or metastases during follow-up are not covered by the European Breast Guidelines, 
but are part of the Guidelines Platform. In addition, ‘women’ has been substituted with ‘persons’, 
because the screening chapter will not cover men; however, the diagnostic procedures will cover 
any person with breast cancer (women and men). 
Three comments were received from those who replied ‘I have concerns’ – two as an 
individual and one on behalf of an organisation – Annex II, table 5. They concerned male 
breast cancer, high-risk groups, and women with a previous diagnosis of breast cancer. 
Following these comments, relevant modifications were made in The Scope, as described in 
the previous paragraph. 
After considering all the comments, the final text in The Scope is the following:
Groups covered:
• persons eligible for breast cancer screening;
• persons accessing breast diagnostic services because of symptoms, referral
(e.g. following a risk assessment) or a recall on the basis of their screening examination.
Regarding the groups that will not be covered by the European Breast Guidelines, the respondents 
were asked to provide feedback on the following text: 
Groups that will not be covered
The following populations will not be specifically addressed by the guidelines:
• Males
• Women with loco-regional recurrences
• Women with metastatic breast cancer
Almost 70 % of the respondents replied that they agreed with the proposed groups and did 
not have comments, about 20 % agreed in general but also provided comments, and 10 % had 
concerns on which they provided comments.
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Figure 10: Adequacy of proposed groups which will not be covered by the 
European Breast Guidelines (n=82)
There were 17 comments received from those who replied ‘Generally I agree’ – 11 as an 
individual and six on behalf of an organisation – Annex II, table 6. 
Comments relating to the inclusion of males in the diagnostic part of the guidelines were 
considered and The Scope was modified – ‘women’ has been substituted with ‘persons’. 
There were several suggestions to include all patients in The Scope, also covering loco-regional 
recurrences, metastatic breast cancer, and second primary tumour. The Scope was modified 
(interventions not covered) to clarify that diagnostic procedures in breast cancer patients with 
suspected recurrences or metastases during follow-up are not covered by the European Breast 
Guidelines but are part of the Guidelines Platform.
Three of the comments were on follow-up (surveillance) of women with breast cancer (screen- 
or non-screen-detected). Since this topic will be covered by the Guidelines Platform, The Scope 
was not modified. 
Following the comments on high-risk patients and hereditary breast cancer, The Scope was 
modified to clarify that breast cancer risk assessment is among the interventions not covered 
by the European Breast Guidelines, but the groups covered include those accessing breast 
diagnostic services because of symptoms, referral (e.g. following a risk assessment) or a recall 
on the basis of their screening examination. Some PICO question may be related to varying the 
screening regimen depending on certain risk factors.
Seven comments were received from those who replied ‘I have concerns’ – one as an 
individual and six on behalf of an organisation – Annex II, table 7.
Four of the comments related to the inclusion of males in the diagnostic part of the guidelines 
and The Scope was modified accordingly – ‘women’ has been substituted with ‘persons’. 
Regarding the comments relating to the inclusion of patients with recurrences and metastases, 
and high-risk individuals, The Scope was modified accordingly, as described above for the 
comments received from those who replied ‘Generally I agree’. 
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
10 %
21 %
69 %
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After considering all the comments, the final text in The Scope is the following:
Groups NOT covered:
The European Breast Guidelines will not address questions concerning issues in these 
specific populations:
• patients with loco-regional breast cancer recurrence;
• patients with metastatic breast cancer.
A note was added: ‘Treatment regimens and surveillance for patients are regularly updated 
in international treatment guidelines. The Guidelines Platform, a collection of existing 
evidence-based guidelines, can include recommendations on treatment for all breast 
cancer patients.’
Perspective
This question related to the clarity of the perspective section in The Scope:
The legal basis of the European Breast Guidelines and, in the past, of the European Guidelines 
for quality assurance in breast cancer screening and diagnosis are the 2003 Council 
Recommendations, which state that ‘the Council […] hereby recommend the Member States to 
[…] implement cancer screening programmes in accordance with European guidelines on best 
practice where they exist and facilitate the further development of best practice for high quality 
cancer screening programmes on a national and, where appropriate, regional level’. 
The first purpose of the European Breast Guidelines, in particular from its European legal 
background, should be to give policy makers and healthcare administrators evidence-based 
recommendations on the implementation of cancer screening programmes and on the 
organisation of diagnostic procedures for breast cancer.
However, one main conclusion of the two workshops held at JRC-Ispra in 2013 was that the 
European Breast Guidelines should be ‘women-centred’. This implies that the perspective 
of users of breast cancer services (citizens and patients) should be taken into consideration 
during all stages of the guidelines development.
On the other hand, for questions related to diagnosis, especially when it happens outside 
of a screening programme, the patients’ and clinicians’ perspective will be prioritised. This 
means that the focus will be on the views of the individual user of the healthcare service 
(citizens and patients) and the healthcare professional that provides that service.
When developing the recommendations of the European Breast Guidelines, a balance 
between different perspectives (e.g., women vs. public health vs. policy support) shall 
be sought. This will be taken into account when choosing the outcomes for each question.

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Finally, quality assurance of breast cancer screening and diagnosis will be a key aspect to be 
addressed by the ECIBC. Although it is anticipated that most quality assurance aspects will 
be covered by the European QA scheme, some questions and sections of the European Breast 
Guidelines will focus on quality assurance aspects of breast cancer screening and diagnosis. 
Eighty-eight percent of the respondents replied positively that the section is clear.
Figure 11: Clarity of perspective of the European Breast Guidelines (n=82)
For 12 % of the respondents the perspective was not clear and they provided nine comments – 
three as an individual and six on behalf of an organisation – Annex II, table 8.
Three of the comments suggested clarification regarding different perspectives, which was taken 
into account in the wording of the final text of The Scope.
Four of the comments pointed out the importance of education about symptoms, explanation 
about over-diagnosis and harm, considering the socio-economic situation, legal and ethical 
frameworks, as well as addressing all settings for cancer screening. All of these will be taken 
into account in the formulation of relevant and specific PICOs and no further changes were made 
in The Scope. 
Two of the comments concerned the clarity of the text and complementing the second paragraph 
with an ‘adequate evaluation’ of programmes and services, which was taken into account and 
The Scope was modified accordingly.
No
Yes
12 %
88 %
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After considering all comments, the final version of the text regarding ‘Perspective’ is the 
following:
The legal basis for the European Breast Guidelines and the previous European guidelines for 
quality assurance in breast cancer screening and diagnosis is the 2003 Council Recommendations. 
It states that ‘the Council […] hereby recommend the Member States to […] implement cancer 
screening programmes in accordance with European guidelines on best practice where they 
exist and facilitate the further development of best practice for high-quality cancer screening 
programmes on a national and, where appropriate, regional level’.
The primary purpose of the European Breast Guidelines, in particular as stated in the 
aforementioned Council Recommendations, should be to give policymakers, as well as 
healthcare users and providers, guidance through evidence-based recommendations, on 
the implementation of population-based breast cancer screening programmes and on the 
organisation of diagnostic procedures for breast cancer, as well as on the adequate evaluation 
of these programmes and services (See chapter 6 Monitoring and evaluation of screening 
and diagnosis).
The perspective of users of these breast cancer services (healthcare users) are being taken 
into consideration during all stages of the European Breast Guidelines development.
For diagnostic services, especially when provided outside of a screening programme, the 
perspectives of healthcare users and clinicians are prioritised. This means that the focus is on 
the views of the individual healthcare user of the breast cancer service and the healthcare 
professional that provides that service.
When developing the recommendations of the European Breast Guidelines, a balance between these 
different perspectives (e.g. healthcare users vs. public health vs. policy support) is being sought. 
This is also taken into account when choosing the outcomes for these recommendations (6).
Finally, quality assurance of all breast cancer care processes is a key aspect to be addressed by 
the ECIBC. Although it is anticipated that most quality assurance aspects are covered by the 
European QA scheme, some questions of the European Breast Guidelines may focus on the 
quality assurance aspects of breast cancer screening and diagnosis.
3.2.3 Healthcare settings
This question investigated whether the proposed healthcare settings, which will be covered by the 
European Breast Guidelines, are adequate. Respondents were asked to reply if they agreed 
or had concerns and to provide comments regarding the following paragraph in The Scope:
The European Breast Guidelines will cover all healthcare settings where services for breast 
cancer screening and diagnosis are delivered.
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Eighty-four percent of the respondents said they agreed with the proposed groups and did not 
have comments, 11 % agreed in general but also made comments, and 5 % had concerns for 
which they provided comments. 
Figure 12: Adequacy of healthcare settings covered by the European Breast 
Guidelines (n=82)
There were seven comments provided by those who replied ‘Generally I agree’ – four as an 
individual and three on behalf of an organisation – Annex II, table 9.
The comments underlined the importance of including both private and public healthcare 
services, for screening and for diagnostic services, which were taken into account and The Scope 
was modified accordingly. The quality assurance aspects will be addressed by the European 
QA scheme. Therefore, this comment, which was provided on behalf of an organisation, was not 
considered for modification of The Scope. The title of the guidelines had already been agreed 
on as the European Breast Guidelines, so the comment on this topic was not considered for 
modification of The Scope.
Two of the comments related to issues regarding implementation of the recommendations 
in different healthcare systems. The European Breast Guidelines will include evidence-based 
recommendations. It may be difficult for some countries to implement them, but since this issue 
has to be addressed in the proper way at country level no change was made to The Scope. 
One comment on behalf of an organisation suggested inclusion of a ‘policy-making setting’. Since 
the European Breast Guidelines are being developed as a web-based application and one of the 
profiles foreseen on the web page is that of policymakers, which will include information 
adapted to their needs, no further modification was made to The Scope.
Two comments were received from those who replied ‘I have concerns’ – Annex II, table 10. 
One suggested including treatment, but since this topic will be covered by the Guidelines 
Platform it was not considered for modification in The Scope. The other comment concerned 
the role of a primary care team, which will be considered in the formulation of PICOs related to 
communication; thus, no further modification to The Scope was required.
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
5 %
11 %
84 %
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After considering all comments, the final text in The Scope, regarding Healthcare 
settings, is the following: 
The European Breast Guidelines cover all healthcare settings, both private and public, where 
services for systematic breast cancer screening and breast cancer diagnostic services are 
delivered.
3.2.4 Types of interventions
Definitions
This question investigated whether or not the proposed definitions are clear. Respondents were 
asked to reply if they agreed or had concerns and to provide comments regarding the following 
paragraph in The Scope:
Definitions
The following classification and definitions are proposed for screening and screening 
programmes (7, 8).
SCREENING: the systematic application of a screening test in a presumably asymptomatic 
population. In cancer screening, it aims to identify individuals with an abnormality suggestive 
of a specific cancer. These individuals require further investigation.
NON-PROGRAMME SCREENING (commonly referred also as opportunistic screening): 
examinations for early detection of cancer performed in a diagnostic or clinical setting, 
independent from the public screening policy (if existing).
SCREENING PROGRAMME: examinations financed by public sources performed in the 
context of a public screening policy documented in a law, or an official regulation, decision, 
directive or recommendation, and where the policy defines, at minimum: the screening 
test, the examination intervals, group of persons eligible to be screened.
ORGANISED SCREENING: screening programme where other procedures (e.g. standard 
operating procedures) are specified and where a team at national or regional level 
is responsible for implementing the policy, i.e., for coordinating the delivery of screening 
services, quality requirements, and reporting on performances and results.
POPULATION-BASED SCREENING: screening programme where in each round of the 
screening the persons in the eligible target area served by the programme are individually 
identified and personally invited. A diagnostic assessment may stem from referral for 
symptoms or palpable mass, or as further investigation of women with a screening 
mammography abnormality suggestive of breast cancer.
Eighty-one percent of the respondents replied that they agreed with the proposed definitions and 
did not have any comments, 12 % agreed in general but also made comments, and the rest had 
concerns for which they provided comments.
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Figure 13: Agreement with proposed definitions in The Scope (n=82)
There were eight comments received from those who replied ‘Generally I agree’ – 
three as an individual and five on behalf of an organisation – Annex II, table 11. Most of the 
comments suggested clarification of the definitions used. The Scope was modified to present 
the definitions as described in the reference provided, e.g. WHO and IARC (International 
Agency for Research on Cancer). All comments provided by respondents regarding these 
definitions will be made available to IARC for possible consideration when an update of the 
definitions is envisaged. 
A suggestion from an individual to substitute the phrase ‘screening mammography abnormality’ 
with ‘screening abnormality’ was considered because there will be PICO questions about different 
modalities used for screening, and The Scope was modified accordingly.  
Six comments were received from those who replied ‘I have concerns’ – five on behalf of 
an organisation and one as an individual – Annex II, table 12. They had remarks on the 
definitions – not really matching the main aspect of screening, not being intuitive/logical, 
presented without the context or quite punitive. The Scope was modified to present the 
definitions as described in the reference provided. All comments provided by respondents 
regarding these definitions will be made available to IARC for possible consideration when an 
update of the definitions is envisaged. 
Since topics relating to referral for further investigation, coordination and invitations, suggested 
in a comment on behalf of an organisation, will be covered by some PICOs and the Guidelines 
Platform, no further modifications were made to The Scope. 
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
7 %
12 %
81 %
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After considering all the comments, the final text in The Scope regarding definitions is the 
following:
The following definitions of a commonly used terminology, based on the European Commission’s 
Report on the implementation of the Council Recommendation on cancer screening and on the 
WHO guide for effective programmes (7, 8) are adopted for use in the European Breast 
Guidelines. 
SCREENING: the systematic application of a screening test in a presumably asymptomatic 
population. In cancer screening, it aims to identify individuals with an abnormality suggestive 
of a specific cancer. These individuals require further investigation.
NON-PROGRAMME SCREENING (commonly referred also as opportunistic screening):
examinations for early detection of cancer performed in a diagnostic or clinical setting, 
independent from the public screening policy (if existing).
PROGRAMME SCREENING: screening examinations financed by public sources performed in 
the context of a public screening policy documented in a law, or an official regulation, decision, 
directive or recommendation, and where the policy defines, at minimum: the screening test, 
the examination intervals, groups of persons eligible to be screened.
ORGANISED SCREENING: programme screening where additional procedures (e.g. standard 
operating procedures) are specified and where a team at national or regional level is responsible 
for implementing the policy, i.e. for coordinating the delivery of screening services, maintaining 
requisite quality, and reporting on performances and results.
POPULATION-BASED SCREENING: organised screening programme where, in each round 
of the screening, the persons in the eligible target population in the area served by the 
programme are individually identified and personally invited to attend screening.
A diagnostic assessment may stem from referral for symptoms or palpable mass, or as further 
investigation of women with a screening abnormality suggestive of breast cancer.
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Interventions that will be covered
This question asked the participants in the survey about their opinion regarding the interventions 
that will be covered. Respondents could reply that they agreed or had concerns and were asked 
to provide comments on the following paragraph in The Scope:
The European Breast Guidelines will cover screening and diagnosis of breast cancer. In 
particular, the desirable and undesirable effects of the following interventions will be 
assessed:
• Breast cancer screening policies and programmes:
• Different modalities of organised population-based screening programmes according
to women’s age, screening intervals and tests
• Opportunistic screening
• Breast cancer diagnostic steps and preoperative staging procedures (that is, the
examinations undertaken after referral and before surgery):
• Criteria for referral of symptomatic patients
• The diagnostic procedures for benign lesions
• Evaluation of different methods for diagnosis and preoperative staging (and, more
in general, breast imaging techniques)
• All biopsy procedures and their pathological examination (including fine needle
aspiration, core biopsy and surgical biopsy). Surgical treatment as such will not be
covered. However, diagnostic procedures during the surgery, such as lymph node
excision by sentinel node biopsy and pathological evaluation of the lymph node
evacuation specimens will be covered.
• Breast cancer surveillance for high-risk women.
• Interventions for primary prevention of breast cancer provided as co-interventions
nested in organised screening programmes.
• Interventions to reduce harms due to breast cancer screening or diagnosis, such as
overdiagnosis or discomfort with screening procedures.
• Interventions to improve communication in breast cancer screening and
diagnosis.
• Interventions to improve organisational aspects of breast cancer screening and
diagnosis (such as multidisciplinary team meetings).
• The European Breast Guidelines will cover the following types of recommendations
related to breast cancer screening and diagnosis:
• Clinical recommendations about interventions and diagnostic tests
• Health systems and public health recommendations (such as recommendations about
population-based screening programmes or recommendations focusing on quality
assurance aspects).
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Among the respondents, 58 % said they agreed with the interventions that will be covered and 
did not have any comments, 32 % agreed in general but also made comments, and the remaining 
10 % had concerns for which they provided comments.
Figure 14: Agreement with interventions covered by the European Breast 
Guidelines (n=82)
Twenty-three comments were received from those who replied ‘Generally I agree’ – Ten as 
an individual and 13 on behalf of an organisation – Annex II, table 13. 
Some comments related to diagnostic procedures for benign lesions, suggesting not to 
differentiate them from diagnostic procedures for malignant lesions. No change was made in The 
Scope because it was considered that there are some differences in the malignant lesions in the 
diagnostic process which are important to point out. 
Different biopsy procedures were also discussed in the context of diagnostic process. Since 
all biopsy procedures and their pathological examination have already been considered in The 
Scope, no further change was made. 
Two comments pointed out the importance of the neoadjuvant treatment and The Scope was 
modified accordingly to clarify that ‘examinations undertaken following referral and prior to 
treatment’ are included.
The Scope was also modified following comments on familial predisposition and screening for 
asymptomatic high-risk women, in order to clarify that breast cancer risk assessment is among 
the interventions not covered in The Scope. However, some PICO questions may relate to varying 
the screening regimen depending on certain risk factors. 
Two comments related to harm and undesirable effects. Harm is included in each PICO question 
among the outcomes. Desirable and undesirable effects are examined using Evidence-to-
Decision Frameworks4 for each PICO in order to decide where the balance lies, which might 
influence the direction of the corresponding recommendation, thus no further change was made 
in The Scope. 
4  Evidence to Decision (EtD) frameworks – an explicit and transparent system for decision-making, pro-
vide a systematic and transparent approach for going from the evidence to the healthcare decision. EtD 
frameworks inform users about the judgments that were made and the evidence supporting those judg-
ments by making the basis for decisions transparent to target audiences. EtD frameworks also include 
detailed justification (undesirable effects, values, certainty of the evidence), sub-group considerations, 
implementation considerations, monitoring and evaluation considerations and research priorities. 
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
10 %
32 %
58 %
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Regarding a comment for inclusion of metastatic disease, The Scope was modified (in the 
interventions section not covered) to clarify that diagnostic procedures in breast cancer patients 
with suspected recurrences or metastases during follow-up are not covered by the European 
Breast Guidelines, but are part of the Guidelines Platform.
The Scope was also modified following a comment to include not only women – the word ‘women’ 
has been substituted with ‘persons’ because the screening chapter will not cover men, although 
the diagnostic procedures will cover any person with breast cancer (women and men). 
The link between screening, diagnosis and other care procedures was pointed out in several 
comments. Therefore, The Scope was modified to include (in the purpose section) a figure about 
the breast cancer care pathway. 
There were eight comments received from those who replied ‘I have concerns’ – four as an 
individual and four on behalf of an organisation – Annex II, table 14. Two of these related to 
evaluation of pathological parameters, which may be covered by some PICO questions in 
the diagnosis chapter or by reference documents that will be provided to support ECIBC 
implementation, so no further change was made in The Scope. 
The Scope was modified to include examinations prior to treatment and pre-treatment staging, 
instead of ‘pre-operative staging’, as suggested in several comments.
Comments relating to high-risk women were followed by a relevant modification of The Scope, 
as already described in the paragraph regarding comments from those who replied ‘Generally 
I agree’. 
After considering all comments, the final text of The Scope regarding interventions that will 
be covered is the following:
The European Breast Guidelines cover the screening and diagnosis of breast cancer.
The desirable and undesirable effects of the following interventions are being assessed 
in order to produce clinical recommendations, as well as health systems and public health 
recommendations:
• Breast cancer screening policies and programmes:
• different modalities of organised population-based screening programmes according
to women’s age, screening intervals and tests
• opportunistic screening.
• Breast cancer diagnostic processes – these include examinations undertaken following
referral and prior to treatment processes, considering:
• criteria for referral of symptomatic persons
• diagnostic procedures for benign lesions
• evaluation of different methods for diagnosis and pre-treatment staging (and, more
in general, breast imaging techniques)

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• all biopsy procedures and their pathological examination (such as fine-needle
aspiration, core biopsy and surgical biopsy).
• Interventions for primary prevention of breast cancer provided as co-interventions
nested in organised screening programmes (e.g. information, counselling).
• Interventions to reduce harms due to breast cancer screening or diagnosis.
• Interventions to improve communication on breast cancer screening and diagnosis.
• Interventions to improve the organisational aspects of breast cancer screening and
diagnosis (such as multi-disciplinary team meetings).
Interventions that will not be covered
This survey question asked the participants for their opinion regarding the interventions that 
will not be covered. Respondents could reply that they agreed or had concerns and were asked 
to provide comments on the following paragraph in The Scope:
Aspects out of The Scope of breast cancer screening and diagnosis. Breast cancer 
treatment, rehabilitation, follow-up or palliative care will not be covered. For example, 
surgical management of lesions detected with mammography will not be covered.
• Diagnostic procedures in breast cancer patients with suspected recurrences or
metastases.
For example: staging procedures in women with suspected recurrences or metastases 
during follow-up will be excluded.
Seventy-three percent of the respondents replied that they agreed with the interventions that will 
be covered and did not have comments, 12 % agreed in general but also provided comments, 10 % 
had concerns for which they provided comments, and 5 % did not want to comment on this question.
Figure 15: Agreement with interventions not covered by the European Breast Guidelines 
(n=82)
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
I do not wish to give comments 
on this question
10 %
5 %
12 %
73 %
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Ten comments were received from those who replied ‘Generally I agree’ – seven as an 
individual and three on behalf of an organisation – Annex II, table 15.
Several comments related to diagnostic procedures for metastatic disease and suspected 
recurrences, and to follow-up and surveillance. The Scope was modified to clarify that diagnostic 
procedures in breast cancer patients with suspected recurrences or metastases during follow-up 
are not covered by the European Breast Guidelines, as well as follow-up and survivorship, but 
are part of the Guidelines Platform.
Some comments related to the link between diagnosis and treatment and suggested including 
surgical management and the pathological parameters evaluated in the surgical specimen. Since 
this will be covered by the Guidelines Platform, no further modification was made to The Scope. 
Eight comments were received from those who replied ‘I have concerns’ – four as an 
individual and 4 on behalf of an organisation – Annex II, table 16. Most related to metastatic 
and recurrent disease, as well as to treatment and follow-up. The Scope was modified to 
clarify these issues, as described above regarding similar comments received from those 
who replied ‘Generally I agree’.
After considering all comments, the final text regarding interventions that will not be covered 
is the following:
Aspects outside The Scope of breast cancer screening and diagnosis care processes. 
Breast cancer treatment, rehabilitation, follow-up and survivorship care, and palliative care 
are not covered (but are part of the Guidelines Platform).
• Diagnostic procedures in breast cancer patients with suspected recurrences
or metastases, such as the staging procedures in persons with suspected recurrences
or metastases during follow-up are not covered (but are part of the Guidelines Platform).
• Breast cancer risk assessment. The European Breast Guidelines do not cover questions 
specifically addressing breast cancer surveillance in women with hereditary breast cancer.
3.2.5 Key stakeholders and users
This question asked the call's participants about their opinion regarding the relevant key 
stakeholders and users whose views will be considered. Respondents could reply that they 
agreed or had concerns and were asked to provide comments on the following paragraph in The 
Scope:
The following are the relevant groups whose views will be sought:
1. Users of breast screening and diagnostic services (women attending breast cancer
screening services or women who undergo diagnostic assessment because of symptoms / 
recall from screening), their families and carers, and the general public who need to be 
informed in a clear and constructive way on this topic. The European Breast Guidelines will be 
‘women-centred’. This implies that the perspective of users of breast cancer services (citizens 
and patients) will be taken into consideration during all stages of the development of the 
guidelines.
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2. Healthcare providers directly responsible for providing breast cancer services, such
as primary care physicians, radiologists, nurses, etc.
3. Managers of breast screening and diagnosis services.
4. Public health officers.
5. Policy-makers, such as those involved in the development of national screening programmes.
Seventy-nine percent of the respondents replied that they agreed with the proposed key 
stakeholders and users and did not have any comments, 13 % agreed in general but also 
provided comments, 5 % had concerns for which they provided comments, and 3 % did not want 
to comment on this question.
Figure 16: Agreement with stakeholders and users proposed (n=82)
There were 11 comments from those who replied ‘Generally I agree’ – four as an individual 
and seven on behalf of an organisation – Annex II, table 17. All of them suggested including 
additional groups of stakeholders and users. These additional groups were taken into 
account and The Scope was modified accordingly.
There were three comments from those who replied ‘I have concerns’ – all on behalf 
of an organisation – Annex II, table 18. They suggested including additional groups of 
stakeholders and users, which were taken into account and The Scope was modified 
accordingly.
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
I do not wish to give comments 
on this question
5 %
3 %
13 %
79 %
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After considering all comments, the final text about stakeholders and users is the following:
The following are the relevant groups whose views are considered:
1.  Users of breast screening and diagnostic services (persons attending breast cancer
screening services or those who undergo diagnostic assessment because of symptoms/
recall from screening/referral), their families and carers, and the general public need
to be informed in a clear and constructive way on this topic. The European Breast
Guidelines are ‘person-centred’. This implies that the perspective of users of breast
cancer services is taken into consideration during all stages of the development of the
European Breast Guidelines.
2.  Healthcare providers directly responsible for providing breast cancer services, such
as general practitioners/family doctors, gynaecologists, radiologists, histopathologists,
surgeons, medical oncologists, radiation oncologists, reconstructive surgeons, palliative
care physicians, breast care nurses, psychologists, genetic counsellors, etc.
3. Managers of breast screening and diagnosis services.
4. Public health officers.
5. Policymakers.
6. Professional bodies/associations/academic societies.
7. Epidemiologists and other researchers.
8. Non-governmental organisations.
9.  Patients organisations, breast cancer support groups, other voluntary organisations
and charities.
10. Industry linked to breast cancer screening and diagnosis.
11. Families of persons with breast cancer.
3.2.6 Existing documents
This question asked the call's participants about their opinion on the existing documents 
relevant to the European Breast Guidelines. Respondents could reply that they agreed with the 
proposed list or had concerns, and provide comments on the following paragraph in The Scope:
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Existing guidelines on breast cancer screening and diagnosis which are likely to be currently 
used in practice:
• World Health Organization. WHO position paper on mammography screening Switzerland
2014 [cited 2015 Nov 5]; Available from: http://www.who.int/cancer/publications/
mammography_screening/en/.
• European Commission. European guidelines for quality assurance in breast cancer
screening and diagnosis. Fourth ed. Perry N, Broeders M, de Wolf C, Törnberg S,
Holland R, von Karsa L, et al., editors. Luxembourg: Office for Official Publications of the
European Communities; 2006. 416 p.
• European Commission. European guidelines for quality assurance in breast cancer
screening and diagnosis. Fourth edition, supplements. Fourth ed. Perry N, Broeders M,
de Wolf C, Törnberg S,Holland R, von Karsa L, editors. Luxembourg: Office for Official
Publications of the European Communities; 2013. 160 p.
This is not an exhaustive list. The JRC is running a systematic search to identify guidelines 
and recommendations on breast cancer screening and diagnosis published after 2005.
Seventy-eight percent of respondents replied that they agreed with the proposed list of documents 
and did not have any comments, 15 % agreed in general but also provided comments, 2 % had 
concerns for which they provided comments, and 5 % did not want to comment on this question. 
Figure 17: Agreement with proposed list of existing documents relevant to the 
European Breast Guidelines (n=82)
There were 12 comments from those who replied ‘Generally I agree’ – six as an 
individual and six on behalf of an organisation – Annex II, table 19. Most of them suggested 
the inclusion of additional research papers and reports from screening programmes. A note was 
added in The Scope to clarify that the bibliography presented is a brief list of documents used 
to prepare The Scope. All the literature which will be used to make the recommendations will 
be included in the ECIBC’s web hub. For the European Breast Guidelines, the literature 
review team has been 
I agree with it; 
I do not have comments
Generally, I agree with it;  
see comments below
I  have concerns; 
see comments below
I do not wish to give comments 
on this question
5 %
2 %
15 %
78 %
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externalised to ensure an independent approach and minimise potential conflict of interest. The 
Iberoamerican Cochrane Centre, Barcelona, will carry out the literature reviews for each specific 
PICO and will consider systematic reviews (if already available) or will carry out de-novo ones. 
Two comments related to the use of other international and national guidelines. Since the 
Guidelines Platform will include recommendations from evidence-based existing guidelines on all 
breast cancer care processes, no additional changes were made in The Scope. 
Two comments were received from those who replied ‘I have concerns’ – on behalf of an 
organisation – Annex II, table 20. They suggested including additional documents as well 
as taking different opinions into account. This will be considered during the literature review, 
as described above for similar comments from those who replied ‘Generally I agree’. 
After considering all comments, the final bibliography in The Scope is the following:
1.  Guidelines International Network (G-I-N), Guideline Development Checklist – Glossary
of Terms. Version 16 December 2013. McMaster University, Hamilton, 2013. Available
from: http://cebgrade.mcmaster.ca/checklistglossaryprintable.pdf
2.  European Commission, European Commission Initiative on Breast Cancer: Concept
document, Publications Office of the European Union, Luxembourg, 2015. Available
from: https://ec.europa.eu/jrc/sites/jrcsh/files/ecibc_concept_document.pdf
3.  National Institute for Health and Care Excellence (NICE). Glossary, 2013. Available
from: http://www.nice.org.uk/website/glossary/glossary.jsp
4.  Schunemann, H., Brożek, J., Guyatt, G., Oxman, A., editors, GRADE handbook for
grading quality of evidence and strength of recommendations, UpdatedOctober 2013.
The GRADE Working Group 2013. Available from: http://gdt.guidelinedevelopment.org/
app/handbook/handbook.html
5.  Perry, N., Broeders, M., de Wolf, C., Törnberg, S., Holland, R., von Karsa, L., et al., editors, 
European guidelines for quality assurance in breast cancer screening and diagnosis, 
Fourth ed., Office for Official Publications of the European Communities, Luxembourg, 
2006.
6.  Moberg, J., Alonso-Coello, P., Oxman, A.D., GRADE Evidence to Decision (EtD) Frameworks
Guidance, Version 1.1 [updated May 2015], The GRADE Working Group, 2015. Available
from: http://ietd.epistemonikos.org/#/help/guidance
7.  Von Karsa, L., Anttila, A., Ronco, G., Ponti, A., Arbyn, M., Segnan, N., et al., editors, 
Cancer screening in the European Union. Report on the implementation of the Council 
Recommendation on cancer screening. First Report, Office for Official Publications of 
the European Communities, Luxembourg, 2008, p. 14-15.
8.  WHO (2007). Cancer control: knowledge into action: WHO guide for effective programmes: 
early detection, p. 3.
A footnote was added for clarification: ‘This is a brief list of documents used to prepare 
The Scope. All literature used to make the recommendations that the European Breast 
Guidelines will provide will be included in the ECIBC’s web hub.
3.3 General comments regarding The Scope
There were 32 general comments – 13 as an individual and 19 on behalf of an organisation – 
Annex II, table 21. They addressed the following main topics: 
• Quality assurance – definition of targets/thresholds for indicators, performance indicators,
evaluation of outcome, availability of data, use of ISO standards, training and licensing
of specialists.
• Differences among countries – organisation of healthcare systems, cultural background,
socio-economic status, legal background and ethical concepts.
• Appropriate language of the guidelines – it has to be clear and plain for patients/
individuals, but must also provide the necessary information for professionals.
• Process of formulating recommendations – evidence-based, using the available scientific
literature, transparent procedures for selecting experts.
• Diagnosis and treatment – including different groups of patients (with metastatic disease,
males, high-risk patients), evaluation of breast cancer specimen, molecular diagnosis,
over-diagnosis and over-treatment.
Some of the suggestions were considered for modifications to The Scope, while others will 
be covered by different chapters of the European Breast Guidelines or by the Guidelines Platform 
and the European QA scheme, as described previously in this report.
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3.4 Questions that should be addressed by the European Breast Guidelines
In this part of the survey the respondents were given the opportunity to suggest questions that 
should be addressed by the European Breast Guidelines. In total, 217 proposals were received 
– 124 (57 %) from an individual and 93 (43 %) on behalf of an organisation. The distribution
of the number of questions by European Breast Guidelines chapter and profile of the respondents 
is presented in table 2.
Table 2: Number of questions proposed by the respondents that should 
be addressed by the European Breast Guidelines*
All questions suggested by the respondents and considered relevant to be addressed by 
the European Breast Guidelines were modified accordingly to PICO model and added to a list 
prepared in advance by the GDG members. This combined list contained more than 200 
questions (Annex IV) which were then prioritised by GDG members voting for the top 
questions for each chapter of the European Breast Guidelines. The questions that were not 
prioritised may be considered in future updates of the European Breast Guidelines. The list of 
both included and excluded questions along with the rationale for the decision is provided in 
Annex III. 
Chapter of the European 
Breast Guidelines
As an  
individual
On behalf of an 
organisation Total
Screening 25 23 48 
Diagnosis 20 14 34
Communication 19 13 32
Training 24 14 38
Interventions to reduce 
inequalities 19 11 30
Monitoring and evaluation of 
screening and diagnosis 17 18 35
Total 124 93 217
*Numbers in this table include all responses, but are not equal to those listed in the tables in Annex
III as some some duplicates or comments, which were not relevant, were excluded.
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4. Conclusions
Overall, the results of this public call for feedback indicate that respondents appreciated 
the openness of the procedure and, on JRC side, the usefulness of this kind of process. For 
these reasons, this same degree of transparency will be applied throughout the ECIBC.
In general, respondents represented the main categories of stakeholders (see Figure 4, Table 1) and 
expressed acceptance and positive consideration of the main features of the European Breast 
Guidelines as presented in The Scope. The percentage of respondents agreeing with the items 
proposed in The Scope varied between 85 % and 96 %, while the negative responses were usually 
below 10 %. These general figures suggest that no major changes to The Scope were required. 
The JRC and GDG carefully evaluated the feedback, in particular the two points commented 
on most by the respondents:
• Interventions that will or will not be covered;
• Target populations – groups that will or will not be covered.
Regarding the first point, The Scope was amended to allow for the inclusion of examinations 
undertaken during the breast cancer diagnostic processes following referral and prior-to-
treatment examinations, considering different methods for diagnosis (also including benign 
lesions) and pre-treatment staging, and all biopsy procedures and their pathological 
examination. Interventions that will not be covered were better detailed and it was clarified 
that, even though the European Breast Guidelines will not provide specific recommendations 
about them, they will be part of the Guidelines Platform. 
With reference to the target populations, The Scope was modified to include males in the 
diagnostic part of the European Breast Guidelines. Furthermore, a note was added explaining 
that although specific recommendations will not be provided for patients with loco-regional breast 
cancer recurrence or metastatic breast cancer, guidelines for diagnostic work-up and treatment 
regimens for these cases will be collected by the Guidelines Platform. 
The large number of suggestions received for questions that should be addressed by the 
European Breast Guidelines demonstrated the interest in this activity, both from individuals and 
organisations.
Although seven countries (Estonia, Finland, Hungary, Iceland, Luxembourg, Montenegro and 
Malta) of the 34 invited did not contribute to the call for feedback, it can be considered that 
the responses and comments received represent the main categories of stakeholders and users 
of these guidelines, and thus the European Breast Guidelines will take them into account. 
The new version of The Scope, published together with this report, integrates a significant number 
of the inputs received; where feedback is not integrated, the reasons are clearly expressed 
in this report. 
The call for feedback has led to an enriched document, thanks to the diversity and meaningfulness 
of contributions. Thus, it can be considered a success and hopefully will contribute to enhancing 
the future implementation of the European Breast Guidelines across Europe.  
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Annex 3
List of comments on different 
parts of The Scope
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
Objective 1 is not clear to me. 
What is meant with ‘guidance 
on breast cancer screening 
and diagnosis’ for patients and 
healthcare providers? This can 
only mean whether to go to 
screening or not, as there is 
usually only one system.
Yes The Scope was modified to 
clarify that the European Breast 
Guidelines will provide guidance 
on breast cancer screening and 
diagnostic services to enable 
healthcare users and healthcare 
providers to make informed 
decisions.
2 On behalf 
of an 
organisation 
To promote informed decisions 
through continuous and regular 
education.
Yes The Scope was modified to 
clarify that the European Breast 
Guidelines will provide guidance 
on breast cancer screening and 
diagnostic services to enable 
(instead of promote) healthcare 
users and healthcare providers to 
make informed decisions. 
The Training chapter of the 
European Breast Guidelines will 
address training issues.
3 On behalf 
of an 
organisation 
With users and health care 
providers in the same paragraph, 
it is not clear to me to what 
kind of decision on health are 
you talking about. I suggest 
to separate users (decision to 
participate) and health care 
providers (how to organize).
Yes The Scope was modified to 
clarify that the European Breast 
Guidelines will provide guidance 
on breast cancer screening and 
diagnostic services to enable 
healthcare users and healthcare 
providers to make informed 
decisions (regarding breast cancer 
screening and diagnosis).
Several PICO questions, particularly 
in the Communication chapter, will 
address as an outcome informed 
decision making.
4 On behalf 
of an 
organisation 
The objective should include 
guidance for healthcare 
professionals and managers 
on how to ensure women 
participate in the screening, as 
this is not always the case. See: 
http://bit.ly/1SkdvXW
No No change in The Scope.
The Communication chapter of the 
European Breast Guidelines will 
address the issue regarding the 
relevant information that has to be 
provided to women. 
5 On behalf 
of an 
organisation 
Evidence based 
recommendations and 
information from broad scale EU 
screening programs.
No No change in The Scope.
The European Breast Guidelines 
will include evidence based 
recommendations. However, when 
needed, Reference documents1 
will be provided to support ECIBC2 
implementation.
6 As an 
individual
In: ‘evidence-based recom-
mendations will be used’, but 
for some of the diagnostic 
procedures no evidence-based 
recommendations are available, 
only a ‘common practice’ 
or an ‘experienced panel 
recommendations’. This should  
be included.
Table 1. Comments on Clarity of objectives of the European Breast Guidelines
1  Reference documents - Reference documents will be collected in support to implementation of evidence-based rec-
ommendations included in the existing guidelines for those aspects, e.g. related to diagnosis, where best practice 
guidance would be useful.
2  ECIBC – European Commission Initiative on Breast Cancer
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
7 On behalf 
of an 
organisation 
The main objective of 
population-based breast cancer 
screening is to reduce cancer 
related mortality. Therefore 
we suggest complementing 
the 2nd sentence of (2) by 
‘particularly regarding outcomes’ 
quality besides structural and 
procedural quality’.
Yes The Scope was modified to clarify 
that there is ‘an emphasis on 
improvement of outcomes and 
quality of the processes’. 
Quality of structure and 
procedures will be addressed by 
the European QA scheme3.
8 On behalf 
of an 
organisation 
To centralize the user 
perspective does not mean 
the objective should be to 
address the women. Therefore 
the objective should not be to 
‘provide women with…’. It should 
be the objective to guide policy 
makers, healthcare providers 
etc. and as a consequence they 
should provide women with the 
best screening (i.e. ideally  
a fully quality assured screening 
programme) they can deliver 
(within their budget and in 
accordance with social and 
cultural background and values).
Yes The Scope was modified to clarify 
that ‘both healthcare users and 
healthcare providers’ will be 
provided with guidance to ‘enable 
them to make informed decisions’. 
It was added to the second 
objective that there is ‘an 
emphasis on improvement of 
outcomes and quality of the 
processes’. 
9 As an 
individual
The guidelines should take 
a population perspective. 
Screening programs are public 
health services.
No No change in The Scope.
It was already included in 
the Objectives section of 
the draft scope that ‘some 
recommendations of the European 
Breast Guidelines include more 
than one perspective, e.g., an 
individual and a population 
perspective’. In addition, in the 
Perspective section it was specified 
that ‘a balance between these 
different perspectives is being 
sought’.
3  European QA scheme - voluntary European quality assurance scheme for breast cancer services, covering all care 
processes, based on the EU legislative framework on accreditation and underpinned by the evidence provided by 
the guidelines.
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 As an 
individual
There is a very clear potential 
for overdiagnosis and 
overtreatment. This needs to be 
addressed as an outcome.
No No change in The Scope. 
Not explicitly stated in The Scope, 
but will be covered when selecting 
outcomes for the PICO4 questions.
2 As an 
individual
I am concerned that specific 
harms such as overdiagnosis are 
addressed and that information 
will be provided in formats such 
as Number needed to treat/screen 
and number needed to harm.
3 On behalf 
of an 
organisation 
I acknowledge the purpose of 
the EU to eliminate inequalities 
between healthcare systems 
within the EU, but this should 
not mean that a well-established 
system lowers its standards 
to enable equality. Some 
countries will not have necessary 
resources.
No No change in The Scope. 
The European Breast Guidelines 
will not propose lowering of 
standards for any country. 
Some countries may not have 
the appropriate resources to 
implement the evidence-based 
recommendations, but this issue 
has to be addressed in a proper 
way at a country level.
4 On behalf 
of an 
organisation 
Add additional outcomes: 
survivorship, participation rates, 
cost effectiveness, patient 
satisfaction, downstaging of 
the disease, numbers needed 
to screen to detect one cancer, 
overdiagnosis, radiation-dose 
exposure to patients.
No No change in The Scope. 
Not all of the suggested outcomes 
are listed in The Scope, but these 
and other relevant ones will be 
taken into account when selecting 
outcomes for the PICO questions. 
In addition, cost effectiveness 
is part of the Evidence to 
Decision (EtD) frameworks5 
that will be used to develop the 
recommendations.
5 On behalf 
of an 
organisation 
Suggestion to add additional 
outcomes expected: cost-
effectiveness optimization, 
data governance, survivorship, 
participation rates, patient 
satisfaction, disease 
downstaging, overdiagnosis; 
radiation-dose exposure to 
patients.
6 On behalf 
of an 
organisation 
Ensure that clear indications are 
included in the guidelines so that 
all those who need screening 
participate in screening 
programmes:  
http://bit.ly/1SkdvXW
No No change in The Scope.
Recommendations about effective 
communication will be included in 
the European Breast Guidelines. In 
addition, the recommendations are 
formulated in lay-person language 
in order to be understandable by all. 
Table 2. Comments on Expected outcomes: by respondents who replied 
with ‘Generally, I agree’
4  PICO format stands for: Population under study (for example women of certain age); Intervention (for example 
a medical examination); Comparator (other main options such as an alternative medical examination); and 
Outcomes (results).
5  Evidence to Decision (EtD) frameworks – an explicit and transparent system for decision making, provide a sys-
tematic and transparent approach for going from the evidence to the healthcare decision. EtD frameworks inform 
users about the judgments that were made and the evidence supporting those judgments by making the basis for 
decisions transparent to target audiences. EtD frameworks include also detailed justification (undesirable effects, 
values, certainty of the evidence), subgroup considerations, implementation considerations, monitoring and evalua-
tion considerations and research priorities. 
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
7 On behalf 
of an 
organisation 
A minor point: Scope would use 
Irrational or Non-rational instead 
of Unnecessary. Or, ‘Variability….’ 
not supported by evidence or 
best practice. Or delete it, as it 
belongs in fact to the previous 
subject, ‘Equity in healthcare’.
No No change in The Scope. 
It was agreed to keep 
‘unnecessary variability’, because 
it is slightly different than ‘equity 
in healthcare’. 
8 On behalf 
of an 
organisation 
The objectives are very 
ambitious. The objectives focus 
on different target groups that 
have different needs in terms of 
content, detailing and language 
use. It will be difficult to provide 
the different target groups 
with adequate information 
simultaneously, and taking the 
differences between countries 
into account. For this reason, I 
also have concerns to realizing 
the outcomes. Besides the 
guideline aims to target different 
cultural backgrounds and has 
to deal with different health 
systems.
No No change in The Scope.
The European Breast Guidelines 
will include evidence-based 
recommendations, also 
considering different population 
subgroups, such as socially 
disadvantaged, illiterate, etc. In 
addition, the recommendations 
will be translated into lay-
person language, in order to be 
understandable by all. Because 
of the differences in healthcare 
systems, it might be difficult for 
some countries to implement the 
recommendations, but this issue 
has to be addressed in a proper 
way at a country level.
9 As an 
individual
The bullet list is not meant to 
be exhaustive but I do think it 
would be good to emphasise in 
this list that the guidelines also 
aim to support more (evidence-) 
informed decision making 
between patients and their 
health professionals.
No No change in The Scope.
These issues will be covered when 
selecting outcomes for the PICO 
questions (in particular for the 
Communication chapter).
10 As an 
individual
I agree as long as not all 
outcome measurements have to 
be impacted and as long as the 
overall balance remains positive.
No No change in The Scope.
Desirable and undesirable effects 
of outcomes are examined using 
EtD frameworks for each PICO 
question in order to decide what 
the balance is, which might 
influence the direction of the 
corresponding recommendation.
11 On behalf 
of an 
organisation 
I suggest to add: Quality of 
breast health care services
No No change in The Scope.
Quality of breast healthcare 
services will be covered by the 
European QA scheme.
12 As an 
individual
Consider that the same 
information presented in terms 
of mortality or of survival has 
a strongly different impact on 
perception (see D. Kahneman, 
‘prospect theory’). I propose 
to write ‘mortality and survival 
associated with breast cancer’.
No No change in The Scope.
Traditionally, for an intervention 
that is done in healthy individuals, 
population mortality is the 
more appropriate metric, rather 
than survival, so it will be kept 
throughout the whole document.
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
The expected outcomes 
influenced by the guidelines 
are listed without stating the 
desirable effect. We suggest 
to complete the list as follows: 
1. Reduction of mortality... 
2.-4. Improvement of ... 5. 
Minimisation of unnecessary ...
No No change in The Scope.
This will be covered when 
selecting outcomes for the 
PICO questions. Desirable and 
undesirable effects are examined 
using EtD frameworks for each 
PICO question. In addition, the 
Monitoring and evaluation chapter 
of the European Breast Guidelines 
will contain recommended 
thresholds of relevant indicators.
2 On behalf 
of an 
organisation 
Define what are primary and 
secondary outcomes as well  
as proxies for outcomes. 
E.g. mortality should be  
a primary outcome.
 ‘Unnecessary variability…’ is  
a secondary outcome and is  
a proxy for … (what?)
If ‘Unnecessary variability’ is one 
of the outcomes, there should 
probably be many, 
many more outcomes than that.
3 On behalf 
of an 
organisation 
Outcomes in terms of harm have 
to be included: Overdiagnosis, 
overtreatment and false positive 
and false negative rates.
4 On behalf 
of an 
organisation 
Impact of interventions 
exclusively in screening is 
likely to be minimal in EU 
(most countries already have 
screening). To really have an 
impact, especially in mortality, 
this project should include 
treatment & organization of 
breast care.
Yes The Scope was modified –  
a footnote was added to the Target 
population section of The Scope 
to clarify that ‘the Guidelines 
Platform6, as collection of existing 
evidence-based guidelines, can 
include recommendations on 
treatment for all breast cancer 
patients’. 
Organisation of breast healthcare 
services will be covered by the 
European QA scheme.
Table 3. Comments on Expected outcomes: by respondents who replied with ‘I have 
concerns’
6  For recommendations on processes of care other than screening and diagnosis (treatment, rehabilitation, follow-up 
and survivorship care, palliative care, and all relevant horizontal aspects), an ECIBC platform for breast cancer 
guidelines (the Guidelines Platform) is envisaged to host existing evidence-based, high-quality guidelines.
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 As an 
individual
Is there an agreement on which 
women are eligible for breast 
cancer screening? Particular 
age groups? Across Europe, 
there are major differences in 
lower and upper age limits for 
screening.
No No change in The Scope.
This will be covered when selecting 
the PICO questions  
to be addressed.
2 As an 
individual
Women’s screening age – starts 
at 40? 45? 50? Ends at 70? 75?
3 As an 
individual
In my country screening 
population roughly covers 50% 
of all diagnosed breast cancers. 
More than 30% of women are 
older the age of 69 and quite 
often we hear that the age limit 
should be extended to at least 
the age of 75.
4 On behalf 
of an 
organisation 
It is important to explain the 
age for the target group to all 
women.
5 As an 
individual
It seems important for the 
European Guidelines to offer 
clear indications on the 
controversial theme of the 
mammographic screening and its 
optimal timing for women aged 
from 40 to 49 years and for the 
ones with 70 or more years.
6 As an 
individual
It must be made clear how 
women on High risk (BRCA1/2 
and other) will get access to 
screening. Usually it starts 
earlier and is done with 
mammography and MRI.
No No change in The Scope.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain  
risk factors.
7 On behalf 
of an 
organisation 
Groups to be covered: Since the 
guideline will not encompass 
women with hereditary 
breast cancer is it possible 
to insert if even a very short 
recommendation related to 
this issue necessary for better 
implementation of the screening 
program?
8 On behalf 
of an 
organisation 
Suggestion to add women with 
positive family history and also 
women under active surveillance 
who are eligible to come back 
into the screening cycle.
9 On behalf 
of an 
organisation 
Also high-risk groups who are 
eligible for surveillance should 
be pointed out as a group that 
will be covered. 
Table 4. Comments on Target population, groups that will be covered: 
by respondents who replied with ‘Generally, I agree’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
10 On behalf 
of an 
organisation 
Surveillance for high-risk women 
(not hereditary) is included and 
here it is not clear where they 
fit: is this screening?
Yes Relevant modifications in The 
Scope were made in order to 
clarify this issue: 1) surveillance 
for high-risk women is included 
in the section ‘Interventions 
not covered’; 2) the groups 
covered include ‘persons eligible 
for breast cancer screening 
and persons accessing breast 
diagnostic services because of 
symptoms, referral (e.g. following 
a risk assessment) or a recall 
on the basis of their screening 
examination’.
11 As an 
individual
What about opportunistic 
screening in women not eligible 
for breast cancer screening  
(I assume within  
a screening programme)?  
It is not necessarily done based 
on symptoms or a recall from  
a previous screening as far  
as I understand it.
No No change in The Scope.
Opportunistic screening has been 
already included in the draft scope 
sent for feedback, in the section 
‘Interventions covered’.
In addition there is a PICO 
question proposed about 
comparison of organised vs. non 
organised screening.
12 As an 
individual
Eligibility for breast cancer 
screening varies according to 
different policies and guidelines. 
The target population should 
be better specified or a note 
added to refer to subsequent 
definitions.
No No change in The Scope.
The target population will be 
clarified for each specific PICO 
(P=Population).
13 As an 
individual
I am not sure whether women 
attending diagnostic services 
because of symptoms/
signs should be in the target 
population.
No No change in The Scope.
Persons with symptoms are not in 
the screening process; however, 
they will be covered by the 
Diagnosis chapter questions.
14 As an 
individual
I suggest that a section (‘Women 
followed-up for breast cancer’) 
be devoted to the option of 
offering (or continue screening) 
to women with a prior diagnosis 
of breast cancer, either screen-
detected and/or detected outside 
the screening setting.
Yes The Scope was modified 
(Interventions not covered) to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part of 
the Guidelines Platform.
15 As an 
individual
I am not an expert in breast 
cancer management (my 
expertise is in research 
methods) so I cannot comment 
on the focus. I will however 
mention that excluding males 
does somewhat go against the 
aim of improving equity. Men do 
get breast cancer.
Yes The Scope was modified – 
‘women’ has been substituted 
with ‘persons’, because the 
Screening chapter will not cover 
men; however, the diagnostic 
procedures will cover any person 
with breast cancer (women and 
men).
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 As an 
individual
Please do not forget that there 
are also male breast cancer 
patients in the world. I am  
a male breast cancer survivor 
since 1999.
Yes The Scope was modified – 
‘women’ has been substituted 
with ‘persons’, because the 
Screening chapter will not cover 
men; however, the diagnostic 
procedures will cover any person 
with breast cancer (women and 
men).
2 On behalf 
of an 
organisation 
Missing population with high 
(!!!) risk of breast cancer 
due to BRCA mutation, PTEN, 
CDH1, CHEK2, Lynch or women 
Hodgkin/chest radiation
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
is among the interventions not 
covered by the European Breast 
Guidelines, but the groups covered 
include ‘persons accessing breast 
diagnostic services because of 
symptoms, referral (e.g. following 
a risk assessment) or a recall 
on the basis of their screening 
examination’.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
3 As an 
individual
Women eligible for breast cancer 
screening. Screening participants 
with breast cancer, regardless 
when they were diagnosed: 
during the screening process or 
following a negative screening 
episode and prior to the next 
screening examination.
Yes The Scope was modified 
(Interventions not covered) to 
clarify that:
-Diagnostic procedures in breast 
cancer patients with suspected 
recurrences or metastases during 
follow-up are not covered by 
the European Breast Guidelines, 
but are part of the Guidelines 
Platform.
- The groups covered include 
‘persons accessing breast 
diagnostic services because of 
symptoms, referral (e.g. following 
a risk assessment) or a recall 
on the basis of their screening 
examination’.
Table 5. Comments on Target population, groups that will be covered:  
by respondents who replied with ‘I have concerns’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 As an 
individual
Males should be included in the 
diagnostic phase
Yes The Scope was modified – 
‘women’ has been substituted 
with ‘persons’, because the 
Screening chapter will not cover 
men; however, the diagnostic 
procedures will cover any person 
with breast cancer (women and 
men).
2 As an 
individual
Although breast cancer in men is 
rare, I feel there should be some 
guidelines for male breast cancer 
as well.
3 As an 
individual
I am not an expert in breast 
cancer management (my 
expertise is in research 
methods) so I cannot comment 
on the focus. I will however 
mention that excluding males 
does somewhat go against the 
aim of improving equity. Men do 
get breast cancer.
4 On behalf 
of an 
organisation 
As male breast cancer is such 
rare disease frequently there 
is uncertainty about diagnostic 
procedures and male patients 
tend to have delayed diagnoses. 
I wonder if the ECIBC wants to 
reconsider the exclusion of male 
citizen from the project.
5 As an 
individual
If the guidelines involve both 
breast cancer screening and 
diagnosis, maybe also diagnosis 
in males could be considered 
although breast cancer in males 
is quite a peculiar and rare 
condition.
6 On behalf 
of an 
organisation 
If the program should be 
complex all patients afflicted by 
BC should be covered.
Yes The Scope was modified 
(Interventions not covered) to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part of 
the Guidelines Platform.
In addition, ‘women’ has been 
substituted with ‘persons’, 
because the Screening chapter 
will not cover men; however, the 
diagnostic procedures will cover 
any person with breast cancer 
(women and men).
7 On behalf 
of an 
organisation 
You will cover metastatic 
disease in sentinel node. Modify 
first sentence: Women with 
loco-regional and/or distant 
recurrences. Delete second 
sentence.
8 As an 
individual
Women with logo-regional 
recurrences can be included in 
the guidelines, because they 
present diagnostic problem and 
it is a local disease, requiring 
special approach.
Table 6. Comments on Target population, groups that will not be covered:  
by respondents who replied with ‘Generally, I agree’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
9 As an 
individual
The diagnosis of loco-regional 
recurrences needs also to be 
included certainly when first 
cancer was detected more than 
ten years earlier: whether it is  
a recurrence or not is not known 
by the first symptoms. 
10 As an 
individual
There could be links 
included what guidelines or 
recommendations should be 
followed in EU in case of loco-
regional or metastatic breast 
cancer (NCCN guidelines, 
Australian guidelines etc).
11 As an 
individual
How can we manage with 
women with second primary 
tumour (contralateral breast)?
12 As an 
individual
I would prefer including  
a short section focusing on the 
differences in diagnosing and 
treating patients belonging to 
these three categories [males, 
loco-regional recurrences, 
metastatic breast cancer] as 
compared with those having 
screen-detected cancers.
13 As an 
individual
I suppose that women with early 
stage breast cancer after 5 years 
of follow-up may follow routine 
screening thereafter.
No No change in The Scope.
Follow-up procedures and 
survivorship care will be covered 
by the Guidelines Platform.
14 As an 
individual
It is not clear if the issue 
of follow up of women with 
breast cancer (BC) is included 
in the guidelines. In my 
opinion that is an argument of 
crucial importance either from 
women’s or health care system 
perspective.
15 On behalf 
of an 
organisation 
It might be unclear where 
diagnosis ends and this should 
probably be defined early on. 
Not every reader will be able  
to understand that there is  
a distinction between diagnosis 
and surveillance after diagnosis 
and treatment. Especially 
because surveillance of high-risk 
groups is within the focus.
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
16 On behalf 
of an 
organisation 
The guideline must exclude the 
‘high risk patient’ group also, 
because after risk assessment 
the patient may have to get 
involved in a high risk screening 
programme.
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
is among the interventions not 
covered by the European Breast 
Guidelines, but the groups covered 
include ‘persons accessing breast 
diagnostic services because of 
symptoms, referral (e.g. following 
a risk assessment) or a recall 
on the basis of their screening 
examination’.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
17 On behalf 
of an 
organisation 
Add: hereditary breast cancer
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
16 On behalf 
of an 
organisation 
The guideline must exclude the 
‘high risk patient’ group also, 
because after risk assessment 
the patient may have to get 
involved in a high risk screening 
programme.
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
is among the interventions not 
covered by the European Breast 
Guidelines, but the groups covered 
include ‘persons accessing breast 
diagnostic services because of 
symptoms, referral (e.g. following 
a risk assessment) or a recall 
on the basis of their screening 
examination’.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
17 On behalf 
of an 
organisation 
Add: hereditary breast cancer
Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
Men also get breast cancer, I 
am not sure why they would 
not be included? There are 
many patients with metastatic 
breast cancer who need support, 
and appropriate facilities and 
services for their care; an area 
that is currently lacking.
Yes The Scope was modified – ‘women’ 
has been substituted with ‘persons’, 
because the Screening chapter 
will not cover men; however, the 
diagnostic procedures will cover 
any person with breast cancer 
(women and men).
2 As an 
individual
Why exclude male patients? 
There is no screening for men, 
but the diagnosis and treatment 
of male patients is almost 
the same as female patients. 
In Belgium the prognosis for 
male patients is worse than for 
women! Why discriminate?
3 On behalf 
of an 
organisation 
Males, while at a much lower 
risk of breast cancer, are 
not completely immune, and 
especially those with a strong 
family history of breast cancer 
should be covered by such 
programmes.
4 On behalf 
of an 
organisation 
Although screening does not 
apply to men perhaps a rationale 
could be given as to why men 
are excluded from the diagnostic 
piece.
5 On behalf 
of an 
organisation 
The Scope of the project is too 
limited to have a real impact. 
Unfortunately and as it is so 
common, metastatic patients are 
forgotten.
Yes The Scope was modified 
(Interventions not covered) to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part of 
the Guidelines Platform.
6 On behalf 
of an 
organisation 
Women with loco-regional 
recurrences should be added as 
they are often already back in 
the screening cycle after active 
surveillance. Guidelines should 
also be issued to specifically 
address the management of 
metastatic cancer.
7 On behalf 
of an 
organisation 
Risk persons should be covered 
(BRCA).
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
is among the interventions not 
covered by the European Breast 
Guidelines, but the groups covered 
include ‘persons accessing breast 
diagnostic services because 
of symptoms, referral (e.g. 
following a risk assessment) 
or a recall on the basis of their 
screening examination’. Some 
PICO questions may be related 
to varying the screening regimen 
depending on certain risk factors.
Table 7. Comments on Target population, groups that will not be covered:  
by respondents who replied with ‘I have concerns’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
It is complicated to handle 
different perspectives in one 
document. Providing  
a good balance between these 
perspectives might not be the 
right solution to handle this 
problem as compromises might 
not lead to the most optimal 
outcomes.
No No change in The Scope.
Each specific PICO will include 
the perspective taken. Every 
recommendation will be 
formulated in a different manner 
depending on the profile chosen 
(patient/citizen, policy maker/
healthcare professional). 
2 As an 
individual
Text: ‘the patients’ and 
clinicians’ perspective will be 
prioritised. This means that the 
focus will be on the views of the 
individual user of the healthcare 
service (citizens and patients) 
and the healthcare professional’ 
==> why ‘citizens and’?
Yes The Scope was modified and the 
phrase ‘citizens and patients’ has 
been substituted with ‘healthcare 
users’.
3 On behalf 
of an 
organisation 
It is not clear to me why 
‘clinicians perspective’ will 
be also prioritised in services 
outside the screening 
programme, but not inside the 
screening programme.
Yes The Scope was modified to clarify 
that: ‘For diagnostic services, 
especially when provided outside 
of a screening programme, the 
perspectives of healthcare users 
and clinicians are prioritised.’
In addition, each specific PICO will 
include the perspective taken.
4 On behalf 
of an 
organisation 
Missing honest information and 
explanation about overdiagnosis 
and harm. No overall mortality 
data. There is nothing wrong 
with not participating to 
screening. Give education about 
symptoms!!
No No change in The Scope.
Harms are included in each PICO 
question as outcomes. Desirable 
and undesirable effects are 
examined using EtD frameworks 
for each PICO in order to decide 
what the balance is, which might 
influence the direction of the 
corresponding recommendation.
5 As an 
individual
As the socioeconomic (and 
geographical) situation impacts 
the use of the recommended 
Guidelines importantly, this must 
be added (for ex: guideline for 
Invasive lobular ca is MRI but 
without availability MRI, another 
recommendation needs to be 
described.
No No change in The Scope
This is part of the implementation 
considerations that will be taken 
into account for each individual 
PICO.
6 On behalf 
of an 
organisation 
Will all settings for cancer 
screening, not only organized 
population-based programmes, 
be within The Scope? This 
is only made explicit for 
diagnostic procedures. 
Opportunistic screening and 
other interventions in chapter 5b 
should be included.
No No change in The Scope.
There is a proposal for a PICO 
question to compare organised vs. 
non- organised screening.
In addition, each individual PICO 
specifies the setting.
Table 8. Comments on clarity of perspective of the European Breast Guidelines 
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
7 On behalf 
of an 
organisation 
The legal framework and the 
centralized vision of users is 
not clear. Legal issues have 
a purpose as well as the fact 
that we screen and diagnose 
women for their well-being. 
Why do we do that or want to 
do that, because it’s unethical 
not to. Therefore your focus 
should primarily be on the 
ethical framework of necessity, 
proportionality and subsidiarity, 
because from there a legal 
as well as a women-centered 
framework will almost logically 
follow.
No No change in The Scope.
The legal framework is defined by 
the Council Recommendations. 
Ethical issues will be considered in 
each PICO question.
8 On behalf 
of an 
organisation 
We suggest to complement the 
2nd paragraph after ‘...for breast 
cancer’ (line 101) by ‘as well as 
on adequate evaluation.’
Yes Adequate evaluation of relevant 
programmes and services is now 
included in the Perspective section 
of The Scope.
9 As an 
individual
The text between the second 
and third paragraphs was 
rather unclear, particularly 
what distinction exactly was 
being drawn between these two 
paragraphs.
Yes The Scope has been modified in 
order to clarify the Perspective 
section.
74
Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 As an 
individual
So, both private and public 
healthcare services?
Yes The Scope was modified to 
clarify that ‘both private and 
public’ healthcare settings will be 
covered.
2 On behalf 
of an 
organisation 
It is also important to describe 
the connection between 
screening and diagnostic 
services.
Yes The Scope was modified to clarify 
that ‘breast cancer screening and 
breast cancer diagnostic services’ 
are covered.
The European Breast Guidelines 
will include recommendations on 
screening and diagnosis, but the 
connection/interfaces between 
different services will be covered 
in the European QA scheme. 
3 On behalf 
of an 
organisation 
Please take our response letter 
to your feed-back call into 
consideration. The institutes 
within the healthcare settings 
should be not only meeting 
the minimal requirements of 
ISO15189 but the increase 
of quality assurance given by 
ISO17020 should be taken into 
account and mentioned.
No No change in The Scope.
This will be covered by the 
European QA scheme.
4 As an 
individual
It should read ‘The European 
Breast CANCER Guidelines’
No No change in The Scope.
The word ‘cancer’ is part of the 
full version of the title (European 
Guidelines for breast cancer 
screening and diagnosis). The GDG 
discussed this point and agreed 
to keep the short version of the 
title as it is – European Breast 
Guidelines.
5 As an 
individual
In the guidelines themselves 
it would be useful to make it 
clear what impact contextual 
differences might have on the 
anticipated benefits of following 
a particular recommendation. 
Evidence generated in one 
context may, for example, show 
strong benefit but that benefit 
is heavily dependent on one 
or other contextual factor (e.g 
access to screening facilities). If 
those factors are not replicated 
in another context, then the 
anticipated benefit of following 
the recommendation may well 
be much less than the evidence 
would suggest. It would be good 
to be clear about this in the 
guidelines.
No No change in The Scope.
The European Breast Guidelines 
will include evidence-based 
recommendations. For some 
countries it may be difficult to 
implement them, but this issue 
has to be addressed in a proper 
way at a country level. 
Table 9. Comments on adequacy of healthcare settings covered by the European 
Breast Guidelines: by respondents who replied with: ‘Generally, I agree’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
6 As an 
individual
Has to acknowledge different 
health care systems in different 
member states – e.g. State 
Provider as per NHS and Private/
Insurance based system.
7 On behalf 
of an 
organisation 
Is it correct not to include the 
policy-making ‘setting’?
No No change in The Scope.
The European Breast Guidelines 
are being developed as a web-
based application and one of the 
profiles foreseen on the webpage 
is the policy maker, which will 
contain information, adapted to 
their needs.
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
Treatment should be included, 
the real outcome of screening 
program is not evaluable if one 
doesn’t consider treatment 
(above all: surgery) using the 
appropriate and already well 
established quality/performance 
indicators.
No No change in The Scope.
Treatment will be covered by the 
Guidelines Platform. Monitoring 
and evaluation chapter of the 
European Breast Guidelines will 
contain recommended thresholds 
of relevant indicators. In addition, 
quality will be covered by the 
European QA scheme.
2 On behalf 
of an 
organisation 
The first European guidelines on 
breast cancer screening included 
a section indicating the role 
of primary health care in the 
provision of patient centered 
information and support; as in 
organised programs patients 
generally are directly invited 
the informative role of the 
primary care team might be 
neglected; the role the primary 
care team has covers phases 
before screening (motivation 
phase; information of on 
invited), during screening and 
after symptomatic presentations 
or positive screening tests; 
moreover the third phase in 
the EU breast cancer initiative, 
i.e. treatment, and eventually 
also end of life are also phases 
primary care plays a role. These 
aspects therefore need also 
to be clarified and guidance 
provided on the role of the 
primary care team and the GP.
No No change in The Scope.
There are PICOs proposed in the 
Communication chapter that cover 
this issue. The general aspects of 
the role of general practitioners 
and primary care team, also 
in relation to treatment and 
end of life care, will be covered 
by the Guidelines Platform. In 
addition, Reference documents 
will be provided to support ECIBC 
implementation.
Table 10. Comments on adequacy of healthcare settings covered by the European 
Breast Guidelines: by respondents who replied with: ‘I have concerns’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
In some countries (usually with 
not existing public screening 
policy) screening is offered/
supported in private sector 
annually by private insurance 
policies or sponsored by 
companies to their eligible 
employees.
No No change in The Scope.
Such examinations are included 
in the definition provided in 
The Scope for non-programme 
screening.
2 On behalf 
of an 
organisation 
Is it to be publicly financed  
a necessary condition for  
a screening programme?
No No change in The Scope.
The definition provided in The 
Scope for programme screening 
refers to ‘examinations financed by 
public sources’.
3 On behalf 
of an 
organisation 
Mammography, Contrast 
Enhanced Spectral 
Mammography (CESM), DBT, 
Automated Breast Ultrasound 
or MR are useful for further 
investigation. Clinical practice 
is moving more towards 
personalized screening.
No No changes in The Scope.
Some PICO questions have been 
proposed on different imaging 
techniques.
4 As an 
individual
Use the term ‘Opportunistic 
screening’ rather than ‘non-
programme screening’. Please 
add: ‘it is more likely to result 
in variability in the definition 
criteria of the eligible individuals 
and in the quality of the 
screening process’.
No No change in The Scope.
Non-programme screening 
is commonly referred to as 
opportunistic screening, as 
described in the definition from the 
reference provided.
5 As an 
individual
For me it is not clear what is the 
difference between ‘screening’ 
and ‘screening programme’.
Yes The Scope was modified to present 
the definitions for screening, 
programme screening, organised 
screening and population-based 
screening, as described in the 
reference provided. 
6 On behalf 
of an 
organisation 
This section could be made 
clearer. For example the UK 
national breast cancer screening 
programme is organised, 
population based, financed from 
public sources and the primary 
test is defined. The programme 
appears to include most of the 
above.
7 On behalf 
of an 
organisation 
The Definitions of the population 
based screening program and 
organized screening program 
could be made more clear.
8 As an 
individual
In the very last sentence I 
would prefer the term ‘screening 
abnormality’ and not ‘screening 
mammography abnormality’ 
as this solution would open for 
the possibility of screening with 
other methods.
Yes The Scope was modified 
accordingly. 
In addition, there will be PICO 
questions about different 
modalities used for screening. 
*  All comments provided by respondents regarding these definitions will be made available to the 
International Agency for Research on Cancer for possible consideration when update of the definitions  
is envisaged.
Table 11. Comments on proposed definitions in The Scope regarding types  
of interventions: respondents who replied with ‘Generally I agree’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
The proposed definitions don’t 
really match to the main aspect 
of a screening that is, firstly in 
the perspective of women and 
then in the health services’ and 
the professionals ones, that of  
a pathway.
Yes The Scope was modified to present 
the definitions for screening, non-
programme screening, programme 
screening, organised screening 
and population-based screening 
as described in the reference 
provided. 
The different perspectives will 
be taken into account in the 
formulation of recommendations. 
2 On behalf 
of an 
organisation 
The definitions used are 
not intuitive logical. In de 
Dutch situation, a screening 
programme is also organized 
and population-based.
3 As an 
individual
To define a non-programme 
screening as ‘opportunistic’ is 
quite punitive especially for 
those asymptomatic women 
that ask for a mammogram 
in country or a region where 
an organized screening is not 
available. I propose to use the 
word ‘spontaneous’.
4 On behalf 
of an 
organisation 
It is difficult without the 
context to see how good these 
definitions are. For many 
readers the differences will 
probably seem only semantics 
without describing what the real 
differences are and why this is 
important.
5 On behalf 
of an 
organisation 
Line 140/143 need rewording – 
screening can be used to detect 
pre-malignant lesions, not just 
cancer.
6 On behalf 
of an 
organisation 
1. Women with unclear imaging
also need further investigation 2. 
Screening programme can also 
be performed in a clinical setting 
3. Please provide a clearer
definition of coordination 
4. Invitation should not be
compulsory (e.g. invitation 
letter).
No No change in The Scope.
Topics related to referral for 
further investigation, coordination 
and invitations will be covered 
by some PICOs and also by the 
Guidelines Platform.
*  All comments provided by respondents regarding these definitions will be made available to the International
Agency for Research on Cancer for possible consideration when update of the definitions is envisaged.
Table 12. Comments on proposed definitions in The Scope regarding types of 
interventions: respondents who replied with ‘I have concerns’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
Delete: The diagnostic 
procedures for benign lesions. 
We do not know in beforehand if 
the lesion is benign. Procedures 
for malignant/benign are the 
same till the pathological 
examination and result.
No No change in The Scope.
All examinations undertaken 
following referral and prior to 
treatment have already been 
considered in The Scope, including 
also diagnostic procedures for 
benign lesions.
Harms are included in each PICO 
question as outcomes. Desirable 
and undesirable effects are 
examined using EtD frameworks 
for each PICO in order to decide 
what the balance is, which might 
influence the direction of the 
corresponding recommendation.
2 On behalf 
of an 
organisation 
The diagnostic procedures 
for benign lesions. When to 
call a lesion benign, at clinical 
examination, at imaging or at 
pathology?
3 On behalf 
of an 
organisation 
Why diagnostic procedures 
for benign lesions only will 
be covered? What kind of 
procedures are you referring to: 
to diagnose?, to characterize? 
a benign lesion. Harms are a hot 
topic we need to address, but 
also interventions to improve 
benefit?
4 As an 
individual
Why ‘diagnostic... for benign 
lesions’: just say all lesions. Add 
after ‘clinical recommendations 
about interventions’: related to 
the socioeconomic situation of 
the health care service in the 
country.
No No change in The Scope.
All examinations undertaken 
following referral and prior to 
treatment have already been 
considered in The Scope.
Resource use and cost-
effectiveness are examined using 
EtD frameworks for each PICO. 
In addition, socio-economic 
considerations will be some of the 
implementation considerations to 
be taken into account at a country 
level.
5 On behalf 
of an 
organisation 
Evaluate both benign and 
suspicious lesions, communicate 
beyond the month of October 
to patients, educate physicians 
on new modalities, provide 
information on low dose 
screening with DBT and ABUS. 
Use CESM for cost effective 
diagnosis. Consider one breast 
stop units.
No No change in The Scope.
All examinations undertaken 
following referral and prior to 
treatment have already been 
considered in The Scope.
Communication, training and 
imaging modalities will be 
addressed in some PICOs in the 
pertinent chapters.
Organisation of breast cancer care 
(breast units) will be covered by 
the European QA scheme.
6 As an 
individual
Diagnostic procedures during the 
surgery should be considered 
within the surgical treatment.
No No change in The Scope.
These procedures will be covered 
by PICO questions in the Diagnosis 
chapter.7 On behalf 
of an 
organisation 
Diagnostic procedures during the 
surgery should be considered 
within the surgical treatment.
Table 13. Comments on interventions that will be covered by the European Breast 
Guidelines: respondents who replied with ‘Generally I agree’
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Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
8 On behalf 
of an 
organisation 
I would not include surgical 
Sentinel Lymph Node Biopsy 
in this point. I would include 
only FNA or Core biopsy 
(+/- ultrasound guidance) of 
suspicious axillary nodes.
No No change in The Scope.
All biopsy procedures and their 
pathological examination have 
been already considered in The 
Scope, including Sentinel Lymph 
Node Biopsy (SNLB).
Several PICO questions are 
proposed on different diagnostic 
procedures.
9 As an 
individual
It is not clear why it will be 
considered the ‘lymph node 
excision by sentinel node biopsy 
and pathological evaluation 
of the lymph node evacuation 
specimens will be covered’? 
This is part of breast cancer 
treatment.
10 As an 
individual
Whilst not routine there should 
also be availability of Vacuum 
Assisted Biopsy?
11 On behalf 
of an 
organisation 
This assumes the patient 
will have surgery as a first 
treatment. Patients may also 
have neoadjuvant chemotherapy 
may not have surgery at all or 
refuse any treatment. Suggest 
using ‘after referral and before 
definitive management is 
recommended’.
Yes The Scope is modified accordingly: 
‘following referral and prior to 
treatment’.
The interfaces between different 
services will be covered by the 
European QA scheme.
12 On behalf 
of an 
organisation 
Some patients will have as 1st 
treatment, systemic therapy and 
not surgery; imaging techniques 
for neoadjuvant approaches 
should be included. Crucial 
is also the link to treatment 
facilities; it must be included 
how and to whom refer patients. 
13 On behalf 
of an 
organisation 
I would strongly encourage 
for an optimal time period 
for the mentioned keeping of 
mammograms to be concocted 
and made available to countries 
carrying out screening programs, 
as well as devoting a number 
of pages to evidence, data 
collection.
No No change in The Scope.
There are PICO questions on 
different imaging modalities and 
implementation considerations are 
considered in the EtD frameworks 
for each PICO.
Issues on data management 
should be a part of Reference 
documents that will be provided to 
support ECIBC implementation.
14 As an 
individual
One of the main risk factors 
is familial predisposition. If 
gene testing is costly, at least 
the guidelines have to provide 
description of the familial breast 
cancer risk in the context of 
surveillance and screening.
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
is among the interventions not 
covered in The Scope. 
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.15 As an 
individual
For asymptomatic high-risk 
women a tailored screening 
should be considered. More 
frequent screening or additional 
screening test.
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16 As an 
individual
The section on interventions to 
reduce harms must include the 
reduction of psychological harm 
as the potential for this is very 
great.
No No change in The Scope.
Desirable and undesirable 
anticipated effects are examined 
using EtD frameworks for each 
PICO. However, benefits and 
harms are convenient terms for 
general use.
17 As an 
individual
I suggest considering ‘undesired 
effects’ or a similar expression, 
rather than ‘harms’ in relation to 
breast cancer screening. ‘Harms’ 
suggests the idea of something 
that is voluntarily wrong; also, I 
should not describe ‘discomfort’ 
as harm.
18 On behalf 
of an 
organisation 
I understand the legal basis for 
the guidelines, but inclusion 
of metastatic disease if at all 
possible would be good.
Yes The Scope was modified 
(Interventions not covered) to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part of 
the Guidelines Platform.
19 On behalf 
of an 
organisation 
We would like to add, again, 
that not only women should be 
covered by such programmes.
Yes The Scope was modified – 
‘women’ has been substituted 
with ‘persons’, because the 
Screening chapter will not cover 
men; however, the diagnostic 
procedures will cover any person 
with breast cancer (women and 
men). 
20 As an 
individual
I was particularly pleased to 
see the interventions linked to 
communication in this list. I also 
think it would be useful to clarify 
what is meant by ‘interventions’.
No No change in The Scope.
All specific interventions 
will be defined in each PICO 
(I=Intervention).
21 On behalf 
of an 
organisation 
Please take our response letter 
to your feed-back call into 
consideration. The institutes 
carrying out such procedures 
should be not only meeting the 
requirements of ISO15189 but 
the increase of QA given by 
ISO17020 should be mentioned.
No No change in The Scope.
This will be covered by the 
European QA scheme.
22 On behalf 
of an 
organisation 
Mainly the chain of care between 
the interventions is missing. 
This is underlined as well 
because the order in which the 
interventions are presented 
isn’t logical. Why is surveillance 
put after diagnosis and primary 
prevention after that?
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
and surveillance in women with 
hereditary breast cancer is among 
the interventions not covered in 
The Scope. 
A pathway of care has been 
defined so each intervention is 
clearly referred to a particular step 
in the pathway – a figure about 
breast cancer care pathway is now 
included in the section Purpose of 
The Scope.
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23 As an 
individual
The question is whether the 
level of ‘obligation’ versus ‘free 
advices’ can be the same for all 
aspects. This should be made 
very clear.
No No change in The Scope.
The European Breast Guidelines 
will contain evidence-based 
recommendations and their 
implementation has to be 
addressed in a proper way at 
a country level.
Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 As an 
individual
Preoperative prognostic and 
predictive evaluation besides 
diagnosis. Diagnostic evaluation 
must include also postoperative 
pathological aspects not 
covered preoperatively: 
margins, grading, pTNM, other 
immunohistochemical markers, 
molecular tests.
No No change in The Scope.
Some PICO questions in the 
Diagnosis chapter may cover this.
This will be also covered by 
the Guidelines Platform or by 
Reference documents that will 
be provided to support ECIBC 
implementation.
2 As an 
individual
The pathological parameters 
as evaluated in the surgical 
specimen represent the most 
important feed-back for the 
radiologist. The guidelines 
should contain definitions 
of histological multifocality, 
tumor size, disease extent and 
heterogeneity.
3 On behalf 
of an 
organisation 
1) Criteria for referral of 
screening detected lesions 
(not symptomatic) is missing. 
2) Purpose of ‘diagnostic 
procedures for benign 
lesions’ unclear. 3) Purpose of 
‘Evaluation of different methods 
for diagnosis and preoperative 
staging’ unclear.
Yes The Scope was modified to include 
‘pre-treatment staging’, not only 
‘pre-operative staging’.
Some PICO questions in the 
Diagnosis chapter may cover these 
issues, together with Reference 
documents that will be provided to 
support ECIBC implementation.
4 On behalf 
of an 
organisation 
(including 
any 
association, 
authority, 
company or 
body)
The 2nd definition is problematic 
as some pre-surgical 
‘examinations’ are only done 
in the context of neo-adjuvant 
therapy. A definition around ‘...
examinations undertaken after 
referral and before treatment 
initiation or surgery’ is more 
appropriate.
Yes The Scope was modified to include 
examinations prior to treatment.
Table 14. Comments on interventions that will be covered by the European Breast 
Guidelines: respondents who replied with ‘I have concerns’
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5 As an 
individual
I’d like to remind you the 
CESM examination as a valid 
alternative to MRI.In fact its 
diagnostic accuracy is recognized 
(see literature).CESM is also 
quick,simple,well tolerated and 
it has lower false positives than 
MRI (that is very expensive).
No No change in The Scope.
There are PICO questions on 
other imaging modalities in the 
Screening and Diagnosis chapter. S
6 On behalf 
of an 
organisation 
Ignoring women with high risk 
of breast (and ovarian) cancer. 
(BRCA, CDH1, Cowden, Lynch, 
CHEK2, Ashkenazi Jewish roots 
and radiation after Hodgkin).  
A European approach to find 
high risk families is necessary. 
Here lives can be really saved.
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
and surveillance in women with 
hereditary breast cancer is among 
the interventions not covered in 
The Scope. 
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
7 On behalf 
of an 
organisation 
High-risk women are not 
defined. 
Interventions for primary 
prevention are out of The Scope 
of ‘screening and diagnosis’. As 
important topic they should have 
a place in the guideline platform. 
Add interventions increasing 
benefit?
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
and surveillance in women with 
hereditary breast cancer is among 
the interventions not covered in 
The Scope. 
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors. 
Interventions for primary 
prevention of breast cancer were 
already included in the draft 
scope sent for feedback as co-
interventions nested in organised 
screening programmes.
Desirable and undesirable 
anticipated effects are examined 
using EtD frameworks for each 
PICO in order to decide what the 
balance is.
8 As an 
individual
Also intermediate risk should 
be included. Why high-risk 
is included and women with 
hereditary predisposition are 
excluded? What’s the difference 
between screening and 
surveillance? Also false positive 
recall may be an example of 
harm.
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1 On behalf 
of an 
organisation 
It would be good to include the 
diagnosis of metastatic disease.
Yes The Scope was modified to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part  
of the Guidelines Platform.
2 As an 
individual
Diagnostic procedures in women 
with suspected recurrences 
have to be included, because 
this is important for treatment 
decision.
3 As an 
individual
As mentioned before the issue of 
follow up is crucial.
4 On behalf 
of an 
organisation 
Add Diagnostic procedures in 
breast cancer patients with 
suspected recurrences (Groups 
that will be covered specified 
above).
5 As an 
individual
I agree. So the focus is only 
on first primary breast cancer: 
should this be specified 
somehow in the title of the 
guideline?
6 On behalf 
of an 
organisation 
Again here it should be pointed 
out that not everybody will 
understand the difference 
between surveillance of high-risk 
groups and the surveillance after 
diagnose and treatment.
Yes The Scope was modified to clarify 
that:
-  aspects, related to follow-up and 
survivorship are not covered by 
the European Breast Guidelines, 
but are part of the Guidelines 
Platform. 
-  surveillance of high-risk women 
will not be specifically addressed 
by the European Breast 
Guidelines.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
7 As an 
individual
I feel sorry some steps of 
breast cancer treatment are 
out of The Scope (e.g. surgical 
management of detected 
lesions). The initial EC guidelines 
highlighted the importance of 
the multi-step multidisciplinary 
procedures.
No No change in The Scope.
This will be covered by the 
Guidelines Platform, which will 
include recommendations from 
evidence-based existing guidelines 
on all breast cancer care 
processes, including treatment 
regimens.
8 As an 
individual
Today the process of diagnostics 
and the one of treatment are 
closely related, especially for 
molecular diagnostics (we use 
the term ‘theranostics’).
Table 15. Comments on interventions that will not be covered by the European 
Breast Guidelines: respondents who replied with ‘Generally I agree’
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9 As an 
individual
The pathological parameters 
as evaluated in the surgical 
specimen represent the most 
important feed-back for the 
radiologist. The guidelines 
should contain a definitions 
of histological multifocality, 
tumor size, disease extent and 
heterogeneity.
No No change in The Scope.
Some PICO questions in the 
Diagnosis chapter may cover this. 
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
10 As an 
individual
There could be links 
included what guidelines or 
recommendations should be 
followed in EU
No No change in The Scope.
For screening and diagnosis the 
recommendations to be followed 
will be those included in the 
European Breast Guidelines. 
In addition, the Guidelines 
Platform, will include 
recommendations from evidence-
based existing guidelines on all 
breast cancer care processes, 
including treatment regimens.
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1 As an 
individual
Pathological diagnostic 
evaluation of metastases and 
recurrences must be in The 
Scope once the samples are 
available.
Yes The Scope was modified to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part of 
the Guidelines Platform. 
2 On behalf 
of an 
organisation 
Diagnostic procedures in breast 
cancer patients with suspected 
recurrences should be covered 
(Groups that will be covered 
specified above)
3 As an 
individual
Screening of women who had  
a previous BC (the most relevant 
group of women at intermediate 
risk) should be included in The 
Scope. In other words, what is 
the limit between follow-up and 
(re-) screening women with  
a previous BC history?
Yes The Scope was modified to clarify 
that:
- aspects, related to follow-up and 
survivorship are not covered by 
the European Breast Guidelines, 
but are part of the Guidelines 
Platform. 
- surveillance of high-risk women 
will not be specifically addressed 
by the European Breast Guidelines.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
4 On behalf 
of an 
organisation 
Treatment should be included. 
Otherwise we’ll be able only to 
evaluate process and output 
indicators (for instance: 
adherence or the number of 
women referred to treatment).
Yes The Scope was modified to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up 
are not covered in The Scope of 
the European Breast Guidelines, 
but are part of the Guidelines 
Platform.
In addition, the Guidelines 
Platform, will include 
recommendations from evidence-
based existing guidelines on all 
breast cancer care processes, 
including treatment regimens.
5 On behalf 
of an 
organisation 
Please see above my deep 
concerns about the very small 
impact of this project if not 
tackling treatment and the 
whole breast cancer spectrum. 
Particularly worrisome is the 
continuous abandonment of 
metastatic patients.
6 As an 
individual
Screen-detected breast cancer 
surgery should be covered, too. 
The existing EU guidelines have 
Quality assurance guidelines for 
surgery. The surgery of clinically 
occult breast cancers differs 
from symptomatic cancers 
surgery.
7 As an 
individual
As noted above, I recommend 
to include follow-up among the 
topics to be covered; not in all 
its implications, but at least as 
far as may be dealt with in  
a screening/diagnostic unit: i.e., 
repeat mammography mainly
Table 16. Comments on interventions that will not be covered by the European 
Breast Guidelines: respondents who replied with ‘I have concerns’
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8 On behalf 
of an 
organisation 
Guidelines – Platform This seems 
to me a rather bureaucratic and 
irrational approach. Instead, 
you should call Guidelines 
A: Screening, Diagnostic… 
and Guidelines B: treatment, 
rehabilitation... Full text 
comment will be sent separately.
Yes A pathway of care has been 
defined so each intervention is 
clearly referred to a particular step 
in the pathway – a figure about 
breast cancer care pathway is now 
included in the section Purpose of 
The Scope.
Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
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1 On behalf 
of an 
organisation 
Professional bodies/associations 
for example in the UK the 
Royal College of Pathologists; 
Royal College of Radiologists; 
The Society and College of 
Radiographers; The Royal 
College of Nursing.
Yes The Scope was modified to include 
professional bodies, associations 
and academic societies.
2 As an 
individual
I do suppose that the 
‘Healthcare provider’ do include 
the people involved in the 
treatment as well? If not, I have 
a concern.
Yes The Scope was modified to include 
an extended list of healthcare 
providers.
3 As an 
individual
Patients’ advocates could also be 
included as stakeholders. 
Yes The Scope was modified to 
include patients’ organisations, 
breast cancer support groups, 
other voluntary organisations and 
charities.
4 On behalf 
of an 
organisation 
I suggest the inclusion of patient 
advocacy groups, support 
groups and other voluntary 
organisations as stakeholder.
5 As an 
individual
Not explicitly mentioned patient 
advocacy groups. This should be 
done.
6 On behalf 
of an 
organisation 
Psychological support should be 
useful.
7 On behalf 
of an 
organisation 
In an ageing population, it is 
important that all care givers, 
and in particular long term 
carers, are aware of options.
No No change in The Scope.
Carers were already included in 
the draft scope sent for feedback.
8 On behalf 
of an 
organisation 
Add (1) Healthcare modalities 
and solutions suppliers (2) 
families of women with breast 
cancer (3) breast cancer 
charities (4) academic societies 
(5) manufacturers of imaging 
and interventional equipment. 
Yes The Scope was modified to include 
the suggested groups.
Table 17. Comments on the proposed list of stakeholders and users: respondents 
who replied with ‘Generally I agree’
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9 On behalf 
of an 
organisation 
Add breast cancer charities, 
academic societies, as well as 
manufacturers of imaging and 
interventional equipment and 
more importantly families of 
women with breast cancer.
10 On behalf 
of an 
organisation 
For diagnosis services also men 
should be considered; if the 
guidelines are only screening-
centred, the focus on women is 
clear for us.
Yes The Scope was modified – ‘women’ 
has been substituted with 
‘persons’, because the Screening 
chapter will not cover men; 
however, the Diagnosis chapter 
will cover procedures for any 
person with breast cancer (women 
and men).
11 As an 
individual
Diffusion of the documents to 
the women and health care 
professionals were not so easy 
with the previous EC guidelines. 
This should be improved with the 
new working group.
No No change in The Scope.
Dissemination of the 
recommendations will be 
emphasised by the EC.
Sequence 
number
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1 On behalf 
of an 
organisation 
Genetic counsellors (for women 
with high risk) – Patient 
organizations – Epidemiologists 
(and not only the ones with 
conflicting interests concerning 
screening) – Oncologists and 
oncological researchers with 
more knowledge of ‘early 
detection’.
Yes The Scope was modified to include 
the suggested groups.
2 On behalf 
of an 
organisation 
We presume it is important 
to highlight communication 
between oncology, gynaecology 
specialists and the primary 
care team; as such I would 
recommend to add specifically 
gynaecologists and oncologists 
in the list under 2.
3 On behalf 
of an 
organisation 
Guidelines are not focused at 
potential participants or patients, 
they are focused on healthcare 
workers and policy makers. 
Putting the users central means 
you seek their perspective when 
formulating a guideline, you e.g. 
don’t look at the clinically best 
(screening or diagnostic) test 
but at the best test given the 
acceptability to the users.
Table 18. Comments on the proposed list of stakeholders and users: respondents 
who replied with ‘I have concerns’
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1 As an 
individual
In addition to a systematic 
research for guidelines and 
recommendations, I would like 
to add that research papers on 
the effect of screening and the 
excellent meta-analysis of the 
previously performed RCTs by 
Cochrane (Gotsche etal) should 
be used.
Yes A note was added in The Scope 
clarifying that the presented 
bibliography is a brief list of 
documents, used to prepare The 
Scope. All literature, used to make 
the recommendations, will be 
included in the ECIBC’s web-hub.
For the European Breast 
Guidelines, the literature review 
team was externalised to ensure 
an independent approach and 
minimise potential conflict of 
interest. The Iberoamerican 
Cochrane Centre, Barcelona, will 
carry out the literature reviews 
for each specific PICO and will 
consider systematic reviews (if 
already available) or will carry out 
de-novo ones. 
In addition, the Guidelines 
Platform, will include 
recommendations from evidence-
based existing guidelines on all 
breast 
2 On behalf 
of an 
organisation 
I would recommend to not 
only use EU oriented papers, 
but also local ‘best practices’ 
from different countries. 
You might want to consider 
the guidelines by the Health 
Council of the Netherlands 
(www.gezondheidsraad.nl/
en) en de RIVM (www.RIVM.
nl/en). You may ask me for 
these documents, but you could 
already have some of these 
documents as I sent them 
before.
3 As an 
individual
Many other documents, 
especially at the national level, 
do exist.
4 On behalf 
of an 
organisation 
Publications from established 
national screening programmes 
in the UK and possibly other 
countries that also have similar 
documents.
5 On behalf 
of an 
organisation 
CESM in patients referred from 
the breast cancer screening 
programme by Lobbes M.B, 
et al, European radiology, 
July 2014, volume 24, Issue 
7, pp 1668-1676. J-Star: 
Japan Strategic Anti-cancer 
Randomized Trial, Lancet. 2015 
Nov 4.
6 On behalf 
of an 
organisation 
Consider CESM in patients 
referred from the breast cancer 
screening programme by Lobbes 
M.B, et al, European radiology, 
July 2014, volume 24, Issue 7, 
pp 1668-1676.
J-Star: Japan Strategic Anti-
cancer Randomized Trial, Lancet. 
2015 Nov 4.
Table 19. Comments on the proposed list of existing documents: respondents who 
replied with ‘Generally I agree’
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7 As an 
individual
Perhaps the recommendation 
of The Breast Health Global 
Initiative (BHGI) in Cancer, 
Supplement: Guidelines for 
International Breast Health and 
Cancer Control–Implementation 
15 October 2008 Volume 113, 
Issue S8 should be added to the 
documents.
8 As an 
individual
Although the Marmot Report on 
Breast Screening referred only 
to the NHS Breast Screening 
Programme in England, the 
report is relevant to any review 
of guide panel did review all 
currently available evidence and 
is more recent and should be 
included.
9 On behalf 
of an 
organisation 
EUSOMA position paper: Quality 
indicators in breast cancer care. 
M. Rosselli Del Turco. European 
Journal of Cancer vol. 46, 2344 
– 2356, 2010.
10 On behalf 
of an 
organisation 
Several other guidelines are 
missing. It will be important to 
see the full list after JRC search.
Yes A note was added in The Scope 
clarifying that the presented 
bibliography is a brief list of 
documents, used to prepare The 
Scope. All literature, used to make 
the recommendations, will be 
included in the ECIBC’s web-hub.
In addition, the Guidelines 
Platform, will include 
recommendations from evidence-
based existing guidelines on all 
breast cancer care processes.
11 As an 
individual
There are, of course, national 
guidelines in some countries 
and perhaps it would be good to 
refer to them where appropriate.
12 As an 
individual
Performance indicators in 
‘European guidelines for... 
2006’ need to be adjusted with 
Supplement – reviewed with 
novelties in radiology, surgery 
and pathology, reviewed in the 
light of best clinical practice.
No No change in The Scope.
This will be part of the Monitoring 
and Evaluation chapter of the 
European Breast Guidelines. 
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1 On behalf 
of an 
organisation 
As the EU guideline is addressed, 
EU must show its will and effort 
in lean quality management 
of screening programmes. As 
it is complicated it is harder 
to implement. The major 
targets for screening must be 
determined. The necessity and 
the recommended interval of the 
screening must be determined.
No No change in The Scope.
The Monitoring and Evaluation 
chapter of the European Breast 
Guidelines will cover this, together 
with the European QA scheme. 
2 On behalf 
of an 
organisation 
I have concerns about the 
quality assurance aspects such 
as performance indicators. It 
is mentioned that they will be 
addressed in both (EU guidelines 
and accreditation scheme). 
It will be difficult to avoid 
redundancy and ensure easy 
access and referral (what is 
written down in which document 
and why).
Sequence 
number
Type of 
response
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 On behalf 
of an 
organisation 
Please refer to earlier documents 
as well highlighting role of 
primary care team.
Yes A note was added in The Scope 
clarifying that the presented 
bibliography is a brief list of 
documents, used to prepare The 
Scope. All literature, used to make 
the recommendations, will be 
included in the ECIBC’s web-hub.
For the European Breast 
Guidelines, the literature review 
team was externalised to ensure 
an independent approach and 
minimise potential conflict of 
interest. The Iberoamerican 
Cochrane Centre, Barcelona, will 
carry out the literature reviews 
for each specific PICO and will 
consider systematic reviews (if 
already available) or will carry out 
de-novo ones.
2 On behalf 
of an 
organisation 
The lists continues to use the old 
way of looking at early detection 
in breast cancer. At least ask 
Peter Gotzsche, Gilbert Welch, 
Luc Bonneux, Archie Bleyer etc 
etc for their opinion. Critics have 
been ignored for too long.
Table 21. General comments regarding The Scope
Table 20. Comments on the proposed list of existing documents: respondents who 
replied with ‘I have concerns’
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3 On behalf 
of an 
organisation 
Population-based breast cancer 
screening predominantly 
aims at a reduction of cancer 
related mortality. Therefore 
the evaluation of outcome, the 
importance of adequate and 
available data like regionalized 
participation rates and the 
requirement of population-
based cancer registry data 
should be mentioned in The 
Scope, possibly in the context of 
expected outcomes.
4 On behalf 
of an 
organisation 
Please take our response letter 
to your call for feedback for The 
Scope of the European guidelines 
for breast cancer screening and 
diagnosis into consideration as 
it is our common goal to ensure 
the highest standard of care. 
Meeting the requirements of 
ISO15189 is the minimum but 
the increase of QA given by 
ISO17020 should be taken into 
account and mentioned. Any 
decision in such a leading area 
of expertise should be made 
with utmost care since it might 
set precedence for other cancer 
entities.
No No change in The Scope.
This will be covered by the 
European QA scheme.
5 On behalf 
of an 
organisation 
Some chapters mentioned 
(training, monitoring and 
evaluation), mainly related 
to quality issues and quality 
assurance are not further 
specifically mentioned in this 
document. Quality assurance 
is crucial maximize benefits/
reduce harms. It is not clear to 
me at this point, with no detailed 
information on the EQA Scheme 
proposal, how EQAS and EBG 
will complement each other, and 
which of the ‘missed’ quality 
assurance topics (organization, 
interventions, etc.) will be finally 
addressed.
No No change in The Scope.
A text was already included in the 
draft scope that ‘the ECIBC aims to 
ensure and harmonise the quality 
of breast cancer services across 
European countries via a quality 
assurance scheme for breast 
cancer services underpinned by 
evidence-based guidelines’. 
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6 On behalf 
of an 
organisation 
Keeping in mind that the 
guideline should and will focus 
on the quality assurance aspects 
of breast cancer screening and 
its diagnosis, it would also prove 
helpful to offer a scheme and/
or table explaining a minimal 
threshold for the quality of 
screening and tips on how 
to obtain it. The training and 
licensing of radiology specialists 
that are to be preforming 
screening mammography 
(first and second readers of 
mammograms, radiologists, 
supervisors), and training 
curricula for it.
No No change in The Scope.
The Monitoring and evaluation 
chapter of the European Breast 
Guidelines will provide a list of 
relevant performance indicators 
with their recommended 
thresholds.
The Training chapter of the 
European Breast Guidelines will 
contain recommendations for 
radiologists.
Licensing of specialists will be 
tackled by the European QA 
scheme and Reference documents 
that will be provided to support 
ECIBC implementation.
7 On behalf 
of an 
organisation 
The project seems to be 
ambitious, however existing 
different health systems in EU 
countries should be respected.
No No change in The Scope.
The European Breast Guidelines 
will contain evidence-based 
recommendations and 
implementation considerations are 
considered in the EtD frameworks 
for each PICO. However, their 
implementation has to be 
addressed in a proper way at  
a country level.
8 On behalf 
of an 
organisation 
The objectives are very 
ambitious. The objectives focus 
on different target groups that 
have different needs in terms of 
content, detailing and language 
use. It will be difficult to provide 
the different target groups 
with adequate information 
simultaneously, and taking the 
differences between countries 
into account. For this reason, I 
also have concerns to realizing 
the outcomes. Besides the 
guideline aims to target different 
cultural backgrounds and has 
to deal with different health 
systems.
No No change in The Scope.
The European Breast Guidelines 
will include evidence-based 
recommendations, also 
considering different population 
subgroups, such as socially 
disadvantaged, illiterate, etc. In 
addition, the recommendations 
will be translated into lay-
person language, in order 
to be understandable by all. 
Implementation considerations, 
taking into account differences 
in healthcare systems, are 
considered in the EtD frameworks 
for each PICO. However, they have 
to be addressed in a proper way at 
a country level.
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9 As an 
individual
The Breast Health Global 
Initiative (BHGI) defines in 
Cancer, Supplement: Guidelines 
for International Breast 
Health and Cancer Control–
Implementation 15 October 
2008 Volume 113, Issue S8 
different levels of screening 
for breast cancer according 
to the socio-economic status 
of the region/country. It is 
very important to consider 
the recommendations of this 
group into the European ones 
as for a lot of countries, not all 
diagnostic imaging and care 
(including breast nurses etc.) 
are available.
10 On behalf 
of an 
organisation 
In order for the document to be 
of a high quality, there is a need 
to include in the guidelines the 
differences that appear among 
European countries in terms 
of health care system as well 
as include the possible ways of 
creating legal tools that could 
allow making European countries 
to apply and implement 
guidelines into health care 
systems in these countries.
11 On behalf 
of an 
organisation 
Given that accreditation in the 
field of medicine is voluntary in 
the Republic of Serbia it is  
a good idea that it is mentioned 
under Perspective that the 
European Breast Guidelines took 
into consideration the EU legal 
background, whereas this will 
help the national policy-makers 
implement the cancer screening 
programmes.
No No change in The Scope.
Implementation considerations are 
considered in the EtD frameworks 
for each PICO. However, they have 
to be addressed in a proper way  
at a country level.
In addition, the European QA 
scheme will tackle the issues 
related to accreditation.
12 On behalf 
of an 
organisation 
Mainly a synopsis: use the 
ethical concepts of necessity, 
proportionality and subsidiarity 
as a framework and from there 
it will naturally follow that the 
users are put central. The Scope 
really is your basis and still 
needs work to become more 
focused.
Yes The Scope was modified (Key 
stakeholders and users) to 
clarify that the European Breast 
Guidelines are ‘person-centred’.
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13 As an 
individual
This new perspective is in 
the continuity of the efforts 
of the previous EC guidelines 
and working teams. Do not 
drop in the archives... In my 
opinion, better diffusion of the 
guidelines to the public and 
related professionals would be 
beneficial. I do not clearly see 
an item on the multidisciplinary 
breast unit and certification. 
No No change in The Scope.
Dissemination of the 
recommendations will be 
emphasised by the EC. 
Organisation of breast cancer care 
(breast unit) and certification will 
be covered by the European QA 
scheme.
14 As an 
individual
This is a clear resumè of  
a potentially very important 
document. The role of breast 
cancer screening has received 
a lot of attention lately and 
to write a ‘women-centred’ 
document is innovative and 
timely. Care should be put 
in using plain language and 
clear definitions also for a lay 
audience, including citizens and 
carers. Nonetheless, evidence 
and controversies should be 
available for a specialized 
audience including primary 
care physicians, radiologists, 
oncologists, breast surgeons etc.
No No change in The Scope.
The recommendations will 
be issued in clear language 
understandable by all and  
a specific patient profile is 
envisaged in the web hub of the 
European Breast Guidelines. It was 
already included in the draft scope 
that more than one perspective 
will be taken into account – e.g. 
an individual and a population 
perspective and the views of all 
relevant groups of stakeholders 
and users are considered.
15 As an 
individual
I agree that the guidelines 
should be women-centred. 
Therefore, patients and citizens’ 
concerns should be addressed 
in a clear, plain language. 
However, some sections should 
be specifically addressed to the 
professionals involved in the 
screening process (i.e. quality 
assurance issues: indicators, 
standards, etc.). Opportunistic 
screening is less efficient in 
terms of resources and harms 
& more costly than organized 
or population-based screening. 
Thus, guidelines should be 
population-oriented.
16 As an 
individual
Important with a straightforward 
English language to pay 
attention to those who are not 
native English speakers.
No No change in The Scope.
The recommendations will 
be issued in clear language 
understandable by all.
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17 As an 
individual
I had problems completing 
the previous section as I was 
prevented from completing an 
edit of wording in second line In 
the Concept Document there are 
several instances of incomplete 
sentences – pages 7, 15 & 25 In 
The Scope Document. Existing 
documents – as in previous 
section, Marmot should be 
included.
Yes The text of The Scope was revised 
to remove errors. 
For the European Breast 
Guidelines, the literature review 
team was externalised to ensure 
an independent approach and 
minimise potential conflict of 
interest. The Iberoamerican 
Cochrane Centre, Barcelona, will 
carry out the literature reviews 
for each specific PICO and will 
consider systematic reviews (if 
already available) or will carry out 
de-novo ones. 
18 As an 
individual
The debate on screening for 
breast cancer has been long 
and strenuous. In breast cancer 
screening policy, emotional 
arguments are dominating the 
debate. However, evidence for 
the efficacy of breast cancer 
screening is scarce (see the 
Cochrane meta-analysis by 
Gotzsche et al). Therefore, I 
think that this guideline should 
be very critical and should 
mostly use rational arguments 
(i.e. evidence based medicine) 
instead of emotional arguments 
when creating this guideline.
No No change in The Scope.
The European Breast Guidelines 
will contain evidence-based 
recommendations. 
The literature review team 
was externalised so to ensure 
an independent approach and 
minimise potential conflict of 
interest. The Iberoamerican 
Cochrane Centre, Barcelona will 
carry out the literature reviews 
for each specific PICO and will 
consider systematic reviews (if 
already available) or will carry out 
de-novo ones.
19 As an 
individual
The document is really timely 
and it will serve both the 
patients and the oncologists.
No No change in The Scope.
Feedback was positively 
appreciated.
20 On behalf 
of an 
organisation 
The GDG should consider to 
include/cover a 7th Chapter in 
their list: The Implementation 
of a Screening programme. 
Countries that are planning to 
set up a screening programme, 
centralized, population based, 
or decentralized, should receive 
advice how to do this based 
on the Guidelines and based 
also on the experience of 
established European screening 
programmes. 
No No change in The Scope. 
Implementation is not explicitly 
mentioned in The Scope, but 
implementation considerations 
are considered in the EtD 
frameworks for each PICO. 
Additional information might be 
provided through the Reference 
documents that will support ECIBC 
implementation.
21 On behalf 
of an 
organisation 
Overall, the guidelines should 
promote further awareness 
around breast cancer screening 
to ensure patient participation 
http://bit.ly/1MbUxM8
No No change in The Scope. 
This issue will be covered in the 
Communication chapter of the 
European Breast Guidelines.
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22 On behalf 
of an 
organisation 
I suggest to include the 
knowledge, proposals and 
referrals of some scientific 
articles that are not included 
in the above mentioned 
guidelines, i.e. * SA Feig. 
Screening Mammography Benefit 
Controversies. Sorting the 
Evidence. Radiol Clin N Am 52 
(2014) 455 -480
No No change in The Scope 
For the European Breast 
Guidelines, the literature review 
team was externalised so to 
ensure an independent approach 
and minimise potential conflict 
of interest. The Iberoamerican 
Cochrane Centre, Barcelona, will 
carry out the literature reviews 
for each specific PICO and will 
consider systematic reviews (if 
already available) or will carry out 
de-novo ones, and all references 
will be adequately cited.
23 On behalf 
of an 
organisation 
What criteria will be used to 
select who will be consulted? 
How will the consulting process 
occur? How to make sure it is 
complete and unbiased? Also 
the criteria for the choices of the 
working groups are not clear.
No No change in The Scope. 
The European Commission rules 
have been followed and the details 
of the selection procedure are 
available on the ECIBC web-site.
24 As an 
individual
This document is missing 
important aspects of the 
diagnostic process of breast 
cancer samples and is biased 
to the screening and clinical 
aspects of diagnosis. If no other 
in depth document is being 
planned for consensus on breast 
cancer specimens’ evaluation, 
the current scope should 
provide deeper instructions not 
only on diagnostic but also on 
prognostic and predictive aspect 
to be considered during the 
management of specimens of 
this cancer.
No No change in The Scope. 
Not explicitly mentioned in The 
Scope, but some PICO questions 
in the Diagnosis chapter will cover 
this topic. Additional information 
might be provided through the 
Reference documents that will 
support ECIBC implementation.
25 As an 
individual
A general comment could be 
that today, as already reported, 
the diagnostic process is 
closely related and conditions 
treatment, especially if we 
consider molecular diagnostics. 
Separating diagnosis from 
therapy cannot really be done 
because a specific diagnosis 
drives the therapy. Thus it is 
a problem to divide diagnosis 
from treatment and it should be 
commented and justified.
No No change in The Scope. 
The Guidelines Platform will 
include recommendations from 
evidence-based existing guidelines 
on all breast cancer care 
processes. In addition, Reference 
documents will be provided to 
support ECIBC implementation.
26 On behalf 
of an 
organisation 
I would like to see metastatic 
disease included if at all possible
Yes The Scope was modified to 
clarify that diagnostic procedures 
in breast cancer patients with 
suspected recurrences or 
metastases during follow-up are 
not covered by the European 
Breast Guidelines, but are part of 
the Guidelines Platform.
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27 As an 
individual
Please do not forget the male 
breast cancer patients.
Yes The Scope was modified – 
‘women’ has been substituted 
with ‘persons’, because the 
Screening chapter will not cover 
men; however, the diagnostic 
procedures will cover any person 
with breast cancer (women and 
men).
28 On behalf 
of an 
organisation 
Would welcome the opportunity 
to share our experience and new 
technology specifically designed 
for screening and diagnostic 
programs. Our technology is 
supported by a large number of 
publications from peer reviewed 
journals. We have also been 
involved in setting up screening 
programs and diagnostic clinics, 
happy to share our experience.
Yes The Scope was modified (Key 
stakeholders and users) to include 
also industry, linked to breast 
cancer screening and diagnosis.
29 On behalf 
of an 
organisation 
We would welcome the 
opportunity to share our 
members’ experience and new 
technology specifically designed 
for screening and diagnostic 
programs. Our members’ 
technology is supported by  
a large number of publications 
from peer reviewed journals. 
Our members have also been 
involved in setting up screening 
programs and diagnostic clinics.
30 As an 
individual
This scope definition does not 
consider risk stratification as  
a key aspect for the future of  
BC screening. There is  
a logic contradiction between 
including in The Scope ‘high-
risk surveillance’ and excluding 
‘surveillance in women with 
hereditary breast cancer’ such 
as those with BRCA1/2, strong 
family history and not proven 
mutations, etc.. This exclusion, 
being in the note 1, is not visible 
when answering the survey. 
Intermediate risk, especially 
women with previous BC, should 
be included.
Yes The Scope was modified to 
clarify that breast cancer risk 
assessment, surveillance in women 
with hereditary breast cancer and 
aspects, related to follow-up and 
survivorship are not covered by 
the European Breast Guidelines, 
but are part of the Guidelines 
Platform.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
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31 As an 
individual
The shared document appears 
to be clear and thorough. An 
introductive chapter in which 
the materials and methods used 
for data analysis are described, 
accompanied by an Evidence 
Based Recommendations scale 
supporting all the guidelines and 
representing in a balanced way 
the necessity to be Evidence 
based, women centred and usable 
in the different participating 
European countries, would be 
desirable. It seems important 
for the European Guidelines 
to offer clear indications on 
the controversial theme of the 
mammographic screening and its 
optimal timing for women aged 
from 40 to 49 years and for the 
ones with 70 or more years. For 
further information it could be 
useful that the treatise about the 
‘Breast Cancer Surveillance for 
High risk Women’ theme should 
not consider only the BRCA1 and/
or BRCA2 mutation bearers but 
also women with high risk for 
breast cancer linked to  
a relevant breast cancer family 
history.
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
and surveillance in women with 
hereditary breast cancer are not 
covered by the European Breast 
Guidelines, but are part of the 
Guidelines Platform.
The Scope includes only a short 
introduction, because most of the 
details mentioned in the comment 
are presented in the ECIBC 
Concept document7, available on 
the web site.
Different age groups 
will be addressed by the 
recommendations for screening.
Some PICO questions may be 
related to varying the screening 
regimen depending on certain risk 
factors.
32 On behalf 
of an 
organisation 
Overevaluating ´early detection 
breast cancer´. No information 
of biogenetic diversity of all 
breast cancers. Small can be 
lethal. Big can be curable. 
Focusing on size and early 
detection of oversimplifying. This 
means harm to breast cancer 
patients. 
Ignoring women with high risk 
pf breast (and ovarian) cancer. 
(BRCA, CDH1, Cowden, Lynch, 
CHEK2, Ashkenazi jewish roots 
and radiation after Hodgkin).  
A European approach to find 
high risk families is necessary. 
Here lives can be really saved. 
Not a word of honest information 
and helping women to decide 
after years of promoting only 
the ‘benefits’ of screening, this 
will need more effort. Normal 
women don’t understand 
overdiagnosis, overtreatment.
Yes The Scope was modified to clarify 
that breast cancer risk assessment 
and surveillance in women with 
hereditary breast cancer are not 
covered by the European Breast 
Guidelines, but are part of the 
Guidelines Platform.
Breast cancer subtypes are not 
explicitly mentioned in The Scope, 
but some PICO questions in the 
Diagnosis chapter will cover this 
topic. 
Recommendations about effective 
communication regarding 
harms and benefits of the 
intervention will be included in the 
European Breast Guidelines. The 
recommendations will be issued in 
clear language understandable by 
all and specific patient, healthcare 
professional and policy maker 
profiles are envisaged in the 
web hub of the European Breast 
Guidelines. 
7  Concept document – a document describing the background of the ECIBC, it’s general goals and objectives, and its 
foreseen outcomes (http://ecibc.jrc.ec.europa.eu/-/ecibc-concept-document) 
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Annex 3
List of suggested topics/questions for 
inclusion in the different chapters of 
the European Breast Guidelines 
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1 Because of the very real risk of overdiagnosing 
and treating women with DCIS the question 
must be addressed as to whether screening 
causes more harm than good.
Yes Questions addressing women 
with DCIS1 were included in the 
prioritisation exercise2.
Overdiagnosis and potential 
harms associated with screening 
are considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes 
are examined using Evidence to 
Decision (EtD) frameworks3 for 
each PICO4 question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
2 What age range should undergo screening? 
How does family history influence the start  
of screening for some patients?
Yes Questions addressing different age 
groups and varying the screening 
regimen depending on certain 
risk factors were included in the 
prioritisation exercise.
3 Age of screening. Frequency of screening 
stratification of screening by risk.
4 Breast cancer related mortality is a poor 
outcome measurement for evaluating the 
efficacy of breast cancer screening. Over the 
years, treatment has improved and led to 
improved outcomes as well and therefore the 
increase in survival could not be explained by 
screening policy alone. Only well performed 
RCTs could provide you with an accurate 
answer for this questions. A better question  
to assess the efficacy of cancer could be: 
Does breast cancer screening lead to a 
decline in incidence of late stage tumors and 
increase or stabilization in incidence of early 
stage tumors (as you expect to happen, 
see Rethinking Screening for Breast Cancer 
and Prostate Cancer, Esserman et al, JAMA 
2009)? What is the estimate of overdiagnosis 
in breast cancer due to screening? Which 
methods to quantify overdiagnosis are used?
Yes Questions addressing monitoring 
and evaluation of screening were 
included in the prioritisation 
exercise.
Overdiagnosis and breast cancer 
mortality are considered looking at 
the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
Table 1. List of questions suggested for inclusion in the Screening chapter of the 
European Breast Guidelines
1 DCIS – ductal carcinoma in situ
2  Prioritisation exercise - All questions suggested by the respondents and considered relevant to be addressed by the 
European Breast Guidelines were modified accordingly and added to a list, prepared in advance by the GDG mem-
bers. This combined list contained more than 200 questions (Annex IV), which then had to be prioritised by voting 
among the GDG members in order to identify the top questions for each chapter of the European Breast Guidelines. 
The questions that were not prioritised may be considered in the future update of the European Breast Guidelines 
recommendations.
3  Evidence to Decision (EtD) frameworks – an explicit and transparent system for decision making, provide a sys-
tematic and transparent approach for going from the evidence to the healthcare decision. EtD frameworks inform 
users about the judgments that were made and the evidence supporting those judgments by making the basis for 
decisions transparent to target audiences. EtD frameworks include also detailed justification (undesirable effects, 
values, certainty of the evidence), subgroup considerations, implementation considerations, monitoring and evalua-
tion considerations and research priorities. 
4  PICO format stands for: Population under study (for example women of certain age); Intervention (for example a medical 
examination); Comparator (other main options such as an alternative medical examination); and Outcomes (results).
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5 What is the optimal screening interval? 12 
months? 18 months? 24 month? Longer? 
Is the interval depending on the woman’s 
breast density and/or age? How to manage 
women with BIRADS density 3 and 4? Is it 
possible to implement a good strategy for 
these women in a screening setting? Offer 
Ultrasound (automatic (ABUS) or hand-held), 
MRI? Offer frequent mammography? What 
is enough breast compression pressure? 
Is it possible to reduce the compression 
pressure without reducing image quality? Is 
the compression force depending on vendor 
and/or radiographers? How to implement 
tomosynthesis in screening? How to optimize 
the examination for women with breast 
implants? Included or excluded these women 
in screening?
Yes Questions addressing the topics 
suggested – screening intervals, 
imaging techniques, age groups, 
identifying women at high risk 
of breast cancer and varying the 
screening regimen depending on 
certain risk factors were included in 
the prioritisation exercise.
6 Clearly define the target population (age) 
and the medium and high risk women (out of 
the standard screening) Define the screening 
procedures for these patients (tools, screening 
frequencies, ...).
7 What is the common technology 
recommended by EU for screening 
mammogram? Digital or analogue 
mammogram or tomosynthesis?
8 Personalised screening by age with related 
procedures (MRI, MX, US, clinical) and by 
individual risk (based on mathematical 
model).
9 If the target population could be extended to 
the age of 75?
10 What is the age group that should be 
included for screening programmes? What 
should the frequency of examination be? 
Should screening consist of full field digital 
mammography, tomosynthesis or both?
11 Consider including chapter/section screening 
by new emerging methodologies e.g. 
tomosynthesis.
12 The guidelines should be clear in providing 
as much information as possible in answer to 
the following questions: What are the harms 
associated with taking part in a screening 
program? What will happen to me if I do not 
take part in screening?
Yes Questions addressing the topics 
suggested were included in the 
prioritisation exercise.
Potential harms associated with 
screening are considered looking at 
the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
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13 1) In the context of individual informed
choice for or against screening (and lower 
participation rates), how can the impact and 
benefit-harm-ratio of a screening program 
be evaluated? How can the gap between the 
public health (and economic) interest and the 
individual interest (choice) be addressed?  
2) recommendation for recall rates in first-
time participants (usually among the youngest 
age group) in an established program  
3) exclusion (permanently or temporarily)
of breast cancer patients from screening 
(how long)?  
4) definition of high risk women
5) relevance of radiation induced cancer
(in the benefit-harm context) 
6) clear minimal documentation record
(set of parameters: screening, diagnoses, 
post-operative outcome – therapy and 
prognostic factors).
Yes Questions addressing varying the 
screening regimen depending on 
certain risk factors and identifying 
women at high risk of breast cancer 
were included in the prioritisation 
exercise.
Informed decision making and 
potential harms associated with 
screening are considered looking at 
the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
Data management will be addressed 
within the European QA scheme5. 
In addition, Reference documents6 
will be provided to support ECIBC7 
implementation.
14 I think that the problem of evaluation of 
new technology (as digital mammography 
or tomosynthesis) in screening programme 
(as well in opportunistic screening) should 
be carefully addressed, at least as general 
recommendations in facing such a problem
Yes Questions addressing imaging 
techniques were included in the 
prioritisation exercise.
15 Is it recommended to be screened regularly 
with a mammography for an average-risk 
women? Balance benefit-harms [critical 
appraisal of literature] Personalized risk-
based screening programs. Are we there 
yet? How to get started? How to assess risk? 
How to establish/define target population 
and screening intervals according to risk 
criteria? How to ensure continued monitoring 
of changes to risk? Efforts needed to identify 
predictive factors of slow-growing tumors. 
What for? Could be useful to reduce the risk 
of overdiagnosis?
Yes Questions addressing varying the 
screening regimen depending on 
certain risk factors, identifying 
women at high risk of breast 
cancer, imaging techniques and 
predictive factors assessed in a 
standard pathologic assessment 
were included in the prioritisation 
exercise.
Overdiagnosis and potential 
harms associated with screening 
are considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
16 Evidence for improved benefits or reduced 
harms for individualized screening based 
on, other than age, women factors (risk 
factors, breast density...). Evidence for new 
technologies: tomosynthesis.
5  European QA scheme - voluntary European quality assurance scheme for breast cancer services, covering all care 
processes, based on the EU legislative framework on accreditation and underpinned by the evidence provided by 
the guidelines.
6  Reference documents - Reference documents will be collected in support to implementation of evidence-based rec-
ommendations included in the existing guidelines for those aspects, e.g. related to diagnosis, where best practice 
guidance would be useful.
7  ECIBC – European Commission Initiative on Breast Cancer.
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17 Question 1.1: Should Digital Breast 
Tomosynthesis be introduced by the European 
Breast Guidelines as a breast cancer screening 
tool? Is the expert panel planning to consider 
the stratification of screening in to sub-
sets defined by risk factors such as breast 
density, and the risk evaluation models. We 
would like you to take into consideration the 
following publications which support the use 
of ABUS in breast cancer screening. J-Star: 
Japan Strategic Anti-cancer Randomized 
Trial, Lancet. 2015 Nov 4. pii: S0140-
6736(15)00774-6. doi: 10.1016/S0140-
6736(15)00774-6 The SomoInsight Study. 
Radiology. 2015 Mar; 274(3): 663-73 ACRIN 
6666. JAMA. 2008; 299(18):2151-2163. 
doi:10.1001/jama.299.18.2151. EASY Study: 
European Asymptomatic Screening Study 
(Submitted).
18 Is personalized screening (in some 
circumstances, like dense breast) preferred 
instead of population based screening?  
Is Digital Breast Tomosynthesis to be 
considered as the new screening modality  
(if financial situation is OK)?
19 Women in which age groups do have a net 
benefit from screening? Do certain groups of 
women (according to determinants such as 
age, education or health related factors) have 
an elevated risk for harms? Does adapting 
screening intervals to the individual risk of 
breast cancer decrease risk of harms? Which 
screening steps (identification/invitation, 
information/decision, radiologic examination 
– reading, diagnostic steps) have most
importance for a balance of benefits and 
harms and for reduction of inequalities.  
This could lead to identification of screening 
steps also amenable to improvement in 
settings outside of organised population-
based screening programmes.
Yes Questions addressing age groups, 
identifying women at high risk 
of breast cancer and varying the 
screening regimen depending on 
certain risk factors were included in 
the prioritisation exercise. 
Potential harms associated with 
screening are considered looking at 
the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
20 Digital as routine? Double Reporting on 
Mammograms – could be aspirational?
Yes Questions addressing imaging 
techniques were included in the 
prioritisation exercise.
21 Will the guidelines address the gaps in 
screening and diagnosis for senior women? 
About 50 percent of breast cancer cases  
are found in women over age 65,  
http://bit.ly/1SQ8dmy A recent study 
published in the journal Radiology suggests 
that early detection with mammography 
reduces the risk of late-stage breast cancer 
diagnosis in women over 75, requiring less 
treatment and improving survival rates. 
http://1.usa.gov/1Q89kgv 
How will the guidelines promote the bridging 
from screening and diagnosis to treatment?
Yes Questions addressing age groups 
were included in the prioritisation 
exercise. 
The interfaces between different 
services will be covered by the 
European QA scheme.
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22 In addition to habitual questions: In the light 
of improving diagnosis do the age group 
specifications for mammographic screening 
still hold? In the light of increased life-
expectancy what should be the provisions 
made for non-programmatic or opportunistic 
screening at 70 and above?
23 What is/are the appropriate test(s) to screen 
for breast cancer? Is there a place for 
tomosynthesis or syntheisized mammography 
in organized breast cancer screening? 
To whom should breast cancer screening 
programs be offered to? At what age should 
average risk women commence screening? 
What is the appropriate interval for screening? 
How are risk stratification and personaled 
screening recommendation based on risk 
profile incorporated into organized screening 
programs?
Yes Questions addressing age groups, 
imaging techniques, identifying 
women at high risk of breast cancer 
and varying the screening regimen 
depending on certain risk factors 
were included in the prioritisation 
exercise. 
Desirable and undesirable effects 
of outcomes are examined using 
EtD frameworks for each PICO 
question in order to decide what the 
balance is, which might influence 
the direction of the corresponding 
recommendation.
24 Does the benefit for patients with cancer 
outweighs the risk to which it is subjected 
to the healthy population? Why is not 
recommended screening in other groups of 
age? Why are not recommended another test 
as tomosynthesis?
25 1.1. Should Digital Breast Tomosynthesis be 
introduced by the European Breast Guidelines 
as a breast cancer screening tool? 1.2. Is 
the expert panel planning to consider the 
stratification of screening in to sub-sets 
defined by risk factors such as breast density, 
and the risk evaluation models? COCIR 
suggests to take into consideration the 
following publications which support the use 
of ABUS in breast cancer screening: • J-Star: 
Japan Strategic Anti-cancer Randomized 
Trial, Lancet. 2015 Nov 4. pii: S0140-
6736(15)00774-6. doi: 10.1016/S0140-
6736(15)00774-6 • The SomoInsight Study. 
Radiology. 2015 Mar; 274(3): 663-73  
• ACRIN 6666. JAMA. 2008;299(18):2151-
2163. doi:10.1001/jama.299.18.2151. 
• EASY Study: European Asymptomatic
Screening Study (Submitted)
26 Role of new diagnostic techniques 
(tomosynthesis/DBT, automated ultrasound/ 
AUS, ...) with emphasis on evidence of 
benefits vs negative effects vs costs/
feasibility. Possible alternative screening 
protocols based on variations in diagnostic 
modalities and/or intervals and/or risk 
factors (tailoring) etc. All the above should 
be analysed with the strongest emphasis on 
feasibility (in strictly financial terms as well as 
staffing/personnel considerations). Possible 
role of CAD in mammography, DBT, AUS
Yes Questions addressing imaging 
techniques, identifying women 
at high risk of breast cancer and 
varying the screening regimen 
depending on certain risk factors 
were included in the prioritisation 
exercise.
27 Should we also include a focus of developing 
new technologies to reduce potential risks of 
ionising radiation
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28 Generally speaking, could the mammographic 
screening be integrated/carried out according 
to different risk profiles? Are the new 
polygene tests available able to integrate the 
mammographic screening in order to select 
different risk groups? Would they be cost-
effective? Could the mammographic density 
be routinely used to enable a differential 
screening according to the breast density at 
different ages?
29 Contrast-enhanced spectral mammography 
(CESM) is a relatively recently introduced 
imaging technique that uses an intravascular 
contrast agent to identify breast cancer on 
the basis of iodine signal enhancement from 
tumor angiogenesis. Contrast enhanced digital 
mammography (CESM) has been shown 
to have a higher sensitivity and specificity 
than standard mammography and similar 
diagnostic accuracy compared to breast MRI. 
Two questions should now be addressed: – Is 
CESM could be used in alternative to MRI in 
the screening of high risk women? – Is CESM 
could be used in alternative to mammography 
in the screening of intermediate risk 
population?
30 The European Breast Guidelines should 
address the age groups of women suggested 
for mammography screening. It is important 
as there is no general consensus and the 
practice is different even in countries having 
a nation-wide mammography screening 
program. The European Breast Guidelines 
should address the specific issues of 
guidelines for screening high-risk women 
(e.g. for women with family history of breast/
ovarian cancer or BRCA1-2 positive women).
Yes Questions addressing age groups, 
identifying women at high risk 
of breast cancer and varying the 
screening regimen depending on 
certain risk factors were included in 
the prioritisation exercise.
31 Best interval of screening. Best method 
including new technologies: a) to include US 
or not; b) to use tomosintesis or not; c) use 
of MRI for BRCA carriers or not. Screening and 
following BRCA carriers as well as women with 
strong family history. Classification of lesions. 
Why and when to call back women. Criteria 
for biopsy and for referral. Quality assurance 
criteria for evaluation of the screening process 
and of the screening units. Provide list of 
adequate places for women to go, in each 
country. Links to Treatment Units.
Yes Questions addressing imaging 
techniques, identifying women 
at high risk of breast cancer and 
varying the screening regimen 
depending on certain risk factors 
were included in the prioritisation 
exercise. 
Quality of breast healthcare services 
will be covered by the European QA 
scheme, as well as the interfaces 
between different 
32 Screening of high risk groups have to be 
defined. Gene carriers etc....
Yes Questions on identifying women 
at high risk of breast cancer and 
varying the screening regimen 
depending on certain risk factors 
were included in the prioritisation 
exercise.
107
Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
33 Age interval of women at average risk to 
be screened (from 40, 45, 50 to 70-75?). 
What to do over 75? Screening intervals 
(1, 2, 3 years?) Recommend preference 
for direct digital (not phosphor plates) 
mammography instead of film-screen 
mammography. Recommend for using 
standardized descriptors and diagnostic 
categories (e.g., BI-RADS, R1-R5) Discuss 
the perspective for implementation of digital 
breast tomosynthesis for screening (ro be 
ready for this). Define facility minimal volume 
limits (mammograms/year; needle biopsies/
year). Define minimal and maximal individual 
volume limits for radiologists Define minimal 
individual volume limits for pathologists 
Define the need of individual proficiency 
test for radiologists and pathologists 
Define individual minimal volume limits for 
technicians.
Yes Questions addressing age groups, 
imaging techniques, volumes and 
training requirements were included 
in the prioritisation exercise.
34 In general, the guidelines should allow 
modifications of screening parameters such 
as the age of the women and the intervals of 
screening exams to individual circumstances 
and requirements
Yes Questions addressing age groups, 
screening intervals and varying the 
screening regimen depending on 
certain risk factors were included in 
the prioritisation exercise.
35 High risk screening groups, age groups, 
screening after breast reconstruction and 
breast cancer.
Yes Questions on identifying women at 
high risk of breast cancer, varying 
the screening regimen depending 
on certain risk factors and imaging 
techniques (addressing also 
different subgroups) were included 
in the prioritisation exercise.
36 How to implement an effective breast cancer 
screening. Risk adapted screening strategies. 
Appropriate use of technology in special 
patient population (e.g. genetic predisposition 
carriers or Hodgkin lymphoma survivors). How 
to integrate genomics, proteomics and liquid 
biopsies in breast cancer screening. Are we 
using the appropriate endpoints to evaluate 
efficacy and appropriateness of screening 
programs?
Yes Questions on identifying women at 
high risk of breast cancer, varying 
the screening regimen depending 
on certain risk factors, imaging 
techniques, diagnostic methods 
and monitoring and evaluation 
of screening were included in the 
prioritisation exercise. 
Desirable and undesirable effects 
of outcomes are examined using 
EtD frameworks for each PICO 
question in order to decide what the 
balance is, which might influence 
the direction of the corresponding 
recommendation.
37 Age of women undergoing the screening, 
frequency of screening examinations, 
organisation structure for covering screening 
in individual countries – the same for all or 
individual per country. 
Yes Questions on age groups and 
screening intervals were included in 
the prioritisation exercise.
The European Breast Guidelines 
will include evidence-based 
recommendations. Their 
implementation has to be addressed 
in a proper way at a country level8. 
8  Lisbon Treaty art. 168 foresees that ‘Union action shall respect the responsibilities of the Member States for the 
definition of their health policy and for the organisation and delivery of health services and medical care. The 
responsibilities of the Member States shall include the management of health services and medical care and the 
allocation of the resources assigned to them.’
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38 Timely innovation of screening programmes is 
important. Innovation should also be evidence 
based. It can be complicated to unite these 
two objectives. It is necessary to pay 
attention to this problem.
Yes Questions on imaging techniques 
and diagnostic methods were 
included in the prioritisation 
exercise. 
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
39 How will women be helped to understand 
overdiagnosis bias, lead time bias and other 
harm? After years of emphasizing only the 
benefits, it is hard to explain women that not 
going to screening without symptoms is not 
wrong at all. What will be done to explain this 
to women? Will women with high risk due to a 
genetic mutation be approached on a different 
way? Will women get psychological support 
after false positive or false negative results?
Yes Questions addressing optimal 
strategy to communicate results 
and identifying women at high risk 
of breast cancer were included in 
the prioritisation exercise.
Informed decision making, 
overdiagnosis and potential 
harms associated with screening 
are considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
In addition, the recommendations 
are formulated in lay-person 
language in order to be 
understandable by all. 
40 1. To what extent should they made 
obligatory? 2. How to cope with variation 
in outcome/results based on social, 
demographic, cultural and other differences? 
3. How to follow the results over time: 
population based studies coupled to the 
screening programme? 4. Who should 
organise it: privately; existing primary/
second line health care/dedicated services/ 
...? 5. Who should pay for it: health 
insurance companies/government/patients/
employers/...? 6. How to prevent over-use of 
"opportunistic" screening? Who pays in that 
case? 7. How to set up, fund, maintain and 
evaluate/publish quality assurance.
Yes Questions addressing the topics 
suggested were included in the 
prioritisation exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
The European Breast Guidelines 
will include evidence-based 
recommendations. Their 
implementation has to be addressed 
in a proper way at a country level. 
The economic aspects will be 
covered in the EtD frameworks.
Questions addressing monitoring 
and evaluation of screening were 
included in the prioritisation 
exercise.
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
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41 1) evidence, data collection, medical records 
and documentation. 2) proposal of optimal 
time period for the keeping of mammograms 
to be concocted and made available to 
countries carrying out screening programs 3) 
to offer a scheme and/or table explaining a 
minimal threshold for the quality of screening 
and tips on how to obtain it 4) The training 
and licensing of radiology specialists that are 
to be preforming screening mammography 
within the screening program (first and 
second readers of mammograms, radiologists, 
supervisors) and training curricula for said 
training programs
Yes Questions addressing monitoring 
and evaluation of screening and 
training of professionals were 
included in the prioritisation 
exercise.
Data management will be addressed 
within the European QA scheme. 
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
42 Please highlight the role of technicians in the 
screening and suggest required numbers of 
screens per year.
Yes Questions addressing training 
requirements for professionals 
were included in the prioritisation 
exercise.
Table 2. List of questions suggested for inclusion in the Diagnosis chapter of the 
European Breast Guidelines
1 What histopathological techical procedures 
must preferentially be used in the initial 
diagnosis of breast cancer (cytology, needle 
biopsy, tumorectomy? in what situation 
each? what are the prognostic and predictive 
pathological markers to be evaluated in 
breast samples and in which type of breast 
samples? will there be an european consensus 
in the criteria for the evaluation of the above 
markers? what and when must molecular 
studies be used in the prognosis and 
prediction of breast cancers?
Yes Questions on histopathological 
procedures and parameters, 
prognostic and predictive 
pathological markers, and training 
requirements for radiologists 
were included in the prioritisation 
exercise.
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
2 Already defined in the previous versions of the 
EC guidelines but need to update with next 
diagnostic tools (e.g. molecular and gene).
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3 Histopathological parameters that only can be 
assessed during examination of the surgical 
(operative) specimen should be included. 
They are tumor size, lesion distribution 
(unifocal, multifocal and diffuse, both for 
the invasive and in situ components of the 
tumor), disease extent, and intratumoral / 
intertumoral heterogeneity. The document 
should include consensus definitions of 
each of these parameters, guidelines to 
their adequate histological assessment, 
suggestions for the way of their reporting, 
and first of all, quality assurance schemes 
for radiological – pathological correlation 
with regard of these parameters. As these 
parameters are preoperatively assessed with 
radiology methods (histological evaluation 
of the biopsy specimens is not sufficient in 
this aspect), the radiologists need this feed-
back as confirmation or modification of their 
preoperative assessment results.
4 Is it worth it? The risk of overdiagnosis, MRI 
guided biopsies.
Yes Questions addressing imaging 
techniques were included in the 
prioritisation exercise. Informed 
decision making and overdiagnosis 
are considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
5 What is the golden standard to achieve breast 
cancer diagnosis? Core biopsy or fine needle? 
(between Sweden and other EU countries)
Yes Questions on diagnostic procedures 
were included in the prioritisation 
exercise.
6 Minimal diagnostic procedures to be done
7 Contrast-enhanced spectral mammography 
(CESM) is a relatively recently introduced 
imaging technique that uses an intravascular 
contrast agent to identify breast cancer on 
the basis of iodine signal enhancement from 
tumor angiogenesis. Contrast enhanced digital 
mammography (CESM) has been shown 
to have a higher sensitivity and specificity 
than standard mammography and similar 
diagnostic accuracy compared to breast MRI. 
Two questions should now be addressed: 
– Is CESM could replace mammography in
symptomatic breast patient? – Is CESM could 
be used as a case solver in diagnostic setting 
in case of inconclusive mammography and 
ultrasonography as an alternative to breast 
MRI?
Yes Questions on imaging techniques 
were included in the prioritisation 
exercise.
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8 Personalised procedure for the diagnosis with 
regards to the biology of the tumors as new 
drug are now available, thus better diagnostic 
methods are required to understand how to 
proper use the drug (ex: neoadjuvant model).
Yes Questions on histopathological 
procedures and parameters, 
prognostic and predictive 
pathological markers were included 
in the prioritisation exercise.
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
9 Can we name the indications for certain 
postscreening examinations (another MG or 
US)?
Yes Questions on imaging techniques 
were included in the prioritisation 
exercise.
10 Is there a role for new diagnostic techniques 
such as CESM in the diagnosis of breast 
cancer?
11 I would like to bring to your attention the 
growing importance of mammography with 
contrast medium (CESM-Contrast Enhanced 
Spectral Mammography) in the diagnostic 
presurgical breast cancer. In particular, this 
examination, based on our experience and 
that of many breast centers in Europe and 
other parts of the world, has a diagnostic 
accuracy comparable to breast MRI. CESM 
also has advantages: useful, rapid execution, 
immediate interpretation, display similar to a 
standard mammography (easier interpretation 
by other specialists: surgeons, oncologists) 
a lower number of false positive than MRI 
and above a lower cost. Because of the 
well documented validity of the method as 
an alternative to breast MRI (see scientific 
literature regarding this matter), where it is 
indicated as an examination of the second 
level, I think it is appropriate to consider the 
CESM between one of the methods useful in 
diagnostic breast imaging protocol.
12 Criteria for classification of lesions. Criteria 
for biopsy, clear criteria for FNA, criteria for 
referral. What to include in the Pathology 
report from biopsies, surgical specimens and 
sentinel lymph node examination; should 
include traditional pathology assessment 
but also needed biomarkers such as ER, PR, 
HER-2, ki67. For the biomarkers describe best 
antibodies to use, cut-offs, quality assurance 
programs to implement in Pathology 
Laboratories. For surgical specimens define 
how to assess margins, what are clear 
margins. For SLNB how to examine LNs, 
define micro and macro metastases as well as 
isolated cells, and their impact in prognosis 
and treatment. Mandatory marking and how 
to mark lesions both pre-surgery and pre-
neoadjuvant systemic therapy (use of clips, 
use of carbon). Quality assurance criteria and 
programs for Screening Units. Multidisciplinary 
approach and discussions between 
radiologists, surgeons, medical oncologists 
and pathologists. Links to Treatment Units.
Yes Questions on histopathological 
procedures and parameters, 
prognostic and predictive 
pathological markers were included 
in the prioritisation exercise.
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
Quality of breast healthcare services 
will be covered by the European 
QA scheme, as well as interfaces 
between different services.
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13 1) clear recommendations for diagnostic
workup (imaging and invasive techniques and 
workflow) 2) clear minimal documentation 
record (set of parameters: screening, 
diagnoses, post-operative outcome – therapy 
and prognostic factors).
Yes Questions on histopathological 
procedures and parameters, 
prognostic and predictive 
pathological markers were included 
in the prioritisation exercise.
Data management will be addressed 
within the European QA scheme.
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
14 How useful is it to reclassify cancers based 
on their molecular profile vs. traditional 
classification based on tissue of origin (i.e. 
connections between basal-like breast cancer 
tumors and some ovarian and lung tumors)?
15 Interventions that will be covered: Breast 
cancer diagnostic steps and preoperative 
staging procedures I would add: Is there a 
role of molecular gene signatures, applied to 
pre-operative diagnostic samples, to guide 
treatment?
16 Question 2.1: Will the expert panel consider 
creating specific guidelines related to the use 
of 2D synthetic images for diagnostic use? 
Question 2.2: Will the expert panel consider 
creating new guidelines related to the use of 
CESM to support breast cancer diagnosis?
Yes Questions on imaging techniques 
were included in the prioritisation 
exercise.
In addition, cost effectiveness is 
part of the EtD frameworks for each 
recommendation.
17 What is the recommendation for breast 
imaging in breast cancer diagnosis if MRI 
is not available (due to geogrpahical or 
economic reasons) for the women? What is 
the recommendation for breast diagnosis in 
breast cancer diagnosis if vacuum assisted 
large needle biopsy is not available (due to 
economic reasons) for the women?
18 Role of new diagnostic techniques 
(tomosynthesis/DBT, automated ultrasound/
AUS, ...) with emphasis on evidence of 
benefits vs negative effects vs costs/
feasibility.
19 Recommend for preference for continuity 
of care between screening and diagnosis. 
Screening reading radiologists should be also 
involved in the diagnosis of suspected case 
(supplemental views, ultrasound, needle 
biopsy, communication of diagnosis). Define 
indications for different biopsy systems, 
from fine needle aspiration cytology to core 
biopsy, to vacuum assisted biopsy under 
different guiding systems (stereotactic 
unit, tomo-guide, ultrasound, magnetic 
resonance imaging). Recommend for using 
cyto-pathologic standardized descriptors and 
diagnostic categories. Define how to manage 
non malignant cases such as "lesions with 
uncertain malignant potential" (B3 lesions) for 
which a tumor board discussion may be useful 
for decision-making.
Yes Questions on diagnostic 
procedures (relevant to all 
lesions), histopathological 
parameters, prognostic and 
predictive pathological markers and 
discussion of the patient cases at 
the multidisciplinary team meeting 
(tumour board) were included in the 
prioritisation exercise. 
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
Quality of breast healthcare services 
will be covered by the European 
QA scheme, as well as interfaces 
between different services.
20 The management of benign lesions such as 
atypical ductal hyperplasia. The management 
of low risk lesions such as lobular carcinoma 
in situ and low grade ductal carcinoma in situ.
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21 Effective management and integration of 
records to ensure efficient transition across 
the pathway particularly where there is a 
private/public interface; to ensure equitable 
care of patients in different healthcare set ups 
across the EU (and elsewhere).
Yes Questions about addressing 
inequalities were included in the 
prioritisation exercise.
Quality of breast healthcare services 
will be covered by the European 
QA scheme, as well as interfaces 
between different services.
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
22 As already reported, diagnosis is closely 
related to treatment and the separation 
should be justified. How can it be justified?
23 The use of MRI of the breast in the screening 
of high-risk groups is of importance and 
should be mentioned.
Yes Questions about imaging 
techniques, varying the screening 
regimen depending on certain risk 
factors, identifying women at high 
risk of cancer and procedures to 
be used to diagnose breast cancer 
in women with familiar hereditary 
risk of cancer were included in the 
prioritisation exercise.
24 Finding these families with HIGH risk of breast 
cancer (BRCA: 60-80%) is very useful. What 
will be done to find these families?
25 1. How to cope with variation in outcome/
results based on social, demographic, 
cultural and other differences? 2. How to 
define, organise and monitor timing and time 
lines; what if this is not respected; quality 
assurance; ... 3. How to follow the results 
over time: population based studies coupled 
to the screening programme? 4. How to avoid 
over diagnosis? 5. Who pays when diagnosis 
is based on patient-demand only?
Yes Questions about addressing 
inequalities and monitoring and 
evaluation of screening were 
included in the prioritisation 
exercise.
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
Overdiagnosis is considered looking 
at the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
The economic aspects will be 
covered in the EtD frameworks.
26 Patients need to be given their diagnosis 
together with explanation of type of tumour 
in a manner suitable to the individual person 
and preferably in presence of relative. Time 
should be given and any questions answered. 
A summary of the diagnosis, discussion and 
next appointment should be given to the 
patient.
Yes Questions addressing and optimal 
strategy to communicate results 
were included in the prioritisation 
exercise.
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
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27 The physician should take enough time during 
the diagnosis to answer questions the patient 
might have and ensure a smooth and timely 
transition into treatment. Will this be part 
of the guideline? http://bit.ly/1ZxyFq1 Will 
there is a recommendation for appropriate 
patient support during the course of the 
treatment starting at the point of diagnosis? 
The psychological aspect of a breast cancer 
diagnosis is not always recognised by health 
professionals http://1.usa.gov/1URJBIl
Yes Questions about optimal strategy to 
communicate results were included 
in the prioritisation exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
Follow-up procedures and 
survivorship care will be covered by 
the Guidelines Platform9.
28 In addition to habitual questions: In the view 
of risk of over diagnosis and unavoidable 
additional work up examinations without 
existence of cancer, what information should 
be provided to women joined to the invitation 
letters and in information provided by the 
primary care team?
29 Although men are excluded, maybe one 
paragraph could be addressed to male breast 
cancer. It gives a recognition of exciting and 
can make policy makers aware of this problem 
(although small) as well.
Yes Questions about diagnostic 
procedures were included in the 
prioritisation exercise and they will 
cover any person with breast cancer 
(women and men).
9   For recommendations on processes of care other than screening and diagnosis (treatment, rehabilitation, follow-up 
and survivorship care, palliative care, and all relevant horizontal aspects), an ECIBC platform for breast cancer 
guidelines (the Guidelines Platform) is envisaged to host existing evidence-based, high-quality guidelines.
115
Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 Will the section on communication include 
who is available to support women through 
this process, especially those who are 
recalled, either where the outcome is benign 
or malignant? Will communication include 
training on both verbal communication and 
the way that written information is provided?
Yes Questions addressing optimal 
strategy to communicate results 
and training of professionals 
were included in the prioritisation 
exercise.
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
2 Recommend to regularly update website. 
Endeavour to have communication and to 
collaborate with national and/or local breast 
screening organizations.
No This was not included in the 
prioritisation exercise, because it is 
a comment, not a question, but it is 
however appreciated.
3 The effectiveness of the communication 
with the female population to assist in their 
understanding of the benefits and risks.
Yes Questions about optimal strategy to 
communicate results were included 
in the prioritisation exercise.
In addition, the recommendations 
will be translated into lay-
person language, in order to be 
understandable by all.
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
4 How to communicate the concept of risk 
and risk reduction to citizens. They found 
something: how to communicate to patients 
a suspicious finding. Mortality zero: an 
unrealistic target?
5 It is important to pay attention to the problem 
of informed choice with special attention for 
the lower social class. Perhaps decision aids 
could be helpful.
6 Availability of list of Screening Units with 
a good quality assurance in each country, 
where women should go. Availability of list of 
Treating Units with a good quality assurance 
in each country, where women should go. 
Educational tools, in lay language, explaining 
importance of screening, what it is, who 
should do it, how and where. Education tools 
to lobby and inform politicians and policy 
makers about the need for screening, quality 
criteria, importance of Breast Units/Services, 
need to include Breast Units in the law of each 
country. Widespread distribution of the final 
product of this project, in conjunction with the 
main European Societies and Organizations 
dealing with Breast Cancer.
Yes Questions about monitoring and 
evaluation of screening, and optimal 
strategy to communicate results 
were included in the prioritisation 
exercise. 
In addition, the recommendations 
will be translated into lay-
person language, in order to be 
understandable by all.
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
Table 3. List of questions suggested for inclusion in the Communication chapter of 
the European Breast Guidelines
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7 The guidelines should be clear in providing as 
much information as possible to organisations 
implementing the guidelines in answer to 
the following questions: How should we best 
communicate the benefits and harms of taking 
part in screening programs? How should 
health professionals ensure that patient 
preference as part of the decision-making 
with regard to screening and the subsequent 
actions that come from the results of that 
screening?
Yes Questions about decision aids that 
explain pros and cons of screening, 
patient experience/satisfaction, 
optimal strategy to communicate 
results and use of social media 
for implementation of a screening 
programme were included in the 
prioritisation exercise. Informed 
decision making and potential 
harms associated with screening 
are considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes, 
as well as women´s values and 
preferences, are examined using 
EtD frameworks for each PICO 
question in order to decide what the 
balance is, which might influence 
the direction of the corresponding 
recommendation.
The recommendations will be issued 
in clear language understandable by 
all and specific patient, healthcare 
professional and policy maker 
profiles are envisaged in the 
web hub of the European Breast 
Guidelines.
8 Include section on Benefits and Risks Include 
section on using social media
9 Addressing the differences between the 
individual view and the public health view in 
the communication with the women.
10 Decision-making How do we need to help the 
women taking part in breast cancer screening 
to make an informed decision? What are the 
best ways (examples) in delivering clear and 
balanced information? Are there examples 
or studies on the impact of the participation 
in function to the information delivered? Are 
there decision-making aid tools validated? 
Provide a list of resources. Add a Q&A section 
for women diagnosed with breast cancer 
concerning prognosis, treatment and follow-
up.
11 1. How to avoid a screening and diagnosis
related unwarranted stress/anxiety? 2. How 
to communicate from the screening service 
to the care system for further diagnosis and 
treatment? 3. How to involve the primary line 
including general practitioners?
Yes Questions about optimal strategy 
to communicate results and 
involving primary health providers 
in communication strategies 
were included in the prioritisation 
exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
12 Define levels of communication related to 
levels of education of the women.
Yes Questions about the use of targeted 
communication in particular 
subpopulations of women were 
included in the prioritisation 
exercise. 
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13 How do women prefer receiving information 
regarding benefits, harms and further aspects 
of screening (which information, written/oral, 
by whom, which form of communication of 
risks)? How do women in different European 
countries prefer receiving an appointment for 
screening (invitation with fixed appointment, 
invitation to contact and make an 
appointment?
Yes Questions about optimal strategy 
for communication with women 
were included in the prioritisation 
exercise. 
Informed decision making and 
potential harms associated with 
screening are considered looking at 
the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
14 All Health Care Professionals in contact 
with screening patients should have 
current accreditation in communication 
skills. High quality, easily accessed pre-
screening information is essential Patient’s 
comprehension of the information received 
should be assessed at the end of consultation.
Yes Questions about training and 
strategies for educating or 
supporting healthcare professionals 
for providing information were 
included in the prioritisation 
exercise. Informed decision 
making is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
15 How will the target audience be identified to 
ensure awareness among all people? While 
the European guidelines for quality assurance 
in breast cancer screening and diagnosis of 
2006 mention the possible development of 
a communication strategy for breast cancer 
screening, the updated guidelines of 2013 
and the concept document of the European 
Commission Initiative on Breast Cancer of 
2015 don’t address the communication aspect 
in detail. The guidelines should provide a 
comprehensive communication strategy on 
this matter. – http://bit.ly/1ORdUig – http://
bit.ly/1PhPL3b – http://bit.ly/1JMyZKx. 
Yes Questions about optimal strategy 
for communication with women 
were included in the prioritisation 
exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
16 A model invite for women to participate in 
screening mammography Communication 
strategy for organised screening program
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17 How is informed consent to participate in 
organized screening achieved? What is the 
necessary information that should be included 
in an invitation to participate in screening? 
How are the results of the screening 
intervention communicated to women and 
their primary care provider? How can decision 
aids and decision tools become incorporated 
into the process of informing women of the 
benefits and harms of screening?
Yes Questions about optimal strategy 
to communicate results, use of 
decision aids, and involving primary 
health providers in communication 
strategies were included in the 
prioritisation exercise. 
Informed decision making and 
potential harms associated with 
screening are considered looking at 
the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
18 Should it be the communication on the 
screening equal in all countries?
Yes Questions about optimal strategy 
to communicate with women 
and strategies for educating or 
supporting healthcare professionals 
for providing information were 
included in the prioritisation 
exercise.
19 A dedicated nurse or a health visitor should 
be mandatory for communication. EU should 
address prepare a statement on this. 
20 In addition to habitual questions on 
communicating results: How to assure good 
communication about the invitation process 
between the organised program management, 
the primary care team , the diagnostic workup 
team and the target population in case of high 
risk, in case of normal or suspect results.
Yes Questions about optimal strategy to 
communicate results in particular 
subpopulations of women and 
involving primary health providers 
in communication strategies 
were included in the prioritisation 
exercise. 
21 Define how information about advantage 
and disadvantages of screening should be 
delivered (balance sheet, etc.) to women with 
different risk level. Discuss the possibility 
of a direct interaction with a physician at 
the first screening event, also but not only 
to verify that women have understood the 
crucial information about pros and cons of 
screening. Define how to verify that clinicians 
have real skills in communication to women. 
Importantly, consider the new approaches to 
the theory of risk and opportunity perception 
which demonstrated that human choices 
are not "rational" and that how data are 
presented strongly determines preferences 
(see: Verna et al. Understanding choice. 
Why physicians should learn prospect 
theory. JAMA 2014). As mentioned before, 
in some analyses, mortality and survival are 
mathematically equivalent but their impact on 
perception is completely different.
Yes Questions about optimal strategy 
to communicate results, strategies 
for educating or supporting 
health professionals for providing 
information and use of targeted 
communication in particular 
subpopulations of women were 
included in the prioritisation 
exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
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22 How will women be helped to understand 
overdiagnosis bias, lead time bias and other 
harm? After years of emphasizing only the 
benefits, it is hard to explain women that not 
going to screening without symptoms is not 
wrong at all. What will be done to explain this 
to women? Will women with high risk due to a 
genetic mutation be approached on a different 
way? Will women get psychological support 
after false positive or false negative results?
Yes Questions on identifying women at 
high risk of breast cancer, optimal 
strategy to communicate results 
and use of targeted communication 
in particular subpopulations of 
women were included in the 
prioritisation exercise. 
Informed decision making, 
overdiagnosis and potential 
harms associated with screening 
are considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
23 Since the use of CESM imaging modality 
is rapidly growing in the field of breast 
disease, there is clearly a need to provide 
a consensus among experts to standardize 
CESM examinations reporting and to reconcile 
terms used to describe features on both LE 
image and subtracted images. The question 
is: – Is a new CESM lexicon of standardized 
terminology designed to standardize CESM 
reporting should be elaborated?
Yes Questions on imaging techniques 
were included in the prioritisation 
exercise. 
24 What lines of communication should 
exist between patient and health care 
professionals?
Yes Questions about optimal strategy 
for communication with women 
and strategies for educating or 
supporting health professionals 
for providing information were 
included in the prioritisation 
exercise. Informed decision 
making is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
120
Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
25 Fundamental. How to diffuse the EC guidelines 
and recommendations (and updates) to the 
women, the patients, the doctors, the breast 
units and the para-medics on an efficient way. 
Yes Questions about optimal strategy 
for communication with women 
were included in the prioritisation 
exercise. 
In addition, the recommendations 
will be issued in clear language 
understandable by all and specific 
patient, healthcare professional and 
policy maker profiles are envisaged 
in the web hub of the European 
Breast Guidelines.
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
26 Will there be and unified document with 
recommendations? will there be obligation to 
follow the consensus of the EU in this matter?
No These are not questions that can 
be addressed in the prioritisation 
exercise and were hence not 
included. 
However, the recommendations 
will be issued in clear language 
understandable by all and specific 
patient, healthcare professional and 
policy maker profiles are envisaged 
in the web hub of the European 
Breast Guidelines.
The European Breast Guidelines 
will include evidence-based 
recommendations. Their 
implementation has to be addressed 
in a proper way at a country level.
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1 Will training include communication skills? Yes Questions about strategies for 
educating or supporting healthcare 
professionals for providing 
information were included in the 
prioritisation exercise. 
2 Will there be any kind of unified 
recommendations or obligations in the 
national training programs for pathologist 
related to breast cancer diagnosis? Will there 
be EU international programs for exchange of 
trainees in breast pathology?
Yes Questions on histopathological 
procedures, specialisation and 
training of pathologists were 
included in the prioritisation 
exercise. In addition, Reference 
documents will be provided to 
support ECIBC implementation.
3 The role of advanced nurse practitioners, and 
advanced practise radiographers. The training 
of sufficient numbers of radiologists etc.
Yes Questions addressing imaging 
techniques, volumes and training 
requirements of different healthcare 
professionals were included in the 
prioritisation exercise. 
The economic aspects will be 
covered in the EtD frameworks.
4 The presence of an appropriate skill mix based 
on defined competencies to enable efficient, 
flexible and cost effective reporting of images.
5 What kind of training should professionals 
have (i.e. radiologists, surgeons, oncologists 
etc). Should there be a distinction between 
regular breast cancer specialist or super 
specialized doctors?
6 Should the different types of training that 
are necessary for screening and diagnosis be 
defined?
7 Training courses with quality certificates for 
people working in Screening Units. Training 
courses on how to communicate a diagnosis 
of a suspicious lesion and of a cancer.
8 Competencies should be defined to ensure the 
development of evidence-based practices and 
the provision of comprehensive, personalized 
care and quality practices. Core Competencies 
for Inter professional Collaborative Practice 
should be defined as well their assurance 
and assessment. Training plan to achieve 
core competencies by type of professional 
(epidemiologist, nurses, radiologists, 
pathologists, biologists,...) should be 
elaborated.
Yes Questions addressing training 
requirements and strategies for 
educating or supporting health 
professionals for providing 
information were included in the 
prioritisation exercise.
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
9 Should include recommendations for training 
for staff e.g. in reading of mammograms, 
taking biopsies, communication skills.
10 The training and licensing of radiology 
specialists that are to be preforming screening 
mammography within the screening program 
(first and second readers of mammograms, 
radiologists, supervisors) and training 
curricula for said training programs. Licensing 
procedure for radiographers (technicians) for 
screening mammography.
Table 4. List of questions suggested for inclusion in the Training chapter of the 
European Breast Guidelines
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11 This means 2 different things: 1. training 
curriculum for radiologists and pathologists 
(post-graduation schools) and graduation 
course (or equivalent) for technicians. 
This is not exactly the same across the 
28 EU member states. Which suggestion 
to harmonize? 2. Specific training for 
radiologists, pathologists, and technicians, 
including proficiency tests (as already 
mentioned above).
Yes Questions addressing training 
requirements of healthcare 
professionals were included in the 
prioritisation exercise.
12 It is worth mention the value of additional 
training for radiologist before entering a 
screening program. Please try to find out 
if there is enough evidence to make it an 
obligatory requirement for radiologist before 
reading screens
13 What qualifications and training required of 
the radiologist who interprets mammography? 
What are the minimum number of 
mammograms a radiologist should interpret 
on an annual basis to maintain proficiency 
in screening mammography? What are the 
qualifications and training required of the 
technologist who acquires the image?
Yes Questions addressing imaging 
techniques, volumes and training 
requirements were included in the 
prioritisation exercise.
In addition, the European QA 
scheme will also address the 
question on radiologist volumes.
14 Training program and certification or exam 
form for radiologists, technologists, med. 
physicists training for screening program 
managers?
15 1) Role of digital systems/databases/ training
sets in order to build up and maintain the 
best performance in film reading 2) Role of 
double reading in various formats (arbitration, 
consensus, etc.) 3) Emphasis on positioning 
4) Emphasis on specific screening reading
skills 5) Emphasis on imaging-guided biopsy 
training. I should stress the importance of 
Reference Training Centre (RTC) at different 
levels (Regional, National, European). It 
should be emphasized the importance of 
setting up RTC/ or cooperate/or make use of 
the most skilled Units and experts for training 
and education.
16 Radiographers continuing education: needs 
for updating the certification? How to handle 
updating and certification after long-time 
sick leave and maternity leave? And the 
radiologists after long-time sick leave and 
maternity leave? Recommend Internal 
refreshers courses?
17 Quality control for technicians. Minimal 
standards for a qualified breast cancer 
screening and diagnosis healthcare center. 
Digital pathology for breast biopsies after 
breast cancer screening.
No Quality of breast healthcare services 
will be covered by the European QA 
scheme.
18 What must be the duration of learning curve 
assigned in the guideline for: reporting a 
screening mammogram, ultrasound, core 
biopsy, vacuum biopsy... etc.
Yes Questions addressing training 
requirements were included in the 
prioritisation exercise.
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19 Dedicated professional to breast: EU agency 
should receive a statement from EU hospital 
about breast program and dedicated person 
requiring a document stating that the 
dedicated professional are involved at 80% of 
their time.
Yes Questions on minimal requirements 
for professionals involved in breast 
cancer screening and diagnosis 
were included in the prioritisation 
exercise.
20 In addition to habitual questions on screening 
professionals’ specific training: What basis 
training should be provided to all medical and 
paramedical professions even if not directly 
involved? How to assure proper understanding 
of age limits for screening invitations 
(i.e. knowledge and updates on results of 
screening pilot studies and further evaluations 
of ongoing programs)? What information 
should be provided in secondary level schools 
to prepare right attitude and knowledge for 
later years among female population?
Yes Questions addressing training 
requirements and optimal strategy 
for communicating information 
about breast cancer screening to 
the general public were included in 
the prioritisation exercise. 
However, questions addressing 
what training should be provided 
to all medical and paramedical 
professional concerning screening 
were not specifically included in 
the prioritisation exercise. Neither 
were questions on what information 
should be provided in secondary 
level schools. 
21 Question linked to chapters 4, 5 and 6. 
If monitoring of diagnostic, treatment 
procedures and training via certified breast 
units are still ongoing (IQA and EQA, audit), 
identifying inadequate interventions could be 
identified and discouraged.
Yes Questions addressing training 
requirements, monitoring and 
evaluation of screening and 
diagnosis were included in the 
prioritisation exercise. 
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
22 Since the use of CESM imaging modality 
is rapidly growing in the field of breast 
disease, there is clearly a need to provide 
a consensus among experts to standardize 
CESM examinations reporting and to reconcile 
terms used to describe features on both LE 
image and subtracted images. The question 
is: Is a new CESM lexicon of standardized 
terminology designed to standardize CESM 
reporting should be elaborated?
Yes Questions addressing imaging 
techniques were included in the 
prioritisation exercise.
23 Could there be a training programme or at 
least suggestion for screening registrars?
Yes Questions on minimal requirements 
for professionals involved in breast 
cancer screening and diagnosis 
were included in the prioritisation 
exercise.
Data management will be addressed 
within the European QA scheme. 
24 1) quality assurance measures such
as: – minimum reading/case numbers; 
training (courses and individual); internal 
quality management with certain individual 
statistics – reading tests, peer reviewing; 
multidisciplinary approach and training – 
sampling tests (image quality, diagnostic 
workup).
Yes Questions addressing training 
requirements and volumes for 
professionals involved in breast 
cancer screening and diagnosis 
were included in the prioritisation 
exercise.
25 Will new European guidelines for breast 
cancer screening and diagnosis propose 
European reference training centers for all EU 
screening programmes personel?
Yes Questions addressing training 
were included in the prioritisation 
exercise.
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26 Shared decision making with honest 
information and no pressure of doing 
screening without symptoms.
Yes Questions about optimal strategy 
to communicate with women 
were included in the prioritisation 
exercise.
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
27 1. Accreditation/training/...: who pays?
Why manages? 2. Separate new group of 
professionals or a second activity of current 
healthcare professionals?
Yes Questions on training and minimal 
requirements for professionals 
involved in breast cancer screening 
and diagnosis were included in the 
prioritisation exercise.
The economic aspects will be 
included in the EtD frameworks of 
PICO questions. 
Accreditations/certification will 
be covered by the European QA 
scheme. 
28 Definition of Training Center Duties of a 
Training Center
29 Availability of training and follow up programs 
of quality on all stages of screening (readings, 
positionning) and dianogstics including biopsy 
techniques Should all radiologists specialised 
in breast cancer diagnosis succed the EDBI 
exam organised by the European Society of 
Breast Imaging (different options here can be 
discussed).
30 Regarding training of pathologists, the 
initiatives of the European Society of 
Pathology, like the European School of 
Pathology – breast pathology arm, as well as 
training centers in the Giordano fellowship 
program may be explored.
31 How will the guidelines ensure that all 
healthcare providers are trained in adequate 
and effective communication around the need 
for timely treatment following diagnosis?
Yes Questions addressing training 
requirements and strategies for 
educating or supporting health 
professionals for providing 
information were included in the 
prioritisation exercise.
32 Should you create a system of accreditation of 
professionals included in population screening 
programs common for Europe?
No Accreditation/certification will 
be covered by the European QA 
scheme.
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1 Will the panel recommend on research 
findings that describe how risk is best 
presented to those with low literacy levels?
Yes Questions addressing optimal 
strategy to communicate with 
women and the use of targeted 
communication in particular 
subpopulations of women were 
included in the prioritisation 
exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
In addition, the recommendations 
will be translated into lay-
person language, in order to be 
understandable by all.
2 Reimbursement of screening not just from 
public services but also insurance companies; 
explain companies the crucial role of 
screening and early diagnosis. Establish ways 
to quickly refer women with suspicious lesions 
to high quality Treatment Units, where care is 
covered either by public system or insurance 
companies.
Yes Questions addressing optimal 
strategy to communicate 
information about breast cancer 
screening to the general public 
and minimal requirements for 
professionals involved in breast 
cancer screening and diagnosis 
were included in the prioritisation 
exercise.
The economic aspects will be 
covered in the EtD frameworks.
In addition, quality of breast 
healthcare services will be covered 
by the European QA scheme.
3 The guidelines should be clear in providing as 
much information for those implementing the 
guidelines as possible the following questions: 
What are the most evidence-based strategies 
for ensuring that underserved populations 
gain the health benefits offered by the 
recommendations?
Yes Questions about optimal strategy to 
communicate with women and the 
use of targeted communication in 
particular subpopulations of women 
were included in the prioritisation 
exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
In addition, the recommendations 
will be translated into lay-
person language, in order to be 
understandable by all.
4 1. How to support public and open
communication? 2. How to prevent 
unwarranted marketing?
Yes Questions about optimal strategy 
to communicate information about 
breast cancer screening to the 
general public were included in the 
prioritisation exercise.
Table 5. List of questions suggested for inclusion in the Interventions to reduce 
inequalities chapter of the European Breast Guidelines
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5 Define different levels of recommendations, 
according to the socioeconomic status of the 
country, as suggested by the Breast Health 
Global Inithiative (Cancer, Supplement: 
Guidelines for International Breast Health and 
Cancer Control–Implementation 15 October 
2008 Volume 113, Issue S8 Pages i–ix, 2215-
2371)
Yes Questions about optimal strategy 
to communicate with women 
were included in the prioritisation 
exercise. 
Informed decision making 
is considered looking at the 
different outcomes. Desirable and 
undesirable effects of outcomes are 
examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
In addition, the recommendations 
will be translated into lay-
person language, in order to be 
understandable by all.
Socio-economic considerations will 
be some of the implementation 
considerations to be taken into 
account at a country level. In 
addition, the economic aspects will 
be covered in the EtD frameworks.
6 How will the guidelines ensure that all women 
who are offered a screening, regardless of 
factors such as socio economic status and 
other factors, will accept the invitation and 
understand the importance of receiving a 
screening?
7 In addition to habitual questions on assuring 
access: How to involve local communities and 
primary care teal to motivate participation 
of non-attenders in organised screening 
programs?
Yes Questions about optimal strategy 
to communicate with women and 
involving primary health providers 
in communication strategies 
were included in the prioritisation 
exercise. 
8 Preference for organized population-based 
screening programs instead of spontaneous 
screening access to breast diagnostic services. 
Important points and priorities: 1. Total 
screening coverage (invitation) of the target 
population aged from 50 to 70 with 2 or 3 
(UK) interval 2. Usage of mobile units to 
cover rural zones 3. Extension from 40 or 45 
(1-year interval) or to 73 or 75 (2- or 3-year 
interval) 3. General transition to direct digital 
mammography for all women 4. Strategies 
for supporting the screening attendance 
and referral to diagnostic services of low-
income women 5. Strategies for supporting 
the screening attendance and referral to 
diagnostic services of women coming from 
extra-EU countries with potential cultural or 
religious barriers (e.g., female technicians are 
essential for this issue).
Yes Questions about age groups, 
screening intervals, organised vs. 
non-organised screening, imaging 
techniques, optimal strategy 
for communicating information 
about breast cancer screening to 
socially disadvantaged women 
were included in the prioritisation 
exercise. 
9 The diagnosis and treatment of breast cancer 
in those over 70 years.
Yes Questions about diagnostic 
procedures were included in the 
prioritisation exercise. 
The Guidelines Platform, as 
collection of existing evidence-
based guidelines, can include 
recommendations on treatment for 
all breast cancer patients.
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10 Encourage cooperation across borders, 
centres. Exchange cases to review both for 
diagnosis and for images quality.
Yes Questions on training and minimal 
requirements for professionals 
involved in breast cancer screening 
and diagnosis were included in the 
prioritisation exercise.
11 The presence of an appropriate skill mix based 
on defined competences to enable efficient, 
flexible and cost effective reporting of images.
12 Question linked to chapters 4, 5 and 6. 
If monitoring of diagnostic, treatment 
procedures and training via certified breast 
units are still ongoing (IQA and EQA, audit), 
inadequate interventions could be identified 
and discouraged.
Yes Questions addressing training 
requirements, monitoring and 
evaluation of screening and 
diagnosis were included in the 
prioritisation exercise. 
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
13 Breast cancer screening in low-middle 
income countries: time for a reappraisal? 
Reimbursement policies to favour universal 
access to breast cancer screening. 
Opportunistic screening for relatives of 
hospitalized patients.
Yes Questions addressing barriers and 
facilitators to screening participation 
were included in the prioritisation 
exercise. 
Socio-economic and organisational 
considerations will be some of the 
implementation considerations to 
be taken into account at a country 
level. In addition, the economic 
aspects will be covered in the EtD 
frameworks.
14 Breast US and clinical examination for low 
income countries?
15 Are there any regulations about how many 
screening units should be on certain amount 
of population?
16 Should be addressed without lowering already 
established high standards in individual 
countries.
17 What are the most effective methods to 
increase participation in hard to reach group? 
Tailored recruitment: Are different strategies 
for recruitment used for different groups in 
the population? Is this effective?
Yes Questions addressing barriers and 
facilitators to screening participation 
were included in the prioritisation 
exercise.
18 Would the expert panel consider the use of 
CESM as an alternative to MRI especially 
considering the case of patients with MRI 
contra indications, patients with limited 
access to MRI or regional areas with limited 
availability of MRI.
Yes Questions about imaging techniques 
were included in the prioritisation 
exercise.
19 This is difficult with the differences in 
availability of screening and in quality of 
screening in different countries. Is it possible 
to have recommended minimum standards 
re availability of screening and the quality of 
imaging technology, reading, unit appearance/
comfort etc.
Yes Questions about training, minimal 
requirements for professionals 
involved in breast cancer screening 
and diagnosis, monitoring and 
evaluation of screening and 
optimal strategy for communicating 
information about breast cancer 
screening to socially disadvantaged 
women were included in the 
prioritisation exercise.
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
20 Try to define the minimum quality criteria for 
mammography equipment used in screening 
as well as reading stations.
21 Basic screening benchmarks data base 
creation and spread in the EU countries for 
evaluation of programs, data collection and 
inequalities reduction.
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22 Would the expert panel consider the use of 
CESM as an alternative to MRI especially 
considering the case of patients with MRI 
contra-indications, patients with limited 
access to MRI or regional areas with limited 
availability of MRI?
Yes Questions on imaging techniques 
were included in the prioritisation 
exercise.
Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
1 Will monitoring and evaluation include 
questions around the patient experience 
of screening, from call, through testing, 
the manner of recall and final delivery of 
screening findings?
Yes Questions about appropriate 
indicators for monitoring informed 
choice, diagnostic process and 
standardized reporting in diagnosis 
in a population-based screening 
program with mammography 
were included in the prioritisation 
exercise.
2 Which are the requirements for an 
independent and adequate evaluation of 
outcome that enables both the public and the 
policy makers to decide on participation or 
continuation?
Yes Questions about the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme and 
appropriate indicators to be 
reviewed in an external audit 
were included in the prioritisation 
exercise.
3 One of the outcomes of the screening in an 
initial phase could be modification of breast 
cancer incidence, modification of the type of 
tumour diagnosed (intraductal carcinomas), 
different stages of tumours. Should also this 
be taken into consideration?
4 It is important to describe the differences 
between monitoring and evaluation. It would 
also be helpful to describe a minimal set of 
relevant indicators (for example based on 
the ECHI method) to facilitate international 
comparison of screening programmes.
5 Will new European guidelines for breast 
cancer screening and diagnosis provide 
new acceptable levels of breast screening 
performance indicators? Will the provide 
clarifications / exact definitions about 
methodology how to calculate those 
indicators? This is necessary for reporting and 
comparisons.
Yes Questions about the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme were included 
in the prioritisation exercise.
In addition, the Monitoring and 
evaluation chapter of the European 
Breast Guidelines will contain 
recommended thresholds of 
relevant indicators. 
6 Quality indicators for evaluation of screening 
with a scheme and/or table explaining a 
minimal threshold for the quality of screening 
and tips on how to obtain it.
Table 6. List of questions suggested for inclusion in the chapter about Monitoring 
and evaluation of screening and diagnosis of the European Breast Guidelines
129
Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
7 I think the evaluation of the impact of 
screening programme on general population 
should be encouraged and properly carried 
out. Experiences as Euroscreen working 
group on this issue should be encouraged to 
continue.
Yes Questions about the most 
appropriate study design to 
evaluate the impact of a population-
based screening program with 
mammography and the relevant 
indicators were included in the 
prioritisation exercise.
8 There should be recommendations re 
audit – especially of recalls and of interval 
cancers – false negatives should be assessed 
and explained to patients as well as 
commissioners & primary care doctors. Patient 
assessment of the screening unit should also 
be sought and suggestions for improvement 
welcomed.
Yes Questions about the most 
appropriate indicators to be 
reviewed in an external audit 
were included in the prioritisation 
exercise.
9 Will the monitoring and evaluation of 
screening and diagnosis also take into account 
how many patients receive appropriate and 
adequate care in a timely manner? One in 10 
women waited ≥ 60 days to initiate treatment 
after a diagnosis of breast cancer. Waiting ≥ 
60 days to initiate treatment was associated 
with a significant 66% and 85% increased risk 
of overall and breast cancer-related death. 
Source http://1.usa.gov/1P2GI9C How will 
the guidelines connect and complement the 
development of national cancer registries and 
their coordination via the European Network 
of Cancer Registries to allow monitoring 
the effectiveness of the fight against breast 
cancer? Source http://bit.ly/1nl7v4D
Yes Questions about the most relevant 
process and performance indicators 
of an efficient diagnostic process 
and an efficient population-based 
screening programme were included 
in the prioritisation exercise. 
Data management will be addressed 
within the European QA scheme. 
10 In addition to habitual questions; How to 
evaluate communication process, over 
diagnosis and risk of overtreatment.
Yes Questions about the appropriate 
indicators for monitoring 
informed choice in a population-
based screening program with 
mammography were included in the 
prioritisation exercise. 
Overdiagnosis is considered looking 
at the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
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Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
11 1/ How to take into account neoadjuvant 
chemotherapy in the reporting of cancer 
stages? 2/ How to take into account the 
molecular signatures (basal type / luminal 
type)? 3/ Set criteria for identifying the 
risk of overdiagnosis (see IDLE condition 
(Indolent Lesion of Epithelial origin), Dr. Laura 
Esserman) Thank you.
Yes Questions on histopathological 
procedures and parameters, 
prognostic and predictive 
pathological markers were included 
in the prioritisation exercise. 
Overdiagnosis is considered looking 
at the different outcomes. Desirable 
and undesirable effects of outcomes 
are examined using EtD frameworks 
for each PICO question in order to 
decide what the balance is, which 
might influence the direction of the 
corresponding recommendation.
In addition, Reference documents 
will be provided to support ECIBC 
implementation.
Data management and the 
quality of breast healthcare 
services (including neoadjuvant 
chemotherapy) will be addressed 
within the European QA scheme. 
12 The new guidelines should define the 
relevance of screening performance analysis, 
not only in terms of attendance rate, 
detection rate, recall rate, benign/malignant 
biopsy rate, tumor size and stage of detected 
cancers, etc, but also in terms of interval 
cancers and T2-stage screen-detected 
cancers for each local screening program. 
This analysis should be strongly suggested 
to all screening programs as one of the best 
indicators of performance, also because the 
open discussion of all the cases among the 
radiologists enhances diagnostic skills.
Yes Questions about the most relevant 
process and performance indicators 
of an efficient diagnostic process 
and an efficient population-based 
screening programme were included 
in the prioritisation exercise.
13 Registration of interval cancers should be 
included as part of a nationwide screening 
program.
14 What is an appropriate population 
particapation rate for organzied population 
bases breast cancer screening? What is an 
appropriate abnormal call rate for initial 
screens and for subsequent screens? What 
is an appropriate PPV for the screening 
test? What is the appropriate length of the 
screening episode? (ie. amount of time from 
an abnormal screening to definitive diagnosis 
of benign or cancer). What proportion of 
cancers, that are screen detected, have 
a tumour size of 15 mm or less? What 
proportion of cancers, that are screen 
detected, have node negative? What is an 
appropriate non-malignant biopsy rate?
Yes Questions about the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme were included 
in the prioritisation exercise.
In addition, the Monitoring and 
evaluation chapter of the European 
Breast Guidelines will contain 
recommended thresholds of 
relevant indicators.
15 Would the expert panel please share their 
evaluation of digital breast tomosynthesis 
equipment and the acceptance criteria for 
screening and diagnosis?
Yes Questions about imaging 
techniques, the most relevant 
process and performance indicators 
of an efficient diagnostic process 
and an efficient population-based 
screening programme were included 
in the prioritisation exercise.
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Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
16 1) I suggest that a minimum set of indicators
should be used for quick check-up, based 
on results at subsequent examinations 
(incidence screening indicators) 2) The 
utmost importance should be given to the 
absolute rate of Stage T2+ advanced cancers 
in the population, regardless of their mode of 
detection as Interval Cancers or as Screen-
Detected Cancer. 3) These T2+ cases should 
form the main basis for radiological revision 
as a means of internal audit and external 
evaluation and training. 4) Monitoring should 
be aimed to get as far as to the individual 
operator level 5) Clear recommendations 
as to the steps to implement should be 
given in cases of insufficient or critically low 
indicators of performance 6) Special funds 
should be reserved for setting up not only 
the monitoring system; Reference Training 
Centres should be adequately funded and 
maintained.
 Yes Questions about the most relevant 
process and performance indicators 
of an efficient diagnostic process 
and an efficient population-based 
screening programme were included 
in the prioritisation exercise. 
Socio-economic and organisational 
considerations will be some of the 
implementation considerations to 
be taken into account at a country 
level. In addition, the economic 
aspects will be covered in the EtD 
frameworks.
17 How can the quality of a breast cancer 
screening programme be assured on a long 
term? What are good examples of how quality 
assurance (QA) activity is implemented in the 
breast cancer screening programme? How 
to assure the quality of the mammography 
production and reading process chain? What 
are the threats to quality assurance in BC 
screening programs (i.e. regression towards 
the mean, insufficient statistical power)?
Yes Questions about the most relevant 
process and performance indicators 
of an efficient diagnostic process 
and an efficient population-
based screening programme, the 
appropriate timescale for each 
(surrogate) impact indicator of 
evaluation of a population-based 
screening programme with respect 
to precision in the estimates 
(statistical power) were included in 
the prioritisation exercise. 
Quality of breast healthcare services 
will be covered within the European 
QA scheme. 
18 The guidelines should be clear in providing 
as much information as possible the 
following questions: How will our health 
system show that its management of breast 
cancer screening and diagnosis is achieving 
important health outcomes for citizens?
Yes Questions about the requirements 
for an independent and adequate 
evaluation of outcomes that enables 
both the public and the policy 
makers to decide on participation 
or continuation of a screening 
programme were included in the 
prioritisation exercise.
19 Dose limitations? Regularly feedback to 
radiographers on image quality? Regularly 
feedback to radiologists on recall rate?
Yes Questions about the process and 
performance indicators that will 
be communicated to professionals 
were included in the prioritisation 
exercise.
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Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
20 Monitoring and release an EU statement on 
the indicators to be followed as Indicator 
Number of screens, Number of 1 screens, 
Number of cancers, Participation Rate, 
Retention Rate, 1 screen, Re-screen, 
Abnormal Screen Rate,1 screen, Re-screen, 
Invasive Cancer Rate,1 screen, Re-screen, 
In Situ cancer Rate,1 screen, Re-screen, 
Diagnostic Interval, No open biopsy, With 
open biopsy, Positive Predictive Rate 1 screen, 
Re-screen, B : M open biopsy ratio, Invasive 
ca tumor size, Node negative cancers, 
Indicator Post Screen Detected, Invasive 
Cancer Rate 2, within 12 months, within 24 
months).
Yes Questions about the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme were included 
in the prioritisation exercise.
In addition, the Monitoring and 
evaluation chapter of the European 
Breast Guidelines will contain 
recommended thresholds of 
relevant indicators.
21 The shape and detail of the quality assurance 
programme.
Yes Questions addressing training 
requirements, monitoring and 
evaluation of screening and 
diagnosis were included in the 
prioritisation exercise. 
Quality of breast healthcare services 
will be covered by the European QA 
scheme.
Socio-economic and organisational 
considerations will be some of the 
implementation considerations to 
be taken into account at a country 
level. In addition, the economic 
aspects will be covered in the EtD 
frameworks.
22 Essential that funding is available to ensure 
that any breast cancer screening programme 
is routinely and objectively evaluated.
23 Question linked to chapters 4 and 6. 
If monitoring of diagnostic, treatment 
procedures and training via certified breast 
units are still ongoing (IQA and EQA, audit), 
identifying inadequate interventions could be 
identified and discouraged.
24 What is the actual effectiveness of 
mammographic screening (according to 
different selected outcomes) in Europe 
performed according to the current EU 
recommendations? How does it differ if 
mammography is performed every year in the 
same age groups? What is the comparative 
cost-effectiveness across different countries? 
What is the rate of interval cancer in the 
screened population when screening is 
performed according to the current EU 
recommendations? What is the rate of over-
diagnosis? What is the combination of timing 
(e.g., once a year, once every two years), 
test/s (e.g., mammography, ultrasound, 
polygene testing) and age/risk profile (e.g., 
age group, mammographic density, genetic 
profile) that could optimize these outcomes?
Yes Questions about the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme, age groups, 
screening intervals, imaging 
techniques and varying the 
screening regimen depending on 
certain risk factors were included in 
the prioritisation exercise.
In addition, cost effectiveness is 
part of the EtD frameworks for each 
recommendation.
25 Will the guidelines include a recommended 
minimum data set for monitoring and 
evaluation of the program?
Yes Questions about the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme were included 
in the prioritisation exercise.
Data management and the quality 
of breast healthcare services will be 
addressed within the European QA 
scheme. 
In addition, Reference documents 
will be provided to support ECIBC 
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Sequence 
number
Comments Consideration for modification of The Scope 
of the European Breast Guidelines
Decision Reasoning
26 Consider defining minimum dataset and data 
formats for facilitating EU-wide comparisons 
of evaluation.
27 Screening data must be published in each 
country and centrally in EU. There must be 
proof that the screening is being effective, 
for example, through the decrease in the 
median size of the tumor at diagnosis, 
from the decrease of late diagnosis. The 
submission of data should be mandatory 
to an independent body, preferably at a EU 
level, that analysis the data and verifies the 
quality of the screening. This is lacking and in 
many countries too much money is wasted in 
bad quality screening programs that have no 
independent verification.
28 1) clear minimal documentation record (set
of parameters: screening, diagnoses, post-
operative outcome – therapy and prognostic 
factors) 2) review and update of existing and 
established performance indicators.
Yes Questions on minimal requirements 
for standardised reporting in 
diagnosis and the most relevant 
process and performance indicators 
of an efficient population-based 
screening programme were included 
in the prioritisation exercise.
29 Evaluation population based screening is 
impossible. Let’s stop to pay money for 
useless research.
Yes Questions about the most 
appropriate study design to 
evaluate the impact of a population-
based screening programme 
were included in the prioritisation 
exercise.
The economic aspects will be 
covered in the EtD frameworks. 
30 1. Accreditation/training/...: who pays?
Why manages? 2. Separate new group of 
professionals or a second activity of current 
healthcare professionals?
Yes Questions about training and 
minimal requirements for 
professionals involved in breast 
cancer screening and diagnosis 
were included in the prioritisation 
exercise.
Accreditation/certification will 
be covered by the European QA 
scheme. 
The economic aspects will be 
covered in the EtD frameworks.
31 Should the results of the evaluation of the 
professionals involved in screening and 
diagnostic unit’s programmes be public?
Yes Questions about the requirements 
for an independent and adequate 
evaluation of outcome that enables 
both the public and the policy 
makers to decide on participation 
or continuation of a screening 
programme were included in the 
prioritisation exercise.
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 List of questions for  
prioritisation for inclusion 
in the European  
Breast Guidelines
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LIST OF QUESTION FOR PRIORITISATION
(The number before each question refers to inclusion in the relevant chapter of the European 
Breast Guidelines – 1. Screening, 2. Diagnosis, 3. Communication, 4. Training, 5. Inequalities, 
6. Monitoring and evaluation; RD – Reference document)
1.1 Which is the optimal age range in which to carry out mammography screening?
1.1.1 Is breast cancer screening effective in reducing breast cancer mortality?
1.1.2 Does breast cancer screening affect deaths from other causes than breast cancer?
1.2  Should mammography screening once a year vs other screening frequencies be used 
for early detection of breast cancer in asymptomatic women?
1.3  Should BIRADS system vs R-type system or others be used to report readings in a 
screening programme for asymptomatic women?
1.4  Should Screening with reader recall triggering vs single reading be used for screening 
asymptomatic women with breast cancer risk
1.5  Should Screening with double reading with consensus or arbitration vs single reading 
be used for screening asymptomatic women with breast cancer risk
1.6  Should Screening using digital breast tomosynthesis vs single reading mammography 
be used for screening asymptomatic women with breast cancer risk
1.7  Should Screening with breast MRI vs single reading mammography be used for screening 
asymptomatic women with breast cancer risk
1.8  Should Screening with breast MRI and mammography vs single reading mammography 
be used for screening asymptomatic women with breast cancer risk
1.9  Should a high number of mammographic views vs a low number of mammographic 
views be used for screening women eligible for BC screening?
1.10  Should ultrasound plus mammography vs mammography by itself be used for screening 
breast cancer in women with dense breasts? 
1.11  Should ultrasound plus mammography vs mammography by itself be used for screening 
breast cancer in women eligible for BC screening? 
1.12  Should physical examination together with mammography vs. mammography alone be 
used for screening for BC in women eligible for BC screening?
1.13  Should screening using digital breast tomosynthesis together with mammography vs 
mammography alone be used for screening for BC in women eligible for BC screening?
1.14  Should screening using digital breast tomosynthesis together with mammography vs 
mammography alone be used for screening for BC in women eligible for BC screening?
1.15  Should screening using MRI vs mammography be used for screening for BC in women 
eligible for BC screening?
1.16  Should screening using MRI together with mammography vs mammography alone be 
used for screening for BC in women eligible for BC screening?
1.17  Should organised screening vs non-organised screening be used for screening 
asymptomatic women with breast cancer risk
1.18  Which risk factors are necessary to assign women to screening protocols different from 
the strategy used for average risk populations?
2.1  Should standardized reporting versus no standardized reporting be used in the reporting 
of imaging results?
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2.2  Which classification system should be used for the different imaging techniques (Mx; 
Ultrasound; MRI; Tomosynthesis/synthetized 2D mammogram; CESM)?
2.3  In women with screening detected abnormalities (“Mx positive”: mass lesion, 
microcalcification, asymmetric density or architectural distortion), what are the effects 
of each technique (Breast examination?; Mx magnification (with and without spot 
compression)?; Ultrasound?; Tomosynthesis/synthetized 2D mammogram?; MRI?; 
CESM (contrast enhanced spectral mammography) depending on the lesion?
2.4  Should contralateral ultrasound vs clinical breast examination or no intervention on 
contralateral breast be used in women with suspect of breast cancer (screening mx positive) 
2.5  In symptomatic women >=40yo with suspicion of breast cancer, what are the effects of 
the different imaging techniques (Should Mx, Ultrasound, Tomosynthesis/synthetized 
2D mammogram, MRI, CESM) depending on the symptoms (swelling of all or part of 
the breast, skin irritation or dimpling, unilateral breast pain, nipple pain or the nipple 
turning inward, redness, scaliness, or thickening of the nipple or breast skin, a nipple 
discharge other than breast milk, a lump in the underarm area) 
2.6  Should Mx, Ultrasound, Tomosynthesis/synthetized 2D mammogram, MRI, or CESM be 
used to diagnose breast cancer in symptomatic women aged <40?
2.7  Should Mx, Ultrasound, Tomosynthesis/synthetized 2D mammogram, MRI, or CESM be 
used to diagnose breast cancer in symptomatic pregnant or breast-feeding women?
2.8  Should MRI or other imaging techniques be used to diagnose breast cancer in patients 
with clinical symptoms who have normal Mx and ultrasound? 
2.9  Should Mx, Ultrasound, Tomosynthesis/synthetized 2D mammogram, MRI, or CESM 
be used to diagnose breast cancer in women with augmentation implants, either 
symptomatic or asymptomatic?
2.10  Should any additional assessment procedure vs standard assessment procedure be 
used to diagnose breast cancer in women with familiar hereditary risk of cancer?
2.11  Should a particular algorithm vs any comparison be used for identifying women at high 
risk of cancer?
2.12  Should US guided FNAC; US guided CNB; Mx guided VAB; Tomosynthesis guided CNB/
VAB; MRI guided CNB; or Surgical biopsy after localization vs. any comparison be used 
in women (screening and symptomatic) with suspect lesions (BI-RADS IV/V: mass 
lesion, microcalcification, architectural distortion)?
2.13  Should cyto/histological sampling and pathological analysis vs no further analysis be 
used in women with symptoms suggestive of cancer but with negative Mx and US?
2.14  Should an increased length of biopsy (up to 22 mm) versus the minimal length (15 mm) 
be used in women positive after imaging second level assessment for breast cancer using 
Tru-cut CNB? 
2.15  Should an increased length of biopsy (up to 7G) versus the minimal thickness (from 
16G) be used in women positive after imaging second level assessment for breast 
cancer using Tru-cut CNB? 
2.16  Should a one use system versus reusable body be used in women positive after imaging 
second level assessment for breast cancer using Tru-cut CNB? 
2.17  Should standard anaesthetic protocol versus alternative protocols be used in women 
positive after imaging second level assessment for breast cancer using Tru-cut CNB?
2.18  Should standard sterilization protocol versus using alternative sterilization protocols be used in 
women positive after imaging second level assessment for breast cancer using Tru-cut CNB?
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2.19  Should increasing length of biopsy versus the minimal length be used in women positive after 
imaging second level assessment for breast cancer using Vacuum Assisted Biopsy (VAB)? 
2.20  Should increasing thickness of biopsy versus the minimal thickness be used in women 
positive after imaging second level assessment for breast cancer using Vacuum Assisted 
Biopsy (VAB)? 
2.21  Should a one use system versus reusable body be used in women positive after imaging 
second level assessment for breast cancer using Vacuum Assisted Biopsy (VAB)? 
2.22  Should standard anaesthetic protocol versus alternative protocols be used in women 
positive after imaging second level assessment for breast cancer using Vacuum Assisted 
Biopsy (VAB)?
2.23  Should standard sterilization protocol versus alternative sterilization protocols be used 
in women positive after imaging second level assessment for breast cancer using 
Vacuum Assisted Biopsy (VAB)?
2.24  Should more than one core sampled versus one core sampled be used in women positive 
after imaging second level assessment for breast cancer and undergoing core-biopsy? 
2.25  Should clip marking of the biopsy site versus no clip marking be used in women positive 
after imaging second level assessment for breast cancer and undergoing core-biopsy? 
2.26  Should imaging control after biopsy versus no imaging control be used in women 
positive after imaging second level assessment for breast cancer and undergoing core-
biopsy, by sub groups
2.27  Should immediate imaging control after biopsy versus delayed imaging control after 
biopsy be used in women positive after imaging second level assessment for breast 
cancer and undergoing core-biopsy needing imaging control after biopsy 
RD 2.1  Which criteria indicate that a biopsy has been performed properly?
2.28  Should pretreatment ultrasound of the axilla and/or of the fossa supraclavicularis versus 
no pretreatment be used in patients with breast cancer to determine node status and 
treatment options?
2.29  In patients with breast cancer who have had ultrasound of the axilla performed, what 
features on ultrasound indicate that fine needle aspiration or core biopsy are required?
2.30  Should sentinel lymph node versus no sentinel lymph node be used in women with 
ascertained DCIS (by sub groups of risk available according to data from assessment 
(diameter; grading; morphology)?
2.31  Should sentinel lymph node versus no sentinel lymph node be used in women with 
ascertained invasive cancer, by sub groups of risk available according to data from 
assessment (clinical T; grading; morphology)?
2.32  In women with ascertained invasive cancer or DCIS that should undergo to SLN, which 
is the adequate detection technique (Radioactive tracer, Blue dye, or both)
2.33  In women with ascertained invasive cancer or DCIS that should undergo to SLN, which 
is the recommended needle size?
2.34  In women with ascertained invasive cancer or DCIS that should undergo to SLN, which 
is the recommended injection site?
RD 2.2  When should the injection be considered non-satisfactory? 
2.35  Should a minimal number of sentinel lymph node sampling strategy (i.e. mostly 1 or 
2) versus multiple SLN sampling strategy be used in women with ascertained invasive
cancer or DCIS?
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2.36  In women with ascertained invasive or DCIS undergoing surgery, which lesions are 
candidates for localization?
2.37  Should imaging localization with blue dye or ROLL versus imaging localization with wire 
be used in women with ascertained invasive or DCIS undergoing surgery and needing 
imaging guided localization?
2.38  Should trans tumoral localization or intratumoral localization versus peritumoral 
localization be used in women with ascertained invasive or DCIS undergoing surgery 
and needing imaging guided localization?
2.39  Which mammographic projections must be performed after wire marking in women with 
ascertained invasive or DCIS undergoing surgery and needing imaging guided localization?
RD 2.3  When is the wire marking non-satisfactory? (QA question)
2.40  Should post surgery imaging versus no post surgery imaging be used in women with 
ascertained invasive or DCIS undergoing surgery, by subgroup of risk (needing or not 
needing pre-surgery localization according to Q1; diameter; clinical characteristics?
RD 2.4  How should post-operative sample imaging be done? (time, piece orientation, disposal..)
2.41  Should same imaging as preoperatory versus any imaging method be used in women 
with ascertained invasive or DCIS undergoing surgery and needing imaging guided 
localization pre and after surgery?
RD 2.5  What are the minimum requirements for standardized workup of the specimens?
2.42  Should step section versus standard sectioning be used to diagnose DCIS/invasive 
carcinomas in women?
2.43  How many step sections are needed to diagnose DCIS/invasive carcinomas in women 
with calcifications sampled by VAB?
RD 2.6  What are the minimum requirements for standardized reporting the results of cyto-/
histological assessment?
RD 2.7  In case of DCIS and invasive breast carcinoma: What are the minimum parameters that 
have to be assessed? 
2.44  In women with A) DCIS or B) invasive breast cancer in breast biopsy for suspect of 
cancer, which are the known prognostic factors and predictive that can be assessed in 
a standard pathologic assessment?
RD 2.8  Which are the prognostic factors needed to be defined pre-surgery therapeutic plan?
RD 2.9  What are the minimum requirements for standardized workup of the specimens?
RD 2.10  What are the indications for intra-operative frozen sectioning?[1][1] Now it is 
recommended: Women with a palpable suspect mass lesion > 1,0 cm: a) without pre-
operative diagnosis (i. e. because of pre-pectoral localization) for definite surgery within 
one intervention; b) for margin assessment. SLN: If positive SLN results in axillary 
dissection. Since ACOSOG Z0011 in Germany most patients with breast conserving 
therapy have no axillary dissection if one or two SLNs are histologically positive. Only 
those women with mastectomy who will not be irradiated are candidates for axillary 
dissection if SLN are positive. In consequence we perform frozen sections of the SLNs 
only in these patients. 
RD 2.11  What are the minimum requirements for standardized reporting the results of histological 
assessment?
RD 2.12  In case of DCIS and invasive breast carcinoma: What are the minimum parameters that 
have to be assessed? 
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2.45  Which are the known prognostic and predictive factors that can be assessed in a 
standard pathologic assessment?
RD 2.13  Which are the prognostic factors to define post-surgery therapeutic plan?
2.46  In patients with invasive breast cancer, which ER and/or PR cut-offs (1% or 10%) 
indicate responsiveness to endocrine therapy? 
2.47  In patients with invasive breast cancer, which parameter ((a) Ki67 and (b) Multiparameter 
molecular test) helps to differentiate ER-positive carcinomas (luminal A- and B-like) 
with regard to responsiveness to cytotoxic therapies
2.48  In patients with invasive breast cancer, which are the most useful multiparameter 
molecular tests to differentiate ER-positive carcinomas (luminal A- and B-like) with 
regard to responsiveness to cytotoxic therapies?
2.49  Should HER2 testing be repeated on surgical specimen versus no repetition of HER2 
testing on surgical specimen be used in patients with invasive breast cancer with 
negative HER2-status on CNB/VAB and histological grade 3?
2.50  Should HER2 testing be repeated on surgical specimen versus no repetition of HER2 
testing on surgical specimen be used in invasive breast cancer with borderline HER2-
status on CNB/VAB (IHC Score 2+ and HER2/CEP17 Ratio <2,0, HER2 copy number > 
4 and < 6/cell)?
2.51  In women with breast cancer, who/what subgroups should have staging investigations 
performed to detect metastases?
2.52  In women with breast cancer who are being staged, what investigations should be 
performed?
2.53  Should all women have quantification of breast density and how should it be done and 
reported?
RD 2.14  What are the minimum quality requirements for the breast imaging techniques: Mx 
(compression, doses, quality of imaging etc.)?; Ultrasound (MHz, transducer, room 
lighting..)?; Tomosynthesis?; MRI?; CESM?
RD 2.15  Should there be a uniform system for radiographic image quality assessment?
2.54  What are adequate quality assurance schemes for radiological-pathological correlation?
2.55  Should imaging follow-up versus not performing imaging follow-up be used in patients 
with benign histopathology (B2) after suspect imaging (BIRADS IV/V) (and when?)?
2.56  Which safety issues must be taken into account when injecting radioisotopes in an 
ultrasound/XR setting?.
2.57  Which is the recommended time period between assessment and diagnosis?
2.58  Which is the recommended time period between diagnosis and intervention?
2.59  Should discussion of the patient’s case at the multidisciplinary team meetings versus 
any comparison be used in breast cancer to improve patient’s outcomes?
RD 2.16  How can we optimize the process between a positive mammography result and 
diagnostic verification (i.e., to minimize delay without losing quality of the services)?
RD 2.17  What are the most effective strategies to develop integrated cancer care during the 
screening and diagnostic processes of breast cancer (for example, by using common 
clinical guidelines, management protocols and strategies of care etc.)?
2.60  Should standard mammography views vs other views be used to diagnose breast cancer 
in women?
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3.1.  What is the optimal strategy used for communicating information about breast cancer 
Screening programmes to the general public?
3.2  Should a multimodal intervention in addition to written information vs only written information 
be used for communicating information about BC screening to the general public?
3.3  What are the currently available strategies for educating or supporting health 
professionals for providing information about BC screening to the general public? 
3.4  What is the optimal strategy for providing the information needed to increase informed 
participation in breast cancer Screening programmes to the general public? 
RD 3.1  What are the key steps in developing and testing BC messages and materials? Which 
characteristics should the written communication tools have in order to be understandable ?
3.5  Should targeted communication vs general communication be used in particular 
subpopulations of women in order to increase informed participation in breast cancer 
screening programmes?
RD 3.2  Which kind of tailored strategies for informing women in screening could be 
recommended? 
RD 3.3  What are the benefits and harms of tailored strategies for informing women in screening 
in different population groups?
RD 3.4  What communication aids should be introduced in BC screening to enhance women’s 
understanding about harms and benefits of BC screening?
3.6  Should primary health providers be involved in communication strategies vs not 
involving them be used for providing information to women invited for screening on BC 
screening
RD 3.5  How can we ensure appropriate communication skills training for all health care 
professionals engaged in a screening?
3.7  Should social media or electronic communication vs other interventions be used to 
implement a BC screening programme?
3.8  Should a community based-intervention vs no intervention be used to implement BC 
screening programmes?
RD 3.6  What characteristics should have the BC screening programme website? 
3.9  Should advocacy groups and other relevant stakeholders vs not involving them be used 
for providing information to the general public on BC screening?
3.10  What quality indicators are currently used to evaluate the effectiveness of communicating 
information to the general public concerning BC screening?
3.11  Which active invitation strategy is more effective in improving participation in breast 
cancer screening among women?
RD 3.7  What are the effects of an individual invitation letter on participation to screening as 
compared to invitation by phone in women aged 50 – 69 years (potentially also in 
women aged 40 – 49 years and 70 – 75 years, if the data exist)?
RD 3.8  What are the effects of sending a flyer on breast cancer along with the invitation letter 
on participation to screening?
RD 3.9  What are the effects of sending a pre-invitation letter before the invitation letter on 
screening participation? 
3.12  Should a telephone or text message reminder vs nothing be used to increase participation 
in breast cancer screening programmes?
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3.13  Should a re-invitation letter vs nothing be used to increase participation of non-
responders to first invitation in breast cancer screening programmes?
RD 3.10  What information should be included in the invitation letter (in case of invitation letter+ 
leaflet) ?
RD 3.11  What information should be included in the leaflet (in case of invitation letter+ leaflet) ? 
RD 3.12  Who, how and when should communicate benefits and harms of mammography 
screening. a. How the concept of BC development risk and risk reduction should be 
communicated to women invited to screening
3.14  Should providing information about benefits and harms vs not providing it be used in 
women invited to participate in screening? 
3.15  Should the GP vs other strategies be used to invite women eligible for screening in 
order to increase well-informed participation of women in breast cancer screening 
programmes?
3.16  Should public campaigns vs nothing be used to increase participation of women in 
breast cancer screening programmes
RD 3.13  What information should be included in the letter and leaflet used to notify results?
3.17  What is the optimal and timely strategy to inform women who have a negative result in 
order to decrease their anxiety
3.18  What is the optimal and timely strategy to invite women for further assessment?
RD 3.14  If further investigations are needed, what is the maximum time limit (in days) for those 
to be performed to avoid mental burden and anxiety?
RD 3.15  How the need of further investigations should be communicated to women to reduce 
the mental burden and anxiety?
3.19  Should a contacting strategy vs no strategy be used in non-responders to further 
assessment to improve BC detection rate? 
3.20  What is the optimal and timely strategy to communicate results to women who were 
positive to screening?
RD 3.16  If further investigation results in a diagnosis of breast cancer, what type of health care 
professionals should this be and what type of communication skills training should be 
mandatory for this person?
RD 3.17  What is the most effective way to ensure proper referral or transition from the screening 
program to treatment in a breast unit.
RD 3.18  How should this referral be communicated to the woman to minimise anxiety?
RD 3.19  What methods should be employed to ensure that a smooth transition has taken place? 
RD 3.20  What are the most effective methods for maintaining clear lines of communication 
between hospital breast units and primary care teams?
3.21  What is the optimal and timely strategy to invite women who tested negative in the 
previous screening round for the next screening round?
RD 3.21  How and how often BC screening outcomes should be communicated to the relevant 
stake holders and to the general population? a. Specifically for what concerns QA 
protocols and QA outcomes
RD 3.22  What kind of interventions intended to promote informed decisions by women in breast 
cancer screening are the most effective?
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RD 3.23  Does giving the patient balanced information decrease anxiety and reduce decisional 
conflict?
3.22  Should an intervention where the radiographer explains the screening procedure vs 
one where he does not explain the procedure be used to increase patient experience/
satisfaction with BC screening programmes
RD 3.24  How does the explanation of the screening procedure by the radiographer affect the 
patient experience and patient satisfaction?
RD 3.25  What communication methods have been shown to be most effective in improving 
women’s satisfaction and/or reducing anxiety?
3.23  Should a decision aid that explains pros and cons of screening vs a normal invitation 
letter be used to inform patients about the benefits and harms of BC screening
RD 3.26  What are the best ways (examples) in delivering clear and balanced information 
concerning screening? 
RD 3.27  How does the information delivered (quality, quantity and means of information) affect 
the participation in screening
RD 3.28  How will the new BC screening Guidelines and updates be disseminated to the public, 
Breast Units, patients and professionals? 
4.1  Should a minimum academic background versus any comparison be used to allow 
radiologist readers to start in a mammography screening program?
4.1.1  What should be the minimum requirements for a reader to start in a mammography 
screening program
4.2  Should a minimum number of readings versus any comparison be used to allow 
radiologist readers to start in a mammography screening program?
4.3  Should a minimum weeks of readings versus any comparison be used to allow radiologist 
readers to start in a mammography screening program?
4.4  Should a minimum threshold in sensitivity and specificity for radiologist readers versus 
any comparison be used to allow readers to start in a mammography screening program?
4.5  Should a minimum number of readings versus any comparison be used to maintain the 
license as a radiologist reader in a mammography screening program?
4.5.1  What should be the minimum requirements for a reader to maintain the license in a 
mammography screening program
4.6  Should a minimum weeks of readings versus any comparison be used to maintain the 
license as a radiologist reader in a mammography screening program?
4.7  Should a minimum threshold in sensitivity and specificity for readers versus not requiring 
any threshold be used to maintain the license as a reader in a mammography screening 
program?
4.8  Should a minimum training versus any comparison be used to maintain the license as 
a reader in a mammography screening program?
RD 4.1  What are the passing thresholds in a yearly reading regarding the sensitivity and the 
specificity?
4.9  Should a maximum number of readings per day versus any comparison be used for 
radiologists working in breast cancer screening?
4.10  Should radiologists specialized in breast cancer imaging versus not being specialized be 
used in breast cancer screening?
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4.10.1  Does the specialization on breast imaging (diagnostic and/or screening) have any 
impact?
4.11  Should radiologists specialized in breast cancer imaging versus not being specialized be 
used in diagnosis of breast cancer?
4.12  Should a minimum number of mammograms versus any comparison be used to maintain 
the license as a radiologist in diagnostic mammography?
4.12.1  What should be the minimum requirements for a radiologist to maintain the license in 
diagnostic mammography
4.13  Should continuous medical education versus any comparison be used to maintain the 
license as a radiologist in diagnostic mammography?
4.14  Should continuing exams versus any comparison be used to maintain the license as a 
radiologist in diagnostic mammography?
RD 4.2  Which courses are mandatory for a radiologist in diagnostic mammography
RD 4.3  What are the rules for maintaining his/her licenses as a radiologist in a diagnostic 
mammography?
RD 4.4  What are the minimum requirements for a radiologist/senologist doing assessment in 
a woman with mammographic abnormalities in the context of a screening program or 
diagnostic procedure?
RD 4.5  What are the minimum requirements for a radiologist/senologist doing assessment in a 
mammography screening program/diagnostic procedure to maintain his/her licence?
4.15  Should a minimum number of readings of mammograms versus any comparison be 
used in mammography diagnosis
4.16  Should a specialisation on breast diagnostic imaging vs no specialisation on breast 
diagnostic imaging be used for radiologists or senologists working in breast cancer 
diagnostic services? 
RD 4.6  Are all these requirements mandatory for radiologist doing diagnostic mammography? 
RD 4.7  What are the minimum standards and requirements for continuous professional 
development (CPD), to ensure that practinioners remain up to date on contemporary 
studies/issues in their field of specialty?
RD 4.8  What are the minimum standards and requirements for continuous professional 
development (CPD), to ensure that practitioners understand links to other disciplines?
4.17  Should a minimum training versus any comparison be used to participate as a 
radiographer in a mammography screening program?
4.18  Should a minimum training versus any comparison be used to participate as a 
radiographer in a diagnostic mammography service
RD 4.9  What are the minimum requirements for a radiographer in a screening program 
regarding quality measured as in performing mammography?
RD 4.10  What are the rules for maintaining a licenseas a radiographer in a screening program/
diagnostic mammography?
RD 4.11  What are the minimimun requirements in respect of academics and test readings for a 
radiographer to start as a reader in a mammography screening program
4.20  Should a minimum training versus any comparison be used to participate as a pathologist 
in a mammography screening program?
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4.21  Should a minimum training versus any comparison be used to participate as a pathologist 
in a diagnostic mammography service
RD 4.12  Which are the minimum requirements for a pathologist, in breast pathology diagnostic 
experience, in a screening program?
RD 4.13  What are the rules for maintaining a licence as a pathologist in a screening program?
4.19  Should a specialisation on breast diagnostic imaging vs no specialisation on breast 
diagnostic imaging be used for pathologists working in breast cancer diagnostic services? 
4.20  Should a minimum training versus any comparison be used to participate as a specialized 
nurse in a mammography screening program?
RD 4.14  What are the contents of : Multidisciplinary trunk/basic course; Mammography course; 
readers course; biopsy course; Ultrasound course; and MRI course
RD 4.15  How is the quality of the teaching courses evaluated?
RD 4.16  How can the effects of the teaching courses be evaluated?
5.1.  What are the barriers and facilitators to screening participation?
5.2.  What is the optimal strategy for communicating information about breast cancer 
Screening programmes to socially disadvantaged women? 
RD 5.1  What are the effects of ethnicity, education, general health, co-morbidities and life style 
on adherence to breast cancer screening?
5.3.  What is the knowledge, attitudes and perceptions of women towards participating in 
screening programmes?
5.4.  Should effective communication techniques on harms and benefits of screening versus 
any comparison be used in hard to reach population groupsto increase their participation 
in screening programmes
RD 5.2  What has been the impact of these interventions on increasing participation in screening
5.5  Should guidelines be used in hard to reach population groups to increase their education 
and communication with regards to screening programmes
5.6  What is the impact of the healthcare system (type of reimbursement,etc..) on information 
and participation in screening programmes
6.1  What are the most relevant process indicators of an efficient population-based screening 
program with mammography?
6.2  What are the most relevant performance indicators of an efficient population-based 
screening program with mammography?
6.3  Does an external audit group, i.e. a group independent of the organization and 
execution of the program, improve the quality and/or increase the trustworthiness of 
the monitoring of a population-based screening program with mammography? 
6.4  What are the most relevant indicators to be reviewed in an external audit? 
6.5  What is the appropriate timeliness and data level, e.g. national, regional, screening 
centre, of the monitoring cycle for process and performance indicators with respect to 
precision in the estimates (statistical power)? 
6.6  Which, if any, of the process and performance indicators will, if communicated to 
professionals, improve the awareness among the professionals? 
6.7  What are appropriate indicators for monitoring a population-based screening program 
with mammography from an equity point of view? 
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6.8  What are appropriate indicators for monitoring informed choice in a population-based 
screening program with mammography?
6.9  What are the threats to monitoring quality assurance in population-based screening 
program with mammography?
6.10  What are the most appropriate impact indicators of an effective population-based 
screening program with mammography? 
6.11  What are the most appropriate surrogate impact indicators of an effective population-
based screening program with mammography? 
6.12  What are the most appropriate indicators to measure indirect impacts of an effective 
population-based screening program with mammography
6.13  What is the appropriate timescale for each (surrogate) impact indicator of evaluation of 
a population-based screening program with mammography with respect to precision in 
the estimates (statistical power)? 
6.14  What are appropriate indicators for evaluating a population-based screening program 
with mammography from an equity point of view? 
6.15  What is the most appropriate study design to evaluate the impact of a population-based 
screening program with mammography? 
6.16  What is the most appropriate method to weigh benefits versus harms of a population-
based screening program with mammography? 
6.17  Does an external audit group, i.e. a group independent of the organization and 
execution of the program, improve the quality and/or increase the trustworthiness of 
the evaluation of a population-based screening program with mammography? 
6.18  Which are the requirements for an independent and adequate evaluation of outcome 
that enables both the public and the policy makers to decide on participation or 
continuation?
6.19  What are the most relevant process and performance indicators of an efficient diagnostic 
process?
6.20  What are minimal requirements for standardized reporting in diagnosis (radiology, 
pathology, etc)? 
6.21  Does an external audit group, i.e. a group independent of the organization and 
execution of the program, improve the quality and/or increase the trustworthiness of 
the diagnostic process
6.22  What are appropriate indicators for monitoring the diagnostic process from an equity 
point of view
6.23  What are the necessary requirements on diagnostic procedures to minimise 
overdiagnosis? 
6.24  What are the most appropriate impact indicators of an effective diagnostic process? 
6.25  Does an external audit group, i.e. a group independent of the organisation and 
execution of the program, improve the quality and/or increase the trustworthiness of 
the evaluation of the diagnostic process?
6.26  What are appropriate indicators for evaluating the diagnostic process from an equity 
point of view? 
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Annex 5 
List of acronyms 
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- MoH: Ministry of Health
- CPO: Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica in Piemonte
- AOU: Azienda Ospedaliero-Universitaria
- EUREF: European Reference Organisation for Quality Assured Breast Screening and Diagnostic 
Services
- BCCERT: Breast Centres Certification
- EUSOMA: European Society of Breast Cancer Specialists
- Europrev: European Network for Prevention and Health Promotion in Family Medicine and 
General Practice
- EFOMP: European Federation of Organisations For Medical Physics
- EUSOBI: European Society of Breast Imaging
- NHS: National Health Service
- SENATURK: Senoloji Akademisi
- EORTC: European Organisation for Research and Treatment of Cancer
- GE: General Electric
- COCIR: European Coordination Committee of the Radiological, Electromedical and Healthcare 
IT Industry
- ITALCERT: Organismo di Certificazione Italiano
148
How to obtain EU publications
Our publications are available from EU Bookshop (http://bookshop.europa.eu),
where you can place an order with the sales agent of your choice.
The Publications Office has a worldwide network of sales agents.
You can obtain their contact details by sending a fax to (352) 29 29-42758.
Europe Direct is a service to help you find answers to your questions about the European Union
Free phone number (*): 00 800 6 7 8 9 10 11
(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may 
be billed.
A great deal of additional information on the European Union is available on the Internet.
It can be accessed through the Europa server http://europa.eu
148
JRC Mission
As the science and knowledge service 
of the European Commission, the Joint 
Research Centre’s mission is to support 
EU policies with independent evidence 
throughout the whole policy cycle.
EU Science Hub
ec.europa.eu/
@EU_ScienceHub
EU Science Hub – Joint Research Centre
Joint Research Centre
EU Science Hub
doi:10.2760/801606 
ISBN 978-92-79-69472-1 
K
J-N
A
-28641-EN
-N
